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ABSTRACT 
The porphyrias are a diverse group of metabolic disorders arising from diminished 
activity of enzymes in the heme biosynthetic pathway. They can present with acute 
neurovisceral symptoms, cutaneous symptoms, or both. The complexity of these 
disorders is demonstrated by the fact that some acute porphyria patients with the 
underlying genetic defect(s) are latent and asymptomatic while others present with 
severe symptoms. This indicates that there is at least one other risk factor required in 
addition to the genetic defect for symptom manifestation. A systematic review of the 
heme biosynthetic pathway highlighted the involvement of a number of micronutrient 
cofactors. An exhaustive review of the medical literature uncovered numerous reports 
of micronutrient deficiencies in the porphyrias as well as successful case reports of 
treatments with micronutrients. Many micronutrient deficiencies present with 
symptoms similar to those in porphyria, in particular vitamin B6. It is hypothesized 
that a vitamin B6 deficiency and related micronutrient deficiencies may play a major 
role in the pathogenesis of the acute porphyrias. In order to further investigate the 
porphyrias, a computational model of the heme biosynthetic pathway was developed 
based on kinetic parameters derived from a careful analysis of the literature. This 
model demonstrated aspects of normal heme biosynthesis and illustrated some of the 
disordered biochemistry of acute intermittent porphyria (AIP). The testing of this 
model highlighted the modifications necessary to develop a more comprehensive 
model with the potential to investigated hypotheses of the disordered biochemistry of 
the porphyrias as well as the discovery of new methods of treatment and symptom 
control. It is concluded that vitamin B6 deficiency might be the risk factor necessary 
in conjunction with the genetic defect to trigger porphyria symptoms.  
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AIP acute intermittent porphyria NAD+ nicotinamide adenine 
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Note for ease of reading, there is a fold-out schematic representation of the heme 
biosynthetic pathway along with a list of abbreviations of the heme biosynthetic 
pathway enzymes and the corresponding porphyrias. 
All other abbreviations can be accessed easily through the fold-out page at the end of 
the thesis. 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
1.1.1 Porphyrins 
“The porphyrin pathway is the source of the “rings of life” and its significance is 
interwoven in the fabric of the biological world.” - Dayan and Dayan.1  
 
Porphyrins are chemical compounds made up of four pyrrole rings (Figure 1.1) that 
are capable of binding metal ions and play essential roles in a variety of important 
biological reactions. They comprise a large class of deeply coloured, fluorescent red 
or purple crystalline pigments.2 Their name is derived from the Greek word for purple 
– porphura. They were given this name when brilliantly coloured dyes extracted from 
indigo plants were found to contain porphyrins. The colourful purple hues provided 
by the porphyrin dyes were colourfast due to the stability of the porphyrins and were 
considered a luxury as a result, hence the term ‘royal purple’. They have also been 
termed “the colours of life”2 partly because they are responsible for the red colour of 
blood (hemoglobin) as well as the green colour of plants (chlorophyll). Porphyrins in 
addition to melanin pigments also account for the rich reds, browns and greens of the 
feathers of some birds. 
 
Due to the ability of porphyrins to bind metal ions, they are capable of playing 
important roles in a variety of biological processes including O2 transport 
(hemoglobin, myoglobin), photosynthesis (chlorophyll), electron transfers 
(cytochromes) as well as drug metabolism (cytochromes P450). In humans, it is the 
porphyrin ‘heme’ that is utilised in myriad crucial metabolic pathways ranging from 
! 2!
oxygen transport to gene regulation.3 Heme biosynthesis is a complex eight-step 
pathway involving a series of porphyrin and heme precursors. The heme biosynthetic 
pathway is tightly regulated by its end product, heme, through feedback inhibition 
(Figure 2.1); this ensures these porphryin precursors do not accumulate in excess 
under normal conditions. 
 
   Figure 1.1 Structure of a Simple Porphyrin. 
 
1.1.2 When Heme Synthesis Goes Wrong 
Other than their role in heme synthesis, the porphyrin heme precursors have no 
known role in human metabolism and never accumulate under normal conditions as 
the heme pathway is tightly regulated. Each of the eight steps of heme biosynthesis is 
catalysed by a specific enzyme (Figure 2.1). Genetic mutations that result in 
diminished activity of one or more of these enzymes lead to a group of metabolic 
disorders called the porphyrias. The reduced enzyme activity can cause a ‘bottleneck’ 
in the normal flux of the heme biosynthetic pathway resulting in a buildup of 
porphyrins and heme precursors prior to the enzymatic ‘block’ in the pathway. 
Porphyrin and heme precursor accumulation is associated with toxic effects resulting 
in a wide spectrum of symptoms. Hence the term ‘porphyria’.  
 
NH
N
N
HN
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The porphyrias can present with myriad detrimental symptoms ranging from acute 
symptoms, e.g. severe abdominal pain, peripheral neuropathies, seizures, 
hallucinations, and psychosis, to chronic symptoms presenting with extreme skin 
photosensitivity and resulting skin damage. The porphyrias are classified as either 
‘acute’ or ‘cutaneous’ depending upon the predominant symptoms. The underlying 
mutation of a heme biosynthetic enzyme(s) results in predisposition for these 
disorders but external factors are required for the manifestation of symptoms. These 
external ‘triggers’ include drugs, chemicals, hormones, stress, fasting, and exercise. In 
addition, many porphyria subjects with an underlying enzyme deficiency remain 
asymptomatic and may never experience symptoms; because of this the exact 
biochemical mechanism required to initiate many of these symptoms is unknown. 
Further research into the biochemistry of porphyria is required to expand current 
knowledge of the biochemical pathogenesis of these disorders which is still lacking in 
many areas. 
 
1.1.3 Porphyria – a Brief Historical Context 
Porphyria is possibly most famous for its suggested role in the madness of King 
George III of Great Britain. Medical detectives have hypothesised that he may have 
had variegate porphyria as he suffered from symptoms similar to those of this acute 
porphyria. King George is reported to have had dark reddish urine characteristic of 
porphyria as well as psychiatric disturbances that are often seen in acute forms of 
porphyria. Although it has been suggested otherwise,4 evidence strongly points that 
King George may have suffered from disturbed heme metabolism in the form of 
variegate porphyria. If this is the case, porphyria may have played a role in world 
events at the time. 
! 4!
 
The artist, Vincent van Gogh, has also been suggested to have suffered from altered 
heme metabolism. He suffered from episodes of acute mental derangement and 
disability yet was in apparent good health between episodes. The wide-spread 
popularity of his paintings has aroused interest in his medical problems and the role it 
played in his life as well as his artwork. It has been suggested in a review of his 
symptoms and history that acute intermittent porphyria best describes his medical 
crises.5, 6 Other suggested theories to explain his symptoms include lead poisoning 
and excessive absinthe consumption, both of which are triggering factors of acute 
porphyria.  
 
In addition to these historical examples, porphyria may currently be of more 
contemporary significance than previously appreciated. It has been suggested that 
20% of mankind may have a predisposition to porphyria and many chronic illnesses 
may actually be porphyria in disguise or due to altered heme metabolism.7  
 
1.1.4 Micronutrients – Treatment Potential? 
The porphyrias are a group of metabolic disorders which present with a wide array of 
symptoms the mechanisms of which are not fully understood. The search for safe 
prophylaxis and treatments for these symptoms is an ongoing area of research. There 
have been reports that suggest the underlying mutation of the heme enzyme(s) in 
these disorders may be augmented by micronutrient deficiencies.8-22 There have been 
reports of successful treatment of the porphyrias with high-dose micronutrient 
supplementation,8, 10, 12, 13, 15, 23-55 although this is not widely acknowledged. 
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A better understanding of the underlying mechanisms of the porphyrias as well as 
current treatments is essential in understanding the pathogenesis of porphyria 
symptoms. Investigations into the heme pathway as well as other connected pathways 
that share common substrates and products will further current knowledge of the 
porphyrias as well as the discovery of new treatment regimes.  
 
1.2 Aims and Objectives 
The aim of this thesis is to develop a greater understanding of the porphyrias and 
underlying nutritional issues through: 
 
1. Reviewing literature on the effects of micronutrients in the porphyrias with the aim 
of developing a testable hypothesis that could aid future treatments.  
 
2. Developing a methodology suitable for testing the hypothesis. 
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CHAPTER 2.  THE HEME BIOSYNTHETIC PATHWAY 
2.1 Introduction 
The heme biosynthetic pathway is one of the most important pathways of human 
metabolism. Heme is essential for biologic oxidations and is a prosthetic group in a 
wide variety of vital proteins including hemoglobin, myoglobin, cytochromes, 
catalases, and peroxidases.56 Hemoproteins are responsible for oxidative reactions, 
electron transfer processes and the delivery of molecular oxygen to cells.57 Due to the 
involvement of heme in myriad important cellular processes, altered heme synthesis 
can result in a variety of detrimental effects. The heme biosynthetic pathway is an 
eight-step pathway involving porphyrin and porphyrinogen precursors that is tightly 
regulated by the end product heme (Figure 2.1). Each step of the pathway is catalysed 
by a specific enzyme. Genetic mutations resulting in the diminished activity of one or 
more of the enzymes of this pathway are the underlying factors of the group of 
hereditary metabolic disorders known as the porphyrias (see Chapter 3). The deficient 
enzyme(s) cause a ‘bottleneck’ in the pathway due to up-regulation of the enzymes 
prior to the ‘block’ in an attempt to meet heme demands. This results in elevated 
levels of heme precursors in the steps prior to the enzyme ‘block’. Each porphyria 
results in a unique precursor overproduction pattern depending on where the 
bottleneck in the pathway occurs. The porphyrias will be discussed further in Chapter 
3.  
 
The heme biosynthetic pathway is a complex pathway. A variety of cofactors are 
required for optimal activity of the eight enzymes involved, as well as for formation 
of the initial substrates glycine and succinyl-CoA.58 These cofactor micronutrients 
include vitamin B6, riboflavin, biotin, pantothenic acid, thiamine, and lipoid acid, as 
! 7!
well as the minerals zinc, iron, and copper (Table 2.1).58  In addition, many heme 
proteins that are reliant on this pathway are also required for the activation and/or 
utilization of some micronutrients e.g. vitamin D.59 Due to the heme biosynthetic 
pathway’s dependence on so many micronutrients it is possible that disordered heme 
metabolism may affect the balance of these essential cofactors. Could this also play a 
role in the manifestations of the porphyrias? A thorough understanding of the heme 
biosynthetic pathway will allow a better understanding of the porphyrias. This chapter 
will provide a background of heme synthesis with an emphasis on the cofactors 
involved.    
2.2 Heme Biosynthesis 
2.2.1 Overview 
Heme biosynthesis begins with the formation of aminolevulinate (ALA), the universal 
precursor for all tetrapyrroles. There are two distinct pathways of ALA synthesis. In 
plants, algae, and most bacteria, ALA is produced from glutamate in a three-step 
reaction.60 In eukaryotes, fungi, and an α-subclass of purple bacteria, ALA is 
produced from succinyl coenzyme-A (succinyl-CoA) and glycine.61 This review will 
focus only on the latter pathway, the Shemin pathway, as it is the route that is 
medically significant for humans and the porphyria discussions in future chapters. In 
humans, succinyl-CoA is supplied from the tricarboxylic acid (TCA) cycle and 
glycine is found in the mitochondrial amino acid pool. The pathway begins in the 
mitochondria with the condensation of succinyl-CoA with glycine to produce ALA. 
ALA is then transported to the cytoplasm where two molecules of ALA are 
condensed to form porphobilinogen (PBG). Four molecules of PBG are then 
converted into uroporphyrinogen followed by coproporphyrinogen which is 
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transported back into the mitochondria where decarboxylation and oxidation steps 
result in the conversion of coproporphyrinogen into protoporphyrinogen and then 
finally protoporphyrin (Figure 2.1). The final step involves the insertion of iron 
 
Figure 2.1 Heme Biosynthetic Pathway.   
This figure illustrates the metabolic pathway of heme synthesis with the disorders relating to heme 
enzyme mutations reported to the left of the respective enzyme. Known cofactors are listed below the 
enzyme in red text and possible cofactors/activators are shown in blue text. The red-dashed arrows 
indicate feedback inhibition. PLP, pyridoxal 5’phosphate (vitamin B6); FAD, flavin adenine 
dinucleotide (riboflavin); 2Fe-2S, iron sulfur clustur. 
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into protoporphyrin IX to form heme. Heme can then be utilised into hemoproteins or 
degraded into bilirubin which is excreted as bile pigment.  Porphyrinogens are 
important to cellular processes due to their metal-binding capability; heme is an iron-
containing compound which is usually found bound to proteins involved in biological 
oxidations and oxygen transport. Chlorophylls are the plant version of heme, and are 
magnesium-porphyrin complexes.  Heme provides blood with its red colour while 
chlorophyll is responsible for the green colour of plants. The porphyrinogen 
precursors, uroporphyrinogen and coproporphyrinogen, along with their isomers and 
intermediates, are rapidly oxidised to porphyrins when exposed to air with a net loss 
of six protons. These porphyrins absorb light at 400-410 nm wavelength and emit a 
fluorescent red colour upon exposure to these wavelengths of ultraviolet (UV) light. 
Porphyrins are continuously excreted from the body either through the urine or as bile 
pigment and have no known biological function other than as precursors for heme.58  
It is the porphyrins, rather than the porphyrinogens that accumulate in the porphyrias 
(Chapter 3).  
 
Eight molecules of succinyl-CoA from the TCA cycle62, 63 and eight molecules of 
glycine from the mitochondrial pool of amino acids are required to produce one 
molecule of heme. Therefore the biosynthesis of these two substrates is also 
significant to heme synthesis as the stoichiometry of these substrates has the potential 
to make them rate limiting.  
 
2.2.2 Succinyl-CoA - the TCA Cycle 
Succinyl-CoA is one of the initial building blocks for heme biosynthesis and is 
derived from the TCA cycle (Figure 2.2). Succinyl-CoA provides the main energy 
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source for the heme biosynthetic pathway.64 Eight molecules of succinyl-CoA are 
required to form one molecule of heme, however, not all heme precursors complete 
the pathway to form heme as some are excreted from the body, making the total 
succinyl-CoA requirement per heme molecule greater than eight.58 Succinyl-CoA is 
not only used in heme synthesis but is also required in ATP production and in the 
recycling of TCA cycle intermediates.65 Depletion of succinyl-CoA due to increased 
enzymatic activity in the early steps of the heme biosynthetic pathway in the 
porphyrias could thus reduce succinyl-CoA availability for other reactions. The co-
factor requirements of the TCA cycle are therefore relevant to heme biosynthesis due 
to the latter pathway’s dependence on succinyl-CoA.  
 
Acetyl-CoA is required in the first step of the TCA cycle and is provided through the 
transformation of pyruvate from the glycolysis pathway. This reaction is catalyzed by 
the pyruvate dehydrogenase enzyme complex and requires the nutrient cofactors 
thiamine pyrophosphate (ThPP), CoA, lipoic acid, flavin adenine dinucleotide (FAD), 
and nicotinamide adenine dinucleotide (NAD+). The TCA cycle then begins with the 
formation of citrate from oxaloacetate and acetyl-CoA which is then transformed to 
isocitrate via a two-step process requiring an iron-sulfur cluster cofactor. Isocitrate is 
subsequently oxidatively decarboxylated to α-ketoglutarate via isocitrate 
dehydrogenase which requires NAD+ as a cofactor. The conversion of α-ketoglutarate 
to succinyl-CoA is also an oxidative decarboxylation catalysed by the α-ketoglutarate 
dehydrogenase complex. This enzyme complex is similar to the pyruvate 
dehydrogenase complex in that it also requires ThPP, CoA, lipoic acid, FAD and 
NAD+ as cofactors. Succinyl-CoA can then enter heme biosynthesis and other 
pathways or it can be converted back into oxaloacetate to complete the TCA cycle. 
! 11!
This involves a further four steps beginning with the conversion of succinyl-CoA to 
succinate coupled with ATP release. Succinate is then transformed to fumarate via 
succinate dehydrogenase, an enzyme which is also part of the electron transport chain 
and which requires an iron-sulfur cluster as well as FAD. Fumarate then proceeds to 
L-Malate and finally, via malate dehydrogenase which also utilizes an FAD cofactor 
as well as NAD+,  back to oxaloacetate and the beginning of the TCA cycle. 
Oxaloacetate is also capable of being formed from pyruvate via carboxylase in a 
biotin-dependent reaction. In summary, the following nutrient cofactors are involved 
in the TCA cycle and thus succinyl-CoA synthesis: biotin, thiamine (ThPP), 
pantothenate (CoA), lipoic acid, niacin (NAD+), riboflavin (FAD) and iron-sulfur 
clusters (Figure 2.2). 
 
The TCA cycle is an amphibolic pathway as its intermediates support both anabolic 
and catabolic processes.66 Oxaloacetate, α-ketoglutarate, citrate, and succinyl-CoA, 
TCA cycle intermediates, are important precursors for the biosynthesis of porphyrins 
and heme, amino acids, and fatty acids (Figure 2.2).58 Other than the porphyrins, the 
metabolites of these pathways turn over to provide the TCA cycle with its 
intermediates. Atamna et al.58 provides a convincing argument that porphyrin/heme 
biosynthesis is energy consuming, that the heme biosynthetic pathway puts a high 
demand on the TCA cycle, and that when heme requirements are high the TCA cycle 
may be drained of its intermediates as well as micronutrient cofactors. Atamna et al.58 
also suggest that this might contribute to ageing. Could the disordered heme 
biosynthetic pathway of the porphyrias also drain the TCA cycle of its intermediates 
and result in cofactor depletion?  
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Figure 2.2 The TCA cycle.   
Schematic representation of the TCA cycle with major metabolic pathways represented by boxes. 
Micronutrient cofactors are shown in red at their respective steps. CoA, coenzyme A (pantothenate); 
ThPP, thiamine pyrophosphate (thiamine); 2Fe-2S; iron-sulfur cluster.  
!  
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2.2.3 Glycine Synthesis 
Glycine is the other initial building block requirement of the heme biosynthetic 
pathway in humans. It is also important in carbon metabolism and is involved in many 
anabolic reactions in addition to heme synthesis, including the synthesis of purine 
nucleotides, glutathione, and creatine. Glycine is not essential in the diet as it is 
capable of being biosynthesized in a reversible reaction from the amino acid serine. 
Serine is derived from 3-phosphoglycerate in a two-step reaction requiring an NAD+ 
cofactor67 as well as a pyridoxal 5’phosphate (PLP) cofactor. Glycine formation from 
serine is catalyzed by serine hydroxymethyltransferase which requires both 
tetrahydrofolic acid (THFA) and PLP as cofactors. THFA is the active form of folate 
which can be used in enzymatic reactions and PLP is the active form of vitamin B6. 
Glycine can also be formed from ammonia, carbon dioxide, and THFA via the 
“glycine cleavage system” (Figure 2.3).68  Vitamin B6 deficiency in rats has been 
shown to result in elevated glycine levels69 as Vitamin B6 (PLP) is essential in the 
metabolism of glycine.  
 
 
 
 
 
              Figure 2.3 Glycine Synthesis from Serine.  
 
2.2.4 Aminolevulinate Synthase  
5-Aminolevulinate synthase (ALAS), a homodimer located on the inner 
mitochondrial membrane,70 catalyzes the first and rate-limiting step of the heme 
Glycine SerineCO2 + NH3 serine 
hydroxymethyltransferase"glycine cleavage system"
Proteins From Diet
THF PLP, THF
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biosynthetic pathway through the condensation of succinyl-CoA and glycine to form 
ALA (Figure 2.4). This is a PLP-dependent reaction. ALAS belongs to the α-
oxoamine family of PLP-dependent enzymes.71 Studies suggest this reaction takes 
place through an ordered bi uni kinetic mechanism, with glycine binding before 
succinyl-CoA followed by ALA dissociation after CO2 and CoA release.72  
 
Figure 2.4 Molecular Details of ALAS Reaction. 
 
There are ALAS isoenzymes that are each encoded by separate genes: ALAS1 is the 
general housekeeping form of the enzyme which is ubiquitously expressed and 
regulated by the free heme pool; and ALAS2 is the erythroid-specific form which is 
regulated the iron availability of iron. The heme that is formed in erythrocytes by 
ALAS2 is utilised primarily for the formation of hemoglobin, whereas heme formed 
by ALAS1 is dedicated towards myoglobin in muscle cells, cytochromes P450, 
mitochondrial cytochromes and other hemoproteins in hepatocytes.3 The regulation of 
ALAS1 in the liver is sensitive to fluctuations of intracellular heme levels as this rate-
limiting enzyme needs to respond rapidly to requirements for heme synthesis. ALAS1 
is up-regulated during heme demand, yet when there is sufficient heme, heme inhibits 
ALAS1 synthesis at both transcriptional and translational steps as well as transfer into 
mitochondria.73 In the porphyrias the feedback inhibition of the heme biosynthetic 
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pathway is disrupted due to the ‘bottleneck’ of the pathway. This results in up-
regulation of ALAS1 and the accumulation of porphyrin precursors.  
 
Studies suggest that ALAS-1 transcription is regulated through the proliferator-
activated receptor coactivator 1 (PGC-1),74 a co-activator of nuclear receptors and 
other transcription factors. PGC-1 controls mitochondrial biogenesis and oxidative 
metabolism in many tissues. PGC-1 expression is dampened by insulin and stimulated 
by glucagon. Elevated PGC-1 levels have been found to cause acute attacks in 
induced porphyria in mice.74 This will be discussed further in Section 4.2.1.  
 
Genetic alterations of the ALAS2 gene resulting in under-expression of ALAS2 are 
known to cause X-linked sideroblastic anemia (XLSA) (Section 3.5.1).75, 76  Genetic 
mutations have also been identified that lead to over-expression of ALAS2 activity 
resulting in a completely different disorder, X-linked dominant protoporphyria 
(XLPP) (Section 3.4.1).77-79 A study investigating a different porphyria, congenital 
erythropoietic porphyria (CEP), caused by a mutation at the third enzyme of the 
pathway, suggests that specific mutations on the ALAS2 gene increase the severity of 
this disorder.80 This indicates that ALAS2 gene mutations may increase the severity 
of erythropoietic disorders as well as causing XLSA and XLPP.  
 
2.2.5 Aminolevulinate Dehydratase   
Aminolevulinate dehydratase (ALAD) is a homooctomer which catalyzes the second 
step of the heme biosynthetic pathway with the condensation of two molecules of 
ALA to form PBG (Figure 2.5). Zinc is a required cofactor for enzymatic activity and, 
as ALAD is an eight-subunit enzyme, this enzyme has the potential to bind eight zinc 
ions. However, only four zinc ions are required for optimal activity. 
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Figure 2.5 Molecular Details of ALAD Reaction.  
 
Mutations of the ALAD gene resulting in diminished ALAD activity cause 
ALAD-P (Section 3.2.1), a rare form of porphyria which is characterized by the 
accumulation of ALA. Lead also inhibits this enzyme and can cause lead poisoning 
symptoms of which resemble ALAD-P (Section 3.5.2). Hepatorenal tyrosemia is 
another disorder of heme biosynthesis at this step of the heme biosynthetic pathway 
and presents with accumulation of succinylacetone which inhibits ALAD (Section 
3.5.4).56 
 
2.2.6 Porphobilinogen Deaminase  
Porphobilinogen Deaminase (PBGD) performs the stepwise condensation of four 
molecules of PBG to form hydroxymethylbilane (HMB), a linear tetrapyrrole (Figure 
2.6).56 This enzyme requires a dipyrromethane cofactor and is also known as 
hydroxymethylbilane synthase or uroporphyrinogen I synthase. This enzyme is 
unusual in that its dipyrromethane cofactor is a product of autocatalytic coupling of 
PBG, the substrate of the reaction.81 This cofactor acts as a primer for the addition of 
another four PBG molecules resulting in a linear hexapyrrole. The linear tetrapyrrole 
(HMB) is then cleaved off leaving the dipyrromethane cofactor still bound to the 
enzyme.82  
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There is evidence that suggests that folate may also be involved in this reaction as a 
non-essential activator of PBGD.83 Folate appears to increase the enzyme’s maximum 
rate of reaction without altering its affinity to PBG.83 
 
 Figure 2.6 Molecular Details of PBGD Reaction.  
 
Like ALAS, there are two forms of PBGD; an erythroid-specific enzyme that may 
play a regulatory role in heme synthesis and a hepatic enzyme. There does not appear 
to be any difference in the kinetic parameters of the two isoforms.84 Defects in PBG-
D activity lead to acute intermittent porphyria (AIP), the most common form of acute 
porphyria (Section 3.2.2). 
 
2.2.7 Uroporphyrinogen III Synthase   
Uroporphyrinogen-III synthase (UROS) closes the linear HMB to form the first 
porphyrin ring of the pathway, uroporphyrinogen III (Figure 2.7). This occurs via 
cyclisation of HMB to form the first cyclic intermediate of the pathway, 
uroporphyrinogen III.85, 86 HMB is unstable and never accumulates in vivo. HMB is 
also capable of spontaneous rapid non-enzymatic cyclisation to form 
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uroporphyrinogen I, however, there is an excess of UROS capacity in normal 
physiological conditions, so little of the I isomer forms (Figure 2.8).3 There is 
evidence that folate may affect the UROS reaction87 in addition to PBGD. However, 
additional studies are required to confirm this.  
 
Diminished activity of this UROS leads to CEP, a porphyria characterized by extreme 
acute photosensitivity and mechanical skin fragility symptoms (Section 3.4.2).   
 
 
    
Figure 2.7 Molecular Details of UROS Reaction. !
!
  Figure 2.8 Structure Comparison of Uroporphyrinogen isomers. 
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2.2.8 Uroporphyrinogen Decarboxylase   
Uroporphyrinogen Decarboxylase (UROD) is a cytoplasmic enzyme that forms 
coproporphyrinogen III from uroporphyrinogen III. It is a dimeric enzyme with two 
single-domain subunits.56 This enzyme catalyses the sequential decarboxylation of the 
four acetate substituents of uroporphyrinogen to form coproporphyrinogen. This 
reaction occurs via hepta-, hexa-, and penta-carboxylate intermediate forms (Figure 
2.9) 88 which are normally detected in small amounts in the urine, liver, and plasma.3 
This reaction appears to occur independently of cofactors or metal ions although its 
activity does appear to be enhanced by lipoic acid.89 UROD also metabolises 
uroporphyrinogen I to coproporphyrinogen I, although this metabolite plays no further 
role in the pathway.  
 
Mutations of this UROD may result in porphyria cutanea tarda (PCT) or 
hepatoerythropoietic protoporphyria (HEP) both of which present with characteristic 
symptoms of acute photosensitivity, mechanical skin fragility, and liver damage 
(Section 3.3). PCT is the most common form of porphyria.  
 
2.2.9 Coproporphyrinogen-III Oxidase   
Coproporphyrinogen-III oxidase (CPOX) catalyses the oxidative decarboxylation of 
coproporphyrinogen III to produce protoporphyrinogen IX (Figure 2.10). CPOX is a 
mitochondrial enzyme located in the inter-membrane space. This enzyme contains 
two internally bound Fe2+ ions and requires the presence of molecular oxygen as an 
electron acceptor. Copper ions may also play a role in this step as an essential 
activator90, 91 although other studies suggest otherwise.92 This enzyme does not utilise  
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Figure 2.9 Coproporphyrinogen and Its Intermediates.  
The intermediary forms of coproporphyrinogen synthesis are shown as well as the 
coproporphyringogen I isomer which plays no further role in the heme biosynthetic pathway.  !!
coproporphyrinogen I as a substrate and the I isomer plays no further role in the heme 
biosynthetic pathway. 
 
Diminished enzymatic activity of CPOX results in the acute porphyria, hereditary 
coproporphyria (HCP) (Section 3.2.3). This is a mixed porphyria that can present with 
both the acute symptoms of AIP and the skin symptoms of the cutaneous porphyrias. 
HCP presents with symptoms similar to AIP (mutation at PBGD) due to inhibition of 
the enzyme PBGD by coproporphyrinogen (Figure 2.1).93 
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Figure 2.10 Molecular Details of CPOX Reaction. !
2.2.10 Protoporphyrinogen Oxidase 
Protoporphyrinogen oxidase (PPOX) synthesizes protoporphyrinogen IX from 
protoporphyrin IX in an oxidation reaction (Figure 2.11). This enzyme is a 
homodimer located on the outer surface of the mitochondria membrane and utilises an 
FAD cofactor which transfers electrons from the substrate to the electron acceptor 
oxygen.85, 94, 95  
 
Diminished activity of PPOX results in VP which can present with acute symptoms 
similar to those in AIP due to the negative feedback of the precursors 
protoporphyrinogen and coproporphyrinogen on PBGD, the enzyme deficient in AIP 
(Figure 2.1).93 
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 Figure 2.11 Molecular Details of PPOX Reaction.   
 
2.2.11 Ferrochelatase  
Ferrochelatase (FECH) catalyzes the final step of heme formation, the insertion of the 
ferrous form of iron into protoporphyrin IX to form heme, the end product of the 
pathway (Figure 2.12). FECH requires both iron and copper for activity and utilizes 
an iron-sulfur cluster as a cofactor. Copper stimulates the activity of FECH and 
increases its affinity for iron. It has been suggested that PLP may also act as a 
coenzyme or non-essential activator of FECH96, 97 although this has not been 
confirmed. This enzyme is dimeric with each subunit consisting of similar domains 
and is located in the mitochondrial inner membrane. Diminished activity of this 
enzyme results in the cutaneous porphyria, erythropoietic protoporphyria (EPP) 
(Section 3.4.3).   
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Figure 2.12 Molecular Details of FECH Reaction. !
2.2.12 Heme Protein Utilisation and Degradation 
2.2.12.1 Heme Proteins 
Heme can be utilised to make up a variety of essential enzymes and thus carries out 
many diverse functions through heme-binding proteins.3 These include mitochondrial 
cytochromes that assist the stepwise transport of electrons down electrochemical 
gradients in electron transport and coupled oxidative phosphorylation including: 
cytochrome oxidases, cytochromes P450, tryptophan pyrrolase and deoxygenases. 
Heme is also a constituent of nitric oxide synthase, myeloperoxidase, and thyroid 
peroxidase which are all involved in oxidation reactions, as well as catalase which 
assists the decomposition of hydrogen peroxidase. Heme can also function as a redox 
sensor where it affects the activity of nuclear receptors and other proteins in signaling 
and metabolism. The majority of heme, however, goes to haemoglobin, myoglobin, 
and neuroglobin which transport oxygen to, and carbon dioxide from, tissues.  
 
Synthesis of heme in erythrocytes accounts for 85% of the total daily heme 
production73 and is utilised in hemoglobin for oxygen transport between the lungs and 
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tissues.85 The remaining 15% of daily heme production occurs in the liver and results 
in the formation of heme-based enzymes.  In hepatocytes, 65% of the heme formed is 
utilized in cytochrome P450 enzymes.98 These enzymes are important for the 
detoxification of foreign substances. When cytochrome P450 enzymes are induced, 
ALAS1 is up-regulated to meet heme requirements. This is significant in the 
porphyrias as the up-regulation of ALAS1 can result in over-production of heme 
precursors when there is deficient enzyme activity at one or more of the steps of the 
heme biosynthetic pathway.  Drugs requiring cytochrome P450 detoxification 
pathways are known to aggravate the porphyric state. Of the remaining heme formed 
in hepatocytes, about 15% is utilised for the synthesis of catalase which is localised in 
peroxisomes, about 8% for synthesis of cytochromes b5, and about 6% goes to 
formation of mitochondrial cytochromes.98 
2.2.12.2 Heme Degradation 
Cellular heme levels are tightly regulated through balancing heme biosynthesis and 
catabolism.63 Heme is broken down by heme oxygenase, the first and rate-limiting 
enzyme of heme degradation, into biliverdin. Biliverdin reductase then transforms 
biliviridin into bilirubin which is excreted as a bile pigment. Both of these reactions 
require nicotinamide adenine dinucleotide phosphate (NADPH).99 Biliverdin and 
bilirubin are both antioxidants capable of protecting mammalian tissues and cells 
from oxidative stress. 
 
2.3 Micronutrient Cofactors 
Through a brief summary of heme biosynthesis, it is apparent that the biosynthesis of 
heme involves a variety of micronutrient cofactors including vitamin B6, riboflavin, 
biotin, pantothenic acid, lipoic acid, zinc, iron, and copper (Table 2.1). These essential 
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micronutrients that are involved in heme biosynthesis will be briefly discussed, 
notably their functions as cofactors and the corresponding implications for the 
porphyrias. 
 
2.3.1 B-vitamins and Heme Synthesis 
The physiological interactions between the B vitamins are complex.100 The B-
vitamins are essential to myriad biosynthetic and metabolic pathways. B-vitamin 
deficiencies have been reported to correlate with increased porphyrin production101 
suggesting a connection to the heme biosynthetic pathway and thus the porphyrias. 
The B-vitamins are tightly interconnected through their metabolic pathways and 
altering levels of one B-vitamin will result in changes to the levels of others.100 Some 
of the B vitamin interrelationships and interdependencies are: the reliance of niacin 
(nicotinic acid) formation from tryptophan on the participation of vitamin B6 (PLP) 
as well as riboflavin; riboflavin is required for vitamin B12 synthesis; riboflavin and 
niacin (nicotinic acid) are both required for vitamin B6 synthesis; vitamin B6 
deficiency results in impairment of vitamin B12 absorption;102 biotin deficiency and 
pantothenate deficiency aggravate one another.100 The complex and tightly regulated 
interdependencies between the B-vitamins may play a significant role in the 
porphyrias if the depletion of one B-vitamin contributes to the depletion of other B-
vitamins. This can result in a cascading detrimental metabolic effect.  !  
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Table 2.1 Micronutrients Involved in Heme Biosynthesis Pathways. 
Nutrient Pathway Enzyme 
Thiamine (ThPP) TCA cycle 
 
Pyruvate dehydrogenase complex 
α-Ketoglutarate dehydrogenase complex 
Riboflavin (FAD) 
 
TCA cycle Pyruvate dehydrogenase complex 
α-Ketoglutarate dehydrogenase complex 
Succinyl-CoA synthetase 
Succinate dehydrogenase 
 HBP PPOX 
Niacin (NAD+) TCA cycle Pyruvate dehydrogenase complex 
α-Ketoglutarate dehydrogenase complex 
Isocitrate dehydrogenase 
Malate dehydrogenase 
Pantothenate (CoA) TCA cycle CoA synthetase 
Vitamin B6 (PLP) HBP ALAS, FECH 
 Glycine synthesis Serine hydroxymethyltransferase 
Biotin  TCA cycle Pyruvate carboxylase 
Folate (THFA) Glycine synthesis Serine hydroxymethyltransferase 
“Glycine cleavage system” 
 HBP PBGD, UROS 
Vitamin B12 TCA cycle Methylnalonyl-CoA mutase 
Lipoic Acid TCA cycle Pyruvate dehydrogenase complex 
α-Ketoglutarate dehydrogenase complex 
 HBP UROD 
Iron (Fe2+) TCA cycle  Aconitase 
Succinyl-CoA synthetase 
 HBP CPOX 
FECH 
Copper (Cu+) HBP  FECH 
Zinc (Zn2+) HBP ALAD 
Nutrients known to be involved in heme biosynthetic pathway (HBP) enzymes either directly or 
through the synthesis of the substrates succinyl-CoA (TCA cycle) or glycine (glycine synthesis).  
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2.3.1.1 Thiamine 
Thiamine (vitamin B1) is an essential nutrient in humans and, as previously 
mentioned, is a prosthetic group of ThPP. ThPP acts as a coenzyme for several 
biochemical reactions including that of the pyruvate dehydrogenase complex for 
pyruvate synthesis and the alpha-ketoglutarate dehydrogenase complex for succinyl-
CoA synthesis in the TCA cycle. Serotonin metabolism may be affected by the 
porphyrias (Section 5.3.2) and cerebral serotonin uptake may be disturbed by 
thiamine deficiency103 leading to elevated serotonin levels in some parts of the 
brain.104 Elevated serotonin levels can result in serotonin syndrome105 and the 
symptoms of serotonin syndrome correspond to many of the symptoms of acute 
porphyria.91 This suggests that thiamine deficiency may play a role in the elevated 
serotonin levels seen in the acute porphyrias.  
 
2.3.1.2 Riboflavin 
Riboflavin (vitamin B2) is the water-soluble precursor of two flavin coenzymes, 
flavin mononucleotide and FAD.106 FAD is involved in a variety of important 
metabolic reactions including four enzymatic processes of the TCA cycle as well the 
protoporphyrinogen oxidase reaction of the heme biosynthetic pathway (Figures 2.1 
and 2.2). Riboflavin deficiency leads to increased urinary coproporphyrins that can 
reach pathological levels101 and has been reported in a case of HCP.8 HCP can present 
with skin symptoms (Section 3.2.3). Deficiency of riboflavin affects collagen content 
and crosslinking in the skin of rats impairing wound healing.107, 108 It is known that 
high levels of porphyrin in erythrocytes result in the cutaneous symptoms of 
porphyria. Could riboflavin deficiency also contribute to the pathogenesis of the skin 
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symptoms of the cutaneous porphyrias? Riboflavin deficiency leads to a vitamin B6 
deficiency as well, due to riboflavin’s role in vitamin B6 synthesis.100 
 
2.3.1.3 Niacin  
Niacin (vitamin B3) is another essential nutrient in the human body. Niacin in the 
form of NAD+109 is an essential cofactor involved in the TCA cycle. This important 
coenzyme is found in all living cells and is involved in redox reactions as a hydride 
transfer agent. It can also be synthesized from the amino acid tryptophan in humans 
(Section 5.3.2).109 Niacin deficiency results in pellagra; symptoms of pellagra are 
complex and involve the skin, digestive tract, and nervous system.110 Pellagra patients 
also excrete increased amounts of coproporphyrins in the urine101 suggesting a 
connection to heme biosynthesis malfunction. Deficiency of this micronutrient may 
also play a role in porphyria symptoms. 
 
2.3.1.4 Pantothenate 
Pantothenate (vitamin B5) is also an essential nutrient and is required as a constituent 
of CoA. Synthesis and oxidation of fatty acids rely on CoA111 as do the pyruvate 
dehydrogenase complex and the alpha-ketoglutarate dehydrogenase complex of the 
TCA cycle (Figure 2.2). Pantothenate is connected to porphyrin metabolism through 
succinyl-CoA (Section 2.2.2).112 Excess porphyrins have been found excreted in the 
tears of pantothenate-deficient rats.113 This suggests that pantothenate deficiency may 
result in an altered heme biosynthetic pathway. Further studies would be required to 
investigate this possible connection.  
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2.3.1.5 Vitamin B6 
Vitamin B6 in its active form of PLP is an essential cofactor in over 300 enzymatic 
reactions including many involved either directly or indirectly in heme synthesis. It 
acts as a coenzyme in transamination reactions as well as decarboxylation and 
deamination reactions of amino acids. PLP plays a major role in the heme 
biosynthetic pathway as it is an essential cofactor of the rate-limiting ALAS enzyme 
of heme synthesis (Figure 2.1), mutations of which cause XLSA among other 
disorders. One-third of patients with XLSA are pyridoxine responsive,114, 115 and 
ALAS2 mutations of this disorder are commonly observed in or near the PLP-binding 
site of the ALAS2 enzyme.116 Pyridoxine is a form of vitamin B6 and is converted to 
the active coenzyme PLP. This illustrates the importance of PLP in the ALAS 
reaction.  
 
Vitamin B6 deficiency has been found to stimulate increased iron deposits.117 
Increased iron deposits are commonly found in porphyria and lead to increased 
oxidative damage. Other important PLP reactions are the conversion of tryptophan to 
both niacin and serotonin. Vitamin B6 is also important in the maintenance of Na+ 
and K+ balance118 as well as Ca2+ and Mg2+ balance.119 In addition, vitamin B6 
deficiency is shown to impair vitamin B12 absorption in rats resulting in a secondary 
vitamin B12 deficiency in addition to the primary vitamin B6 deficiency.102 The 
peripheral neuropathy resulting from a vitamin B6 deficiency is similar to that found 
in the porphyrias.120-122  
 !  
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2.3.1.6 Biotin 
Biotin (vitamin B7) plays an important role as a cofactor in the metabolism of 
carbohydrates, lipids, and proteins123 as well as in the regulation of genetic expression 
of mitochondrial carboxylases in rats.124 It is a cofactor for pyruvate carboxylase, 
propionyl-CoA carboxylase, beta-methylcrotonyl-CoA carboxylase and acetyl-CoA 
carboxylase. These biotin-dependent carboxylases are found in the mitochondria 
where they replace intermediates in the TCA cycle that are regularly removed to feed 
other processes.125 In biotin deficient states, methylcrotonyl-CoA accumulates in the 
mitochondria and reacts with glycine, which may lead to glycine depletion. 
Deficiency of biotin may therefore reduce both succinyl-CoA and glycine levels due 
to diminished enzymatic activity of biotin-dependent enzymes. This could affect 
heme biosynthesis as succinyl-CoA and glycine are the initial building blocks of the 
heme biosynthetic pathway. 
 
2.3.1.7 Folate 
Folate (vitamin B9) is an essential cofactor in DNA synthesis and repair as well as 
acting as a cofactor in many other biological reactions. Its biologically active form is 
THFA, which is involved in the metabolism of amino acids as well as nucleic acids. 
Serine hydroxymethyltransferase is a THFA-dependent enzyme that provides a route 
to glycine synthesis through the reversible conversion of serine to glycine (Figure 
2.3). Folate may also act as a non-essential activator of PBGD,83 the enzyme with 
reduced activity in AIP. There is also evidence that folate activates uroporphyrinogen 
III synthetase, the enzyme that has reduced activity in CEP.87 Folate metabolism is 
connected with vitamin B12 metabolism and deficiencies of either of these vitamins 
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can result in severe neurological and psychiatric disturbances.126 Some of these 
symptoms are similar to those found in the porphyrias.  
 
2.3.1.8 Vitamin B12 
Vitamin B12 (cobalamin) is a cofactor in the conversion of homocysteine to 
methionine and the conversion of methylmalonyl-CoA to succinyl-CoA. A vitamin 
B12 deficiency alters levels of other B-vitamins with lowered riboflavin and vitamin 
B6 levels as well as elevated folate levels.127 Levels of all B vitamins returned to 
normal with vitamin B12 supplementation.127 The methylcobalamin form of vitamin 
B12 may also induce increased melatonin production. Melatonin acts as an important 
antioxidant in the porphyrias.128-132 Deficiency of vitamin B12 can have severe 
manifestations126, 133 including peripheral neuropathy, seizures, and paralysis; 
symptoms that can also be found in the acute porphyrias.  
 
2.3.2 Other Micronutrients in Heme Synthesis 
In addition to the B vitamins, the micronutrients lipoic acid, copper, iron and zinc are 
also essential to heme biosynthesis.  
 
2.3.2.1 Lipoic Acid 
Lipoic acid is an important cofactor in a variety of enzyme complexes and is an 
essential cofactor of the TCA cycle. Lipoic acid supplementation has been shown to 
improve cognitive functioning134 and acts as an antioxidant, reversing iron-induced 
oxidative stress.108 UROD activity, deficiency of which causes PCT, has been 
suggested to be enhanced by lipoic acid possibly through activation as a non-essential 
cofactor.89 It is suggested that supplementation with lipoic acid alleviates some of the 
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symptoms of PCT through its free-radical scavenging ability and through directly 
enhancing the activity of uroporphyrinogen decarboxylase.  
 
2.3.2.2 Iron 
Iron-sulfur clusters are cofactors in several enzymes relating to the heme biosynthetic 
pathway including FECH, the final enzyme in the pathway, as well as two reactions 
of the TCA cycle. The formation of iron-sulfur clusters from cysteine desulfurase is a 
PLP-dependent reaction.135 Deficiencies of iron, PLP, sulfides or loss of enzymatic 
activity could result in a failure to produce iron-sulfur clusters.136, 137 Along with 
heme, iron-sulfur clusters are essential for the assembly and optimal activity of 
electron transfer complexes where they act as prosthetic groups. Iron-sulfur clusters 
are involved in reducing oxygen to water which generates the proton gradient across 
the inner mitochondrial membrane for ATP production. ATP production is essential 
for the normal function of every cell and processing of iron into heme and iron-sulfur 
clusters is important for both mitochondria maintenance and ATP production. Lack of 
synthesis of either heme or iron-sulfur clusters can result in massive oxidative damage 
in mitochondria, cells, and tissue.138 Could this play a role in the symptomology of the 
porphyrias?  
 
2.3.2.3 Copper 
Copper is involved in electron transport as well as oxygen transport. Copper has been 
suggested to stimulate both CPOX90 and FECH activity in the heme biosynthetic 
pathway (Table 2.1). Deficiency of copper results in impaired utilization of iron for 
hemoglobin production139 and thus increased dietary iron absorption.140 Deficient 
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FECH activity is the underlying factor in EPP making adequate copper concentrations 
a potential concern in patients with this porphyria.  
 
2.3.2.4 Zinc 
Zinc is an essential trace element that is involved in almost 100 known enzymatic 
reactions.141 Zinc deficiency results in oxidative damage to DNA as well as 
inactivation of zinc-containing proteins.142, 143 It is a required cofactor for the 
conversion of ALA to PBG by ALAD, with four zinc ions needed for optimal 
activity. Zinc deficiency has been suggested to be a factor in some of the symptoms of 
porphyria144 although little supporting data is present. However zinc has been 
reported to successfully treat AIP patients resulting in pain relief.26, 27, 145 This 
suggests that zinc may indeed play a role in the symptomology of the acute 
porphyrias. 
 
2.4 Summary of Chapter 2  
The heme biosynthetic pathway is of paramount importance to understanding the 
porphyrias due to the diminished activity of one or more enzymes of this pathway 
being a fundamental requirement in the manifestation of these disorders. The key to 
understanding the porphyrias lie not only in an understanding of heme biosynthesis 
but also of the many interconnected and related biochemical pathways. The 
biochemical pathways that are impacted by disordered heme metabolism are wide-
reaching and can affect every system of the body. The dependence of the heme 
biosynthetic pathway on a vast array of micronutrients and the complex 
interrelationships and dependencies of these micronutrients on each other highlight 
the biochemical intricacies of heme biosynthesis. A thorough examination of these 
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pathways may lead to an explanation of the biochemical mechanisms underlying the 
symptomology of the porphyrias and offer insights into rational treatments and 
prophylaxis of these disorders.  
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CHAPTER 3. THE PORPHYRIAS 
3.1 Background 
The porphyrias are a group of inherited metabolic disorders involving diminished 
activity of one or more of the enzymes of the heme biosynthetic pathway (Figure 2.1). 
As previously described, this diminished enzyme activity results in a hyper-metabolic 
state prior to the partial block(s) caused by the diminished enzyme activity(ies). This 
‘bottleneck’ in the heme pathway results in excess accumulation of precursors before 
the affected enzyme and abnormal biochemical precursor patterns. Each porphyria 
presents with a unique precursor accumulation pattern (Table 3.1) depending on 
where the ‘bottleneck’ in the pathway occurs. The increased activity of the heme 
biosynthetic pathway is due to up-regulation of the initial rate-controlling enzyme, 
ALAS, as the pathway continues to attempt to meet the demand for heme.  
 
The porphyrias are generally classified in one of two ways: (1) as hepatic or 
erythropoetic depending on the main site of precursor accumulation, or (2) as acute or 
cutaneous depending on the predominant symptoms (Table 3.1).  
 
The acute porphyrias are characterized by acute neurovisceral attacks and can present 
with a wide variety of symptoms leading acute porphyria to have been termed the 
“little imitator”.146 Acute attacks can be triggered by a number of factors including 
drugs, chemicals, hormones, fasting, sun exposure, infections and exercise. Some of 
the symptoms that can present in acute porphyria include abdominal pain, autonomic 
instability, and mental disturbances. Between 70-90% of the carriers of a genetic 
mutation associated with an acute porphyria remain latent or asymptomatic and may 
never present with symptoms.147, 148 For the discussions in the following chapters the 
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term ‘porphyria’ and any of the specific porphyria abbreviations will assume the 
symptomatic form of the disorder and ‘latent’ will be used to refer to the 
asymptomatic form. The acute porphyrias include AIP (acute intermittent porphyria), 
VP (variegate porphyria), HCP (hereditary coproporphyria), and ALAD-P 
(aminolevulinate dehydratase deficiency porphyria). VP and HCP can present with 
cutaneous symptoms as well as acute symptoms (Table 3.1) and have been referred to 
as mixed porphyrias as a result.  
 
The cutaneous porphyrias are characterized by varying degrees of photosensitivity 
with resulting skin damage and include PCT (porphyria cutanea tarda), HEP 
(hepatoerythropoietic porphyria), EPP (erythropoietic protoporphyria), CEP 
(congenital erythropoietic porphyria), and the recently described XDPP (X-linked 
dominant erythropoietic protoporphyria). Other disorders involving abnormalities of 
the heme pathway include XLSA (X-linked sideroblastic anemia), iron deficiency 
anemia, tyrosemia, and lead poisoning. 
 
 Most of the acute porphyrias are inherited in an autosomal dominant pattern although 
the rare ALAD-P is inherited in a recessive pattern (Table 3.1). There are reports of 
cases of the common acute porphyrias being inherited in different patterns as well, 
e.g. a case of VP inherited in an autosomal recessive pattern.149 The majority of the 
cutaneous porphyrias are inherited in an autosomal recessive fashion (Table 3.1). 
There have also been reports of two types of porphyria in one family,150-152 as well as 
two types of porphyria in one patient (dual porphyria).152-155 The latter is usually a 
combination of AIP and VP (Chester Porphyria) or a combination of PCT and VP. 
Other reported dual porphyrias include deficiencies of both CPOX and ALAD activity 
in one patient156 and the co-existence of HCP and PCT in another.157 
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3.2 The Acute Hepatic Porphyria’s 
There are six hepatic porphyrias: AIP, VP, HCP, ALAD-P, PCT, and HEP. Of these 
only four are considered acute: AIP, VP, HCP, and ALAD-P (Table 3.1). The “acute 
attack” characteristic of the acute porphyrias usually manifests with severe pain that is 
most often abdominal (although sometimes peripheral) along with central nervous 
system (CNS) dysfunction. As mentioned above, the genetic defect in these 
porphyrias is necessary but not sufficient to cause acute attacks as most patients with 
the mutation remain latent and may never experience an attack.147, 148 An external 
factor is required to trigger the symptoms including but not limited to drugs and 
chemicals that induce cytochrome P450 enzymes, enzymes which require a heme 
prosthetic group,158, 159 surgery, stress, alcohol consumption, smoking, fasting, 
exercise, and hormonal changes.  
 
As mentioned earlier, an external factor as well as the inherited enzyme deficiency is 
necessary to cause an acute attack. Anderson suggested that 90% of those with an 
inherited mutation may never experience an acute attack.160 The external precipitating 
factors are thought to put strain on the heme pathway through induction of heme-
containing enzymes and hepatic ALAS1. Cytochrome P450-inducing drugs and 
chemicals are arguably the most common contributing factors that trigger an acute 
attack. Many drugs are metabolized and detoxified through cytochrome P450 
enzymes which contain a heme prosthetic group. Therefore, when exposed to a drug 
that is metabolized via the cytochrome P450 pathways, heme demands are increased 
resulting in ALAS1 induction at the beginning of the heme biosynthetic pathway. 
This activity at the beginning of the heme biosynthetic pathway is exaggerated due to 
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a partial block of the heme pathway at PBGD resulting in the elevated precursors.161, 
162 
 
Endocrine factors can also trigger an acute attack; AIP is more common in women 
than men and usually presents after puberty. Some women experience premenstrual 
porphyrinogenic symptoms every month and acute attacks are less common after 
menopause. Oral contraceptives and other exogenous steroids can trigger acute 
attacks. Pregnancy has also been reported to provoke porphyria,163 although 
pregnancy appears well tolerated in a review of pregnancies in acute porphyria 
patients.164 Kauppanin and Mustajoki164 conducted a study including 76 women with 
AIP and VP and 176 pregnancies. 92% of these patients reported no porphyria 
symptoms during pregnancy. If pregnancy does not usually trigger severe attacks,3 
could this be due to avoidance of harmful drugs and optimised nutritional status 
during pregnancy?164 Diet and nutritional status are important contributors to 
porphyria, but they are not well studied as accurate dietary histories are often difficult 
to obtain. However, low carbohydrate diets and fasting are known to trigger acute 
attacks, and glucose is a common treatment of acute attacks through suppression of 
ALAS1  (see Chapter 4).165 Optimal micronutrient status is also likely to play an 
important role in the porphyrias due to the reliance of heme biosynthesis on so many 
micronutrient cofactors (Table 2.1).  
 
Characteristic of the acute hepatic porphyrias is increased excretion of the porphyrin 
precursors ALA and PBG due to diminished activity of ALAD or PBGD. In AIP this 
occurs genetically through mutations of PBGD and in VP and HCP through inhibition 
of PBGD by the accumulation of protoporphyrinogen and/or coproporphyrinogen 
(Figure 2.1).93 In ALAD-P it is decreased activity of ALAD rather than PBGD that 
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causes the altered heme metabolism resulting in ALA buildup with normal PBG 
levels (Table 3.1). The pathophysiology of the acute attack is not fully understood and 
will be discussed in Chapter 5. Suggested mechanisms include accumulation of 
neurotoxic porphyrin precursors (e.g. ALA), deficiency of heme leading to altered 
metabolism in heme-dependent pathways, and depletion of essential cofactors and 
substrates (e.g. PLP, folate, zinc).73 Management of the acute porphyrias will be 
discussed in Chapter 4.  
 The!manifestations!of!the!acute!symptoms!of!the!different!acute!porphyrias!are!similar!in!presentation!although AIP tends to be the most severe.  
 
3.2.1 ALAD Deficiency Porphyria (ALAD-P) 
ALAD-P is a very rare porphyria, with less than 10 cases reported worldwide. ALAD-
P is characterized by depressed ALAD activity (>90%) and can manifest with 
homozygous167, 168 and compound heterozygous cases. Lead depresses ALAD activity 
and lead poisoning presents with the same symptoms as ALAD-P. Unlike the other 
acute hepatic porphyrias which have been successfully reversed with liver transplants, 
as will be described in Section 4.4, a case of a liver transplant in ALAD-P resulted in 
persisting acute symptoms suggesting this porphyria may originate in other tissues in 
addition to hepatocytes.169 Clinically ALAD-P mimics AIP (discussed below), 
however, it results in increased ALA and coproporphyrin levels in the urine but with 
normal PBG levels (Table 3.1). As ALAD-P is rare with only a few  
!! ! ! ! ! !
Table 3.1 Classification and Precursor Patterns of the Porphyrias. 
 
Table based from Balwani et al. 2012.166 The top highlighted band reports the acute hepatic porphyrias, the middle band reports the chronic hepatic porphyrias and the 
bottom band reports the cutaneous erythropoietic porphyrias.  NV; neurovisceral, CP; cutaneous photosensitivity, AR; autosomal recessive, AD; autosomal dominant, XL; 
X-linked.  
Porphyria Deficient enzyme Inheritance Pattern 
Major 
symptoms 
Enzyme activity 
% of normal Erythrocytes Urine Stool 
ALAD-P ALAD AR NV ~ 5 Zn-protoporphyrin ALA, coproporphyrin III — 
AIP HMBS AD NV ~ 50 --- ALA, PBG, uroporphyrin — 
HCP CPOX AR NV + CP ~ 50 — ALA, PBG coproporphyrin III 
coproporphyrin III 
 
VP PPOX AD NV + CP ~ 50 — ALA, PBG, coproporphyrin III 
coproporphyrin III, 
protoporphyrin 
PCT UROD AD CP < 20 uroporphyrin 7-carboxylate porphyrin 
uroporphyrin 
7-carboxylate- 
porphyrin 
isocoproporphyrin 
HCP UROD AR CP < 10 Zn-protoporphyrin 
uroporphyrin 
7-carboxylate- 
porphyrin 
coproporphyrin 
CEP UROS AR CP ~ 1 - 5 uroporphyrin coproporphyrin 1 
uroporphyrin I 
coproporphyrin I coproporphyrin I 
EPP FECH AR CP ~ 20-30 free protoporphyrin — protoporphyrin 
XLP ALAS2 XL CP > 100 Zn-protoporphyrin — protoporphyrin 
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confirmed cases worldwide, severity and age of onset as well as biochemical 
mechanisms and treatment have not been well studied. 
 
3.2.2 Acute Intermittent Porphyria (AIP) 
Genetic mutations resulting in diminished PBG-D activity lead to AIP, the most 
common as well as most severe form of acute porphyria. Those with this genetic 
defect generally experience good health but are at risk of developing an acute attack. 
These attacks be life threatening and can vary in duration from several days up to 
several months.  
 
It is the effects on the nervous system that appear to lead to most of the clinical 
features of AIP. Symptoms of AIP are non-specific and highly variable making AIP 
easily confused with other diseases including appendicitis, pancreatis, and gallstones. 
This porphyria has been termed the ‘little imitator’ due to its ability to mimic and be 
easily misdiagnosed as many other diseases. Acute attacks of AIP can present with 
any one or a combination neurovisceral dysfunction characterized by the classic triad 
of symptoms: excruciating abdominal pain; peripheral neuropathy and psychiatric 
disturbances. Symptoms can include weakness, paraesthesiae, numbness, 
constipation, nausea, vomiting, tachycardia, hypertension, seizures, fever, anxiety, 
and psychosis.73, 170 Seizures can be challenging to treat as the most common anti-
epileptics are porphyrinogenic; exacerbating an acute attack. Mortality of AIP was 
three times that of the general population according to a study in 1996,171 and death is 
usually the result of respiratory paralysis from trunk muscle weakness.172 Porphyria is 
most dangerous when undiagnosed as porphyrinogenic drugs can be inadvertently 
prescribed resulting in worsening symptoms or death.  
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AIP is inherited in an autosomal dominant pattern with the onset of symptoms usually 
after puberty. Initial diagnosis is through urinary ALA and PBG levels. AIP patients 
present with elevated ALA and PBG levels in the urine but with normal erythrocyte 
and fecal porphyrins (Table 3.1), ALA and PBG levels are elevated further during 
acute attacks. Urine is often recorded as pink, brown, dark red, and even black with 
exposure to air and light.3, 173, 174 This is interesting as ALA and PBG, the elevated 
precursors in this disorder, are colourless.  However, PBG can be non-enzymatically 
converted into uroporphyrin and as a result uroporphyrin and coproporphyrin levels 
are often elevated in the urine of AIP patients as well, with uroporphyrin 
predominant.3 These porphyrins emit a fluorescent red colour when exposed to light. 
In addition, dypyrromethane, a degradation product of PBG as well as the cofactor of 
PBGD, is a brown colour.160 Thus it may be a combination of porphyrins and 
dipyrromethane that results in the brownish-red ‘Coca-Cola’ colour of urine in AIP 
patients.160 
 
Although initial diagnosis is through heme precursor levels in urine, diagnosis can 
also be confirmed by determination of PBGD activity levels in erythrocytes.  PBGD 
activity is normally reduced in both acute and latent forms of AIP to about 50% of 
normal activity.172 However, there is an overlap of activity levels between porphyria 
and normal patients so the disorder cannot always be exclusively diagnosed through 
determination of PBGD activity. DNA analysis is by far the most definitive diagnostic 
tool but with more than 100 reported mutations of PBGD in AIP it is also very 
complicated.3, 161 
 
! 43!
3.2.3 Hereditary Coproporphyria (HCP) 
HCP combines the clinical features of the acute and cutaneous porphyrias. It presents 
with approximately 50% diminished activity of CPOX leading to overproduction of 
coproporphyrinogen which inhibits PBGD activity (Figure 2.1).93 Acute symptoms 
are similar to AIP although this porphyria is less severe. Onset of acute symptoms 
usually occur after puberty which is characteristic of the acute porphyrias due to 
increased hormone levels. Levels of ALA exceed PBG, and HCP presents with 
elevated coproporphyrin levels in stool as well as mildly elevated levels in urine. 
ALA and PBG levels return to normal more easily between attacks than in AIP. 
Cutaneous symptoms manifest as vesculo-bullous dermatitis on sun-exposed skin; 
usually the face and hands. Skin lesions often heal with changes in pigmentation and 
scarring.  
 
3.2.4 Variegate Porphyria (VP) 
The enzyme affected by a genetic defect in VP is PPOX, which is present at 
approximately 50% of normal enzyme activity. This disorder is most highly prevalent 
in South Africa due to a founder affect with up to 3/1,000 of the population with the 
genetic defect. VP presents with increased levels of ALA, PBG, coproporphyrins and 
protoporphyrins. Protoporphyrin is the major accumulated and excreted porphyrin. As 
is the case in HCP, coproporphyrinogens and protoporphyrinogens that accumulate in 
VP inhibit PBGD activity93 and, as a result, the acute symptoms of VP also mimic 
those seen in AIP. As with AIP and HCP, acute symptoms generally do not develop 
till after puberty. In addition to acute attacks, VP also presents with cutaneous 
symptoms similar to HCP although more common and severe. Photosensitivity and 
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dermatitis often develop at an early age with ulcers forming after minimal trauma to 
light exposed skin that often result in scarring. 
 
Initial diagnosis is conventionally through fecal porphyrin levels, although diagnosis 
can also be through porphyrin levels in the urine and plasma. DNA analysis is the best 
diagnosis method as excretion of precursors are often normal between acute attacks, 
unlike AIP.  
 
VP has been associated clinically with George III of Britain as well as related royalty 
and thus may have influenced world events although this claim is controversial4, 175 
and the royal family denies it.  
 
3.3 The Cutaneous Hepatic Porphyrias 
The hepatic porphyrias can be described as  “acute” or “chronic”. The acute hepatic 
porphyrias include ALAD-P, AIP, HCP, and VP (discussed above). The chronic 
hepatic porphyrias, or hepatic cutaneous porphyrias, do not present with acute 
neurovisceral symptoms and include PCT and HEP which are due to partial (~50%) 
or near total (>90%) deficiency of UROD respectively. PCT is the more mild of the 
two and occurs mainly in adult men with underlying liver disease and iron overload. 
Severe UROD deficiency results in HEP which manifests in childhood or infancy and 
continues lifelong with more severe skin symptoms then found in PCT.  
 
3.3.1 Porphyria Cutanea Tarda (PCT) 
PCT is the most common form of porphyria. There are three different types of 
PCT.176  Type I (70-80% of cases) is sporadic without familial history and presents 
with normal erythrocyte UROD activity but decreased hepatic UROD activity. Type 
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II PCT (~20% of cases) is familial, inherited in an autosomal dominant pattern, and 
characterized by decreased UROD activity in both red cells and in the liver. Type III 
PCT (>5% of cases) is also familial, however, erythrocyte UROD activity is normal 
and this form is solely due to decreased UROD in hepatocytes.  In addition to the 
inherited defect in type II and type III, additional acquired factors are still essential for 
development of the disorder and those with partial (heterozygous) hereditary defects 
often remain asymptomatic. Multiple factors are known to have an influence and 
effect on UROD activity in this disorder and include hepatis C infection, estrogen, 
human immunodeficiency virus (HIV), and increased hepatic iron content. 
 
Chile has the highest frequency of familial PCT with 50% of patients having Type II 
PCT.177 In comparison, a study of 152 PCT patients in Barcelona, Spain showed 25 
with familial PCT (16.4%) while the remaining 127 PCT patients (83.6%) were 
classified as having sporadic PCT.178 
 
UROD activity is decreased to 50% of normal enzyme activity in the different types 
of PCT. In the acquired form, enzyme activity is reduced in the liver alone and is 
potentially reversible. In the inherited form, type II, activity is reduced in peripheral 
red blood cells in addition to the liver and the enzymatic defect lasts lifelong. UROD 
catalyses the decarboxylation of both the isomer I and the isomer III series of 
uroporphyrinogens (Figure 2.8). UROD carries out decarboxylation of the isomer I 
series which is not metabolised beyond coproporphyrinogen I at a slower rate than the 
isomer III series which is a precursor to heme. Uroporphyrins and hepta-
carboxylporphyrins accumulate in the liver and both of these porphyrins can be 
detected in the plasma, urine and stool (Table 3.1).  
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The main clinical features of PCT are acute photosensitivity, mechanical skin 
fragility, and liver damage. The hepatic abnormalities of this disease do not result in 
acute attacks. The cutaneous symptoms are a result of interactions between UV 
radiation from the sun and high amounts of circulating porphyrins which originate 
from the liver and accumulate in the skin.179 The skin symptoms can manifest as 
blisters, bullae, vesicles, and sores that occur on UV light-exposed areas; most often 
the face, hands, forearms and legs. These symptoms are not the result of acute 
photosensitivity but are rather the result of mild trauma to sun-exposed skin. The 
fluid-filled vesicles that form rupture easily and often heal slowly, becoming crusted 
and resulting in scarring. The skin lesions of PCT are identical to those in the acute 
hepatic ‘mixed’ porphyrias HCP and VP. The liver disease resulting from this 
porphyria is often associated with alcohol abuse, alcoholic liver disease, iron loading, 
and cigarette smoking. A review of 132 PCT patients in Italy reports that 66% of 
these patients were alcohol abusers at the onset of PCT.180 In the acquired form of this 
porphyria, alcohol is the major precipitating agent with excessive intake in more than 
90% of acquired PCT patients.181 Factors leading to oxidative stress in the liver are 
thought to increase oxidation of uroporphyrinogen either to its corresponding 
porphyrin or to other intermediates which inhibit UROD activity. Uroporphyrin levels 
are greater than coproporphyrin levels in PCT compared to levels found in HCP and 
VP.  
 
3.3.2 Hepatoerythropoietic Porphyria (HEP) 
HEP is an uncommon inherited cutaneous porphyria that is related to type II PCT and 
results in a very severe (>90%) deficiency of UROD in both erythrocytes as well as 
hepatocytes.182 It presents in infancy with severe photosensitivity with the formation 
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of blisters and vesicles similar to those in CEP (Section 3.4.2). This porphyria 
presents with lifelong massive overproduction, accumulation, and urinary excretion of 
uroporphyrins and heptacarboxyl porphyrins (Table 3.1). Accumulation of zinc-
protoporphyrin is also found in erythrocytes distinguishing it clinically from PCT and 
CEP. Because the defect of this porphyria occurs in all tissues, a bone marrow 
transplant or a liver transplants on their own is not curative.183  
 
3.4 The Cutaneous Erythropoietic Porphyrias 
The cutaneous erythropoietic porphyrias include CEP, EPP and the recently described 
XLPP. The cutaneous erythropoietic porphyrias are characterised by excess excretion 
of porphyrins rather than the heme precursors ALA and PBG. The predominant 
symptom is extreme photosensitivity with resulting skin damage. This can present as 
lesions with skin fragility, sub-epidermal bullae, hypertrichosis, hyper- and hypo-
pigmentation. As mentioned previously, porphyrins absorb light at a wavelength of 
400-410 nm, and interactions between high levels of circulating porphyrins and light 
result in porphyrin-induced photosensitivity.179, 184 For control of skin symptoms, 
protective clothing and opaque sunscreens are recommended. Normal sunscreens are 
not beneficial as they do not screen out solar radiation of 400-410 nm.185 
 
3.4.1 X-linked Protoporphyria (XLPP) 
This is a rare porphyria due to a gain of function mutation of the erythroid-specific 
ALAS2 gene leading to over-expression of ALAS2 activity.77-79, 79 The over-activity 
of ALAS2 in XLPP leads to an accumulation of protoporphyrin IX in erythrocytes as 
well as other tissues resulting in photosensitivity and liver disease. As there is more 
protoporphyrin production than heme requirement, FECH, the enzyme that converts 
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protoporphyrin IX into heme through the insertion of iron, uses zinc as an alternative 
substrate resulting in zinc-protoporphyrin accumulation in the erythrocytes.79 The 
symptoms of this porphyria are indistinguishable from the cutaneous photosensitivity 
of EPP, the porphyria resulting from impaired FECH activity (Section 3.4.3).  
 
3.4.2 Congenital Erythropoietic Porphyria (CEP) 
CEP is a rare porphyria due to diminished activity of UROS.186, 187 The diminished 
activity (<10%) of UROS results in accumulation of hydroxymethylbilane which is 
then non-enzymatically converted to uroporphyrin I. As uroporphyrin I plays no 
further role in the heme pathway (Figure 2.1), levels of uroporphyrin I as well as 
coproporphyrin I isomers are elevated. Thus this porphyria presents with gross 
overproduction of uroporphyrin I as well as other porphyrin I isomers. Porphyrins 
accumulate in the normoblasts of bone marrow and are excreted into the urine and 
feces. Porphyrins deposited in bone and teeth result in pink-brown discolouration, 
which fluoresces bright red at 400 nm.  
 
This porphyria manifests from birth with photosensitivity and variable clinical 
presentations including formation of vesicles and bullae, which often results in facial 
scarring, hirsutism, and fluorescent teeth (erythrodontia).3 Severe cases of recurrent 
vesicles and infection can lead to scarring and deformities including loss of digits and 
facial features including the eyelids, nose, and ears. Changes in bone structure are 
also often seen in CEP and are thought to be due to vitamin D deficiency as light 
avoidance is a necessity in this porphyria188, 189 although bone changes may also be 
due to porphyrin deposits.190 
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3.4.3 Erythropoietic Protoporphyria (EPP) 
EPP is more common than CEP and is a result of reduced FECH (15-25%) activity. 
This is also a chronic cutaneous porphyria and presents in early childhood with pain, 
burning, and swelling of skin with sun exposure as well as exposure to other UV 
lights. This usually occurs after only brief exposure and can develop within 
minutes.191 With continuous exposure, erythema, edema, and itching become worse191 
and symptoms are described as an unbearable burning sensation of sun exposed skin. 
Burning and itching can occur without any skin damage. Vesicles are uncommon in 
this porphyria although the skin of patients with chronic, repeated sun exposure often 
becomes leathery. Increased skin fragility and deformed facial features and digits are 
not characteristic of this porphyria; teeth do not fluoresce and neurovisceral 
symptoms do not occur. Patients can, however, develop liver disease due to high 
levels of free protoporphyrins leading to organ damage. 
 
Protoporphyrins are increased without high levels of coproporphyrins in the plasma, 
red cells, and sometimes stool of EPP patients. Urinary porphyrins are normal as 
protoporphyrins are not excreted in the urine. Lipid-soluble protoporphyrins deposited 
in dermal blood vessels are photo-activated with sun exposure leading to the 
characteristic skin changes seen in this porphyria. It is photo-activation of the water-
soluble uroporphyrins, on the other hand, that lead to the chronic blistering seen in 
CEP and PCT.  
3.5 Other Disorders Involving Heme Biosynthesis 
In addition to the porphyrias discussed above, X-linked sideroblastic anemia, iron 
deficiency anemia, lead poisoning and tyrosemia are also the result of altered heme 
metabolism.  
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3.5.1 X-Linked Sideroblastic Anemia (XLSA) 
XLSA is a result of reduced ALAS activity. This is a recessive disorder and results in 
iron accumulation due to lack of protoporphyrin IX synthesis.75, 76, 192, 193 The excess 
iron in bone marrow is deposited in the erythroblast mitochondria clustered around 
nuclei as non-ferritin iron; hence the descriptive term ‘ringed sideroblasts’. Iron 
overload resulting from increased iron delivery to the tissues eventually leads to 
secondary hemochromatosis which may result in diabetes, liver and heart failure 
without treatment.194, 195 This disease is typically pyridoxine-responsive114, 115 as 
pyridoxal-5-phosphate is an essential cofactor of ALAS and helps restore ALAS 
activity. 
 
3.5.2 Iron deficiency anemia  
Iron deficiency anemia, as its name suggests, is a result of iron deficiency usually 
from the diet. As iron is essential for the final step of heme formation, as iron 
deficiency results in a heme deficiency and reduced capacity to transport oxygen to 
and from tissues. Mild iron deficiency anemia is common in menstruating women and 
is often associated with vegetarian diets. In severe cases of iron deficiency, 
erythrocyte protoporphyrin elevations are elevated as FECH requires iron to complex 
with protoporphyrin to form heme (Figure 2.1). These elevated protoporphyrin levels 
rarely reach those seen in EPP and protoporphyrin is usually found complexed with 
zinc instead.196 
3.5.3 Lead poisoning  
Lead is an inhibitor of ALAD and the symptoms of lead poisoning resemble those of 
the acute porphyrias.197 Like ALAD-P, ALA is elevated without PBG elevation. If 
treated early this acquired ‘acute porphyria’ is reversible. Removing exposure to lead 
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as well as lead removal from the body through chelating agents can help reverse the 
symptoms. It has been suggested that ancient Romans may have been exposed to high 
levels of lead in their tap water. If this is the case, this ‘acquired porphyria’ may have 
influenced world events.  
 
3.5.4 Hepatorenal tyrosemia 
Hepatorenal tyrosemia is a result of deficiency of fumarylacetoacetate hydrolase, an 
enzyme of the degradation pathway of the amino acid tyrosine. Deficiency of this 
enzyme results in a buildup of succinylacetone which has an inhibitory effect on 
ALAD.198 Inhibition of this enzyme can result in an altered heme metabolism similar 
to that of ALAD-P and lead poisoning.56 
 
3.6 Summary of Chapter 3 
Disruption of heme biosynthesis can result in a variety of disorders of metabolism, 
mainly the porphyrias. Porphyria, in severe cases, can present with poor quality of life 
and occasionally fatalities. The incidence of the porphyrias may be underestimated,7, 
199 which can be dangerous. If unrecognized or misdiagnosed, a porphyria patient may 
be prescribed porphyrinogenic drugs which will only aggravate symptoms and can 
potentially be life-threatening. Further investigations into the heme biosynthetic  
pathway will result in a better understanding of these disorders and their complex 
biochemistry.   
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CHAPTER 4.  TREATMENT OF THE PORPHYRIAS 
4.1 The Search for a Prophylaxis – Background 
The search for safe and effective treatment of the porphyrias is an ongoing area of 
research. Successful treatments provide insight into the biochemistry and the 
pathophysiology of the porphyrias; the amelioration of the disordered biochemistry 
gives clues as to what is disordered in the underlying biochemistry. As the porphyrias 
are genetic disorders resulting from mutations of enzymes, treatment and control of 
symptoms are more likely to be established than a cure. Most patients with a mutation 
of an enzyme in the heme biosynthetic pathway remain asymptomatic with a slight 
increase in heme precursor levels and normal levels of heme. Many drugs and 
chemicals as well as fasting, hormones, stress and exercise are known triggers of 
acute porphyric attacks. Tolerance of some triggering factors may vary from 
porphyria to porphyria and sometimes from patient to patient. The most commonly 
recommended and important method for control of porphyria symptoms is avoidance 
of the triggering factors that are known to precipitate symptoms. This requires early 
diagnosis and education of both doctors and patients regarding porphyria and its 
triggers, especially in relation to drugs that induce cytochromes P450 and thus 
precipitate acute attacks. There are currently many readily available safe and unsafe 
drug lists for use in the porphyrias.200 
Avoidance of triggering factors is the first line of defense in the acute hepatic 
porphyrias. However, treatment is required once a patient is in an acute attack as the 
symptoms can lead to respiratory paralysis and death. The major target of treatment of 
the acute porphyrias is repression of ALAS1, the rate-limiting enzyme of the hepatic 
heme biosynthetic pathway, and thus reduction of ALA and PBG accumulation, see 
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Figure 2.1. Traditionally the acute attack has been and is treated with glucose which 
represses ALAS1 activity165 although heme arginate now appears to be the preferred 
method of treatment which also represses ALAS1 activity through feedback inhibition 
(Figure 2.1).201 Severe cases of acute porphyrias have been treated with liver 
transplants which in most acute porphyria cases reverses the porphyria202-207 
highlighting the connection of these porphyrias to the liver. Alternatively there is a 
long history of the porphyrias being treated with micronutrients, especially B vitamins 
(Table 4.3). However, this method of treatment is geographically localized and does 
not appear to be popular in the current literature and is rarely mentioned in current 
reviews. In Argentina, the acute porphyrias have been successfully treated with folate 
in addition to vitamin B-complex and glucose syrup for over 30 years,24 yet papers 
recording this are published in Spanish and thus are not readily available to the 
English-speaking world. As discussed in Section 2.3, micronutrients play a major role 
in heme synthesis (Table 2.1). Is dismissal of porphyria treatment with micronutrients 
in the current literature justified? This chapter will review reports of micronutrient 
therapy as well as the other previously discussed treatments of porphyria. 
 
4.2 Treatment with Glucose 
One of the recommended approaches for treatment and prevention of acute porphyria 
attacks is a high carbohydrate diet or intravenous glucose therapy. Acute attacks can 
be triggered through fasting or low calorie diets165 and, prior to heme arginate 
availability (Section 4.3), carbohydrate loading was the standard treatment.201 The 
beneficial effect on the porphyrias attributed to carbohydrates has been termed the 
‘glucose effect’.165 The underlying mechanism of the ‘glucose effect’ is through 
suppression of ALAS1 expression by glucose. This slows down the overproduction of 
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the precursors ALA and PBG and has been reported to alleviate symptoms.165, 208-211 
Glucose does not, however, correct the altered heme biosynthesis in the acute 
porphyrias as it is deficient activity of enzyme(s) further down the pathway that result 
in the majority of these disorders. Effects of glucose therapy are not consistent and 
vary from improvement to no improvement.212  
 
Increased carbohydrate intake through the diet including glucose-containing drinks 
and high energy foods are beneficial only in prophylaxis of mild attacks. Here we will 
focus mainly on intravenous glucose therapy. 
 
4.2.1 Glucose Therapy 
Glucose is the primary metabolic energy source in humans and plays a key role in 
ATP and NADPH generation via glycolysis and the TCA cycle, thus maintaining 
positive energy balance in the cell which is important for healthy cell growth and 
function. Blood glucose levels are maintained by the balance between glucose uptake 
by peripheral tissue and glucose secretion by the liver. The hormone insulin facilitates 
uptake of glucose from the blood into the cells where it is utilised for essential growth 
and energy requirements. When mammals fast, glucose homeostasis is achieved by 
triggering expression of gluconeogenic genes in response to glucagon and 
glucocorticoids. The pathways act synergistically to induce gluconeogenesis (glucose 
synthesis). Insulin controls hepatic glucose output by counteracting the actions of 
glucagon and catecholamines in the liver. In summary, glucagon raises the blood 
glucose during fasting whereas insulin lowers blood glucose during feeding.  
 
As mentioned before, the beneficial effect glucose has on the porphyrias appears to be 
due to repression of ALAS activity,208 although the mechanism by which this occurs 
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is not fully understood. Regulation of ALAS expression during fasting and feeding 
also appears to be mediated by the counter-regulatory hormones insulin and 
glucagon.213, 214 Insulin has been found to indirectly inhibit ALAS gene expression213, 
215, 216 with insulin treatment of primary mouse hepatocytes resulting in reduced basal 
levels of ALAS mRNA.74 Insulin and glucose together have a greater effect on 
reducing ALAS expression than insulin alone suggesting that glucose also plays a role 
in ALAS transcription.74 It is possible that the glucose effect may be a result of 
increased insulin levels in response to glucose rather than glucose itself.  
 
The effect of glucose and insulin on ALAS may be explained at the transcriptional 
level through PGC-1. PGC-1 is a coactivator of nuclear receptors and other 
transcription factors that control mitochondrial biogenesis and oxidative metabolism 
in many tissues.217, 218 PGC-1 also appear to play a role in the control of ALAS 
expression in the fasted and fed liver at the transcriptional level.74, 219 In vivo, PGC-1 
is induced in the liver during fasting and stimulates expression of the ALAS gene in 
hepatocytes.74 These elevated PGC-1 levels have been shown to cause acute attacks in 
induced porphyrias in rats.74 Because of this, drugs that elevate hepatic PGC-1 levels 
should be avoided in patients with hepatic porphyrias. High levels of insulin appear to 
down-regulate the expression of PGC-1.219 Glucagon induces PGC-1 expression, and 
rising blood glucose reduces glucagon secretion.218, 219 This suggests that PGC-1 may 
be the major target of the “glucose effect” in the porphyrias.218 If PGC-1 expression is 
reduced by insulin and PGC-1 induces ALAS expression, the lack of induction of 
ALAS expression by PGC-1 in the presence of insulin may be the mechanism by 
which glucose and the subsequent elevation of insulin can ameliorate an acute 
porphyric attack.74 
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4.2.2 Complications of Glucose Therapy  
Although glucose has been recommended as a porphyria treatment, there are potential 
complications that can result from intravenous glucose therapy or high carbohydrate 
diets which include weight gain and increased risk of developing diabetes mellitus.  
 
4.2.2.1 Diabetes and Weight Gain  
Diabetes mellitus is a metabolic disorder in which the patient has an inadequate 
insulin response, resulting in a propensity to hyperglycemia. Because high 
carbohydrate diets and intravenous glucose therapy offer relief from porphyric 
attacks, it is not unreasonable to suggest that diabetes-induced hyperglycemia could 
have a similar affect. There are reports of AIP porphyria patients who obtain better 
control and in some cases cessation of symptoms after developing diabetes.220-222 
However, a case report suggests that diabetes can also antedate AIP with porphyria 
symptoms developing in a patient 12 years after hyperglycemia which was controlled 
through herbal medications.223 It is worth noting that in this case there were fewer 
acute attacks as the patients glycemic control diminished.223  
 
Interestingly, it has also been reported that diabetes is prevalent in patients with the 
cutaneous hepatic porphyria PCT.178, 224, 225 A study of 81 PCT patients showed 41% 
(33 patients, 25 with diabetes mellitus and 8 with impaired fasting glucose) having 
glucose metabolism alterations.224 A previous study by the same authors of 152 
patients showed a 23.7% prevalence of diabetes mellitus and 11.9% prevalence of 
impaired fasting glucose.178 This is in comparison to a 13% prevalence in the general 
population of the area.226 As diabetes is highly prevalent in PCT, it is possible that 
alterations of porphyrin metabolism may correlate with insulin resistance.225 It 
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appears that diabetes mellitus development results in symptomatic relief in patients 
with severe AIP. For those with latent AIP or PCT, diabetes may simply result in 
undesired diabetic complications. 
 
4.2.2.2 Hyponatremia 
Perhaps one of the most severe potential complications of intravenous glucose is the 
risk of hyponatremia. Stein et al. 227 reports a tragic case of a 17 year old school girl 
presenting with AIP suffering from a severe acute attack. She was treated with 50% 
glucose infused through a central venous line and suffered from respiratory arrest. 
Post mortem suggested this was due to profound hyponatraemia aggravated by 
intravenous glucose solution.227 Glucose and Na+ levels have to be carefully balanced 
as serum Na+ concentration decreases with increasing glucose concentration as water 
shifts from the intracellular to extracellular compartment.228 Hyponatremia is a 
common complication in AIP,229-233 making intravenous glucose a potentially 
dangerous option. 
 
4.2.2.3 Micronutrient Depletion 
Depletion of micronutrients is also a concern in glucose therapy. A study of nine 
healthy patients who ingested a glucose solution after a 12 hour fast resulted in a 
decrease in plasma concentration of PLP.234 PLP is the active form of vitamin B6 and 
as already mentioned is an important co-factor in over 300 enzymes including the 
ALAS catalyzed reaction in the heme biosynthetic pathway. Due to the increased 
activity of the PLP-dependent, rate-limiting enzyme ALAS in the porphyrias, PLP 
may already be depleted (Section 4.5). Thus, intravenous glucose may exacerbate a 
pre-existing vitamin B6 (PLP) deficiency in porphyria patients. Another potential 
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complication of intravenous glucose therapy is thiamine deficiency resulting in 
Wernicke’s encephalopathy.235 Wernicke’s encephalopathy is a life threatening 
neurological disorder that results from thiamine deficiency.235, 236 If any patient is 
treated with glucose infusions without having thiamine levels tested first, they run the 
risk of developing severe thiamine deficiency leading to Wernicke’s 
encephalopathy.237, 238 Severe thiamine deficiency leads to respiratory failure if 
untreated; respiratory failure is the main cause of death in an acute attack. Because of 
this, determining vitamin status should be a common procedure before glucose 
therapy in all patients requiring glucose infusions.   
 
4.2.2.4 Summary of Glucose Therapy 
The possible complications of glucose therapy include weight gain, diabetes, 
micronutrient deficiency, and hyponatremia as well as B-vitamin depletion. These 
potential side-effects of glucose therapy make it clear why glucose therapy is no 
longer the method of choice for treatment of the acute porphyrias.  
4.3 Heme Therapy 
4.3.1 Heme Treatment 
Heme therapy involves the intravenous infusion of heme in the form of hemin or 
heme arginate (Figure 4.1); it will be assumed that the term ‘heme’ refers to either of 
these compounds. This therapy is well studied and widely used and is considered a 
safe method of treatment.239 As heme regulates its own biosynthetic pathway through 
feedback inhibition of ALAS1 (Figure 2.1), ‘heme’ infusions lower ALAS1, which 
reduces precursor accumulation, and results in symptom relief.230, 240 ‘Heme infusions 
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also supply the body with heme which may be deficient due to the enzyme ‘block’ in 
heme synthesis in porphyria.  
 
Hemin (trade name Panhemin) consists of protoporphyrin IX with an iron ion and a 
chloride ligand, whereas heme arginate (trade name Normosang) is a compound of 
heme where arginine is added to prevent rapid degradation (Figure 4.1). A study 
suggests that heme arginate is more stable than hemin.241 However, both forms are 
widely used. Normosang appears to be the heme of choice in Europe, whereas 
Panhemin is mainly used in the United States.201 These heme products are the most 
popular forms for use in heme therapy with recent studies showing successful 
symptom control upon administration.230, 242-244  
 
Figure 4.1 Structures of Heme.  
The structure of protoheme is compared to that of hemin and heme arginate, the commonly used forms 
of heme for porphyria treatment.  !
4.3.2 Complications of Heme Therapy 
Heme therapy improves symptom control, but does not appear to reverse any 
established neuropathy although it may prevent further neuronal damage.201 Potential 
complications of frequent ‘heme’ infusions are hemochromatosis, hypotension,245 
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coagulopathy,246 acute renal tubular damage, and phlebitis.202  In addition to these 
potential side-effects, ‘heme’ therapy is a very expensive treatment with a standard 
four-day treatment costing approximately $8,000 US,247 and is not readily available in 
some countries, for example, India.245 
 
Frei et al.203 reports a case of an AIP patient who received an accidental 6-fold 
overdose of heme arginate that resulted in severe coagulation and acute liver failure 
resulting in an emergency liver transplant. Although the patient was doing well a year 
after the successful liver transplant, liver transplantation may have been averted if a 
normal dose had been given. Medical error is thus another potential complication of 
heme therapy.  
4.4 Liver Transplantation. 
4.4.1 Treatment with Liver Transplantation 
Liver transplantation has successfully reversed acute porphyria202-207 resulting in 
normalisation of heme precursors. In addition, porphyric livers from AIP patients 
transplanted into non-porphyric patients have resulted in AIP developing in these 
patients.248, 249 These cases highlight the importance of the liver in the 
pathophysiology of this disorder. Liver transplantation imports a pristine hepatic 
biochemistry into the patient and reverses the porphyria. This is not a permanent 
treatment for the acute porphyria ALAD-P however,169 suggesting that in this 
porphyria more than the liver may be affected. 
 
Liver transplants have also been reported to successfully treat liver disease in EPP 
patients250-252 although a review reports EPP reoccurrence in 11 out of 17 EPP 
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patients with liver transplants253 as EPP is an erythropoietic rather than hepatic 
disorder. 
 
4.4.2 Complications of Liver Transplants 
Dowman et al.254 who reviewed liver transplantation in ten AIP patients reported an 
80% success rate and a high rate of hepatic artery thrombosis. They also observed that 
previous neuronal damage is not improved by transplantation. The two patients in this 
study who died did so from multi-organ failure. The other eight were free of 
porphyria symptoms after surgery. In addition, anesthetics, as mentioned earlier, can 
cause an acute attack255 and anesthetics must be selected carefully before any surgery 
is performed on an acute hepatic porphyria.  
 
 As porphyrins are excited by UV light resulting in photo-cutaneous and photo-
visceral damage, special filters are needed on all lighting if surgery is performed on a 
porphyria patient presenting with cutaneous symptoms and porphyrin 
accumulation.253, 256 Porphyrin accumulation in the intra-abdominal tissue can result 
in severe damage to this tissue and surrounding organs if exposed to UV light. 
However, Wahlin et al.256 reported two patients with phototoxic injury even though 
they were protected by filters during surgery. 
 
Although liver transplantation appears to correct the acute porphyrias in most cases, it 
is not always successful254, 255 and factors that could alter the outcome include choice 
of anesthetics as well as appropriate light filters if cutaneous symptoms are present 
(VP and HCP in addition to the cutaneous porphyrias). 
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4.5 Micronutrient Therapy 
It has been made clear that nutrients play a significant role in the heme biosynthetic 
pathway and the nutrients required range from macronutrients such as glucose 
(Section 4.2) to the micronutrient cofactors essential for enzyme function (Table 2.1). 
Atamna et al58, 257 have suggested that inadequate dietary intake of micronutrients 
results in altered heme biosynthesis, which leads to mitochondrial decay and 
oxidative damage to DNA, and that this could be a factor in the ageing process. 
Inadequate amounts of dietary micronutrients also lead to a decline in critical 
enzymatic activities of the electron transport complexes. This increases the production 
of reactive oxidants and the functional decay of mitochondria.257, 257 Could 
micronutrient deficiencies, if they have such an effect on heme synthesis also play a 
role in the porphyrias? Could the increased enzymatic activity of the porphyrias prior 
to the ‘bottleneck’ in the pathway deplete micronutrient cofactors resulting in 
micronutrient deficiencies?  
 
Ames et al.258 present evidence supporting the treatment of genetic disorders resulting 
from defective enzymes with high-dose vitamin therapy of the vitamin component of 
the corresponding coenzyme. In his discussion, Ames uses vitamin B6 (pyridoxal) 
treatment of sideroblastic anemia to boost ALAS activity as an example. He also 
suggests that VP may be treated with riboflavin. This treatment may partially restore 
the deficient enzyme activity and increase the enzyme’s affinity for the corresponding 
cofactor thus relieving some of the symptoms.258 
 !  
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4.5.1 Micronutrient Deficiencies in Porphyria 
Many of the symptoms of vitamin deficiencies are similar to those presented by the 
porphyrias (Table 4.1). While these possible connections may be unrelated, it is 
possible that the correlations between vitamin deficiency symptoms and symptoms of 
the porphyrias could provide a new perspective and understanding of the 
pathophysiology of the porphyrias. Consumptive tissue depletion of essential 
micronutrients during acute porphyria attacks could result from the enhanced 
condition of the heme pathway caused by abnormally high enzyme activity prior to 
the enzyme ‘bottleneck’ characteristic of the porphyria.  
 
Vitamin deficiencies are common in the general population.257, 259 Consumptive tissue 
depletion of vitamin cofactors during an acute attack could thus aggravate underlying 
deficiencies. Due to the many inter-relationships between levels of different nutrients, 
depletion of one or more nutrients can result in the depletion of others resulting in a 
cascading effect (Section 2.3). This, along with overproduction of precursors, would 
affect various pathways generating a variety of symptoms depending on where the 
metabolic imbalance resides in a particular patient. Table 4.1 reports some commonly 
reported porphyria symptoms along with analogous symptoms resulting from vitamin 
deficiencies. 
 
Garcia-Diz did a dietary study of 16 AIP patients through a lifestyle questionnaire 
which showed an increased risk of malnutrition.260 Porphyrias have been treated with 
micronutrients for over 60 years.261 although this is not considered a mainstream 
treatment in the medical literature written in the English language. Different 
micronutrients can support the heme biosynthetic pathway through essential and non-
essential co-factor roles as well as protect the body against oxidative stress and free  
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Table 4.1 Systems of Porphyria Similar to Those in Micronutrient Deficiencies. 
Porphyria symptoms Micronutrient deficiencies with analogous symptoms 
Peripheral Neuropathy (acute) Thiamine, Vitamin B6, Vitamin B12, Vitamin E 
Severe abdominal pain (acute) Calcium, Folate, Pantothenate, Vitamin B12, Vitamin D 
Constipation (acute) Niacin, Thiamine, Vitamin B12,  
Nausea, vomiting (acute) Folate, Magnesium, Vitamin B12, Vitamin D 
Diarrhea (acute) Folate, Niacin, Vitamin B12, Zinc 
Liver problems Vitamin B6, Vitamin D 
Back pain (acute) Calcium, Vitamin D  
Headaches (acute) Magnesium, Vitamin B12, Vitamin D 
Pain in limbs (acute) Thiamine, Vitamin B6, Vitamin B12, Vitamin D 
Edema Niacin, Thiamine, Vitamin B6, Vitamin B12 
Dysthesias and parasthesias (acute) Biotin, Pantothenate, Vitamin B12 
Muscle weakness (acute) Copper, Folate, Magnesium, Niacin, Pantothenate, 
Thiamine, Vitamin B12, Vitamin D, Vitamin E  
Muscle cramps (acute) Biotin, Calcium, Pantothenate, Thiamine 
Muscle paralysis (acute) Vitamin B12 
Seizures  (acute) Magnesium, Vitamin B6, Vitamin B12, Vitamin D 
Tremors (acute) Magnesium, Riboflavin, Thiamine, Vitamin B6, Vitamin 
B12, Vitamin E 
Depressed or absent tendon reflexes (acute) Magnesium, Thiamine, Vitamin B12 
Difficulty breathing (acute) Copper, Vitamin B12, Vitamin D 
Arrhythmias (acute) Copper, Folate, Magnesium, Thiamine, Vitamin B12 
Hypertension (acute) Lipoic Acid, Magnesium, Vitamin D 
Lowered immunity (acute) Calcium, Copper, Lipoic acid, Vitamin A, Vitamin C 
Fatigue (acute) Copper, Folate, Magnesium, Pantothenate, Vitamin B6, 
Vitamin B12, Vitamin D, Vitamin E  
Depression (acute) Biotin, Folate, Magnesium, Thiamine, Vitamin B6, 
Vitamin D, Vitamin C, Vitamin B12 
Psychosis, paranoia, hallucinations (acute) Vitamin B12 
Irritability (acute) Folate, Magnesium, Thiamine, Vitamin B12, Vitamin D 
Delirium (acute) Magnesium, Vitamin B12 
Confusion (acute) Folate, Niacin, Vitamin B12, Vitamin D 
Insomnia (acute) Calcium, Folate , Magnesium, Niacin, Pantothenate, 
Thiamine, Zinc  
Anxiety/Restlessness (acute) Magnesium, Pantothenate, Vitamin D 
Anemia Biotin, Copper, Folate,, Riboflavin, Vitamin B12, Vitamin 
E, Zinc 
Skin photosensitivity (cutaneous) Riboflavin 
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Porphyria symptoms Micronutrient deficiencies with analogous symptoms 
Itches (cutaneous) Vitamin B6, Vitamin C 
Blisters (cutaneous, not found in EPP) Vitamin B6, Vitamin E 
Rashes (cutaneous) Biotin, Vitamin B6 
Changes in skin pigmentaton (cutaneous) Copper, Folate, Vitamin B12 
Slowed wound healing (PCT) Niacin, Vitamin C, Vitamin E, Zinc 
Nail abnormalities (EPP) Calcium, Zinc, 
Skin lesions (cutaneous) Niacin, Zinc 
 
Table 4.2 Reports of Micronutrient Deficiencies Recorded in Porphyria. 
Micronutrient 
deficiency 
Porphyria Number of patients Reference 
Riboflavin HCP 1 8 
Vitamin B6 AIP; VP 11; 1 9 
 AIP 4 10 
 AIP 13/24 11 
 AIP 2 12 
 AIP 21 13 
 AIP 1 14 
Folate AIP 1 15 
Vitamin A PCT 34 16 
Vitamin E PCT 34 16 
Vitamin C PCT 7 17 
 PCT 13 18 
Vitamin D HCP 1 8 
 EPP 22/48 19 
 EPP 84% of 42 20 
 EPP 126/201 21 
Magnesium Acute attacks “Common” 22 
    Cases of porphyria patients presenting with micronutrient deficiencies.  !
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radicals through antioxidant properties. There have been many micronutrient 
deficiencies reported in the porphyrias (Table 4.2); here we will provide a much 
needed review on reports of micronutrient therapy of the different porphyrias. 
4.5.2 Treatment of the Porphyrias with Micronutrients 
Over the past sixty years there have been numerous reports of successful treatments of 
the acute and cutaneous porphyrias with a variety of micronutrients (Table 4.3). 
However, vitamin therapy is rarely included in reviews of porphyria treatments.3, 201, 
247, 262, 263 and if it is, it is usually dismissed. Is this dismissal justified? Could 
micronutrient therapy be a safer alternative to heme arginate treatment? As mentioned 
in Section 4.1, folate in addition to a vitamin B-complex is reported as the main 
treatment and preventative for acute attacks in Argentina.24 Reports of successful 
treatment of AIP with folate (30 mg), vitamin B-complex (vitamin B1, 15 mg; 
vitamin B2, 15 mg; vitamin B6, 5 mg; vitamin B12, 5 mg; vitamin B5, 20 mg; 
vitamin B3, 100 mg; vitamin C, 600 mg; vitamin E, 30 U) and two to four 
tablespoons of glucose syrup per day has been reported to have already successfully 
treated over 65 patients in 1985;24 this is still the main method of treatment in 
Argentina today. Reported micronutrient treatment of each of the major classes of 
porphyria is presented below.  
 
Table 4.3 Reported Successful Treatment of Porphyria with Micronutrients. 
Porphyria Micronutrient Number of 
Patients  
Amount Reference 
AIP Vitamin B6 and glucose 1 --- 23 
 Vitamin B6 (pyridoxine) 4 in remission  40-60 mg/day 10 
 Vitamin B6 (pyridoxine) 2 400 mg/day 12 
 Vitamin B6 (pyridoxal) 2 100 mg, single dose 13 
 Folate, B-complex, and 
glucose syrup 
> 65 30 mg/day 24 
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Porphyria Micronutrient Number of 
Patients  
Amount Reference 
 Folic acid 3 30 mg/day 272 
 Folate and red blood cell 
infusions 
1 0.5 mg/day 15  
 Zinc 1 220 mg/8hours 27 
 Magnesium Sulfate 1 3 g then 1 g/hour IV
  
28 
VP Vitamins C and E 12 --- 29 
 Vitamin E 2 --- 30, 31 
HCP Riboflavin 1 “large doses” 8 
PCT Pyridoxal-5-phosphate 4 500 mg/day IV 32 
 Vitamin B6 2 500 mg/day IV 33  
 Pyridoxal-5-phosphate 3 500 mg/day IV 34 
 Riboflavin, niacin, and 
Vitamin C 
39 --- 37 
 Thiamine, riboflavin, 
Niacin and Vitamin C 
80 --- 38 
 Vitamin E 5 1 g/day 39 
 Vitamin E 2 100 mg/day 41  
 Vitamin E 7 1600 IU/day 31 
 Vitamin E 5 --- 43  
 Vitamin E  --- 44 
 Vitamin B12 and folate 1 --- 45 
EPP PLP 2 1 g/day and 30 
0mg/day 
46 
 Vitamin C 8/12  1 g/day  47 
 Beta carotene 7 50-250 mg/day 48 
 Beta carotene 19/23 --- 279 
 Zinc  1 600 mg/day  50 
 Cysteine 9/10 500 mg/twice daily 51 
 N-acetylcysteine 1 400 mg/twice daily 53 
 N-acetylcysteine 1 1200 mg/day 54 
CEP Pyridoxal-5-phosphate 
 
1 30 mg/day 
subcutaneous injection 
55 
Reports of successful treatment of the different porphyrias with micronutrients. IV, intravenous; IU, 
international unit. 
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4.5.2.1 Treatment of the Acute Porphyrias With Micronutrients 
(i) B-vitamins 
 As PLP (vitamin B6) is an essential cofactor for the production of neurotransmitters, 
vitamin B6 has also been used as a therapeutic adjunct in seizures, Parkinson’s 
disease, depression, chronic pain, headache, behavioral abnormalities, peripheral 
neuropathies, carpal tunnel syndrome, and premenstrual syndrome.120 As many 
porphyria symptoms are similar to those of B6 deficiency (Table 3.1), and in light of 
the therapeutic potential of vitamin B6 in other disorders, there is the potential for its 
use as a therapeutic aid in the porphyrias as well.264 Treatments of the acute 
porphyrias with vitamin B6 stems from the hypothesis that there is consumptive tissue 
depletion of this vitamin due to excessive demand of the PLP-dependent ALAS in the 
porphyria state resulting in a vitamin B6 deficiency;265 this will be discussed further 
in Section 5.4. 
 
There have been case reports of AIP symptoms resolved following administration of 
vitamin B6 plus glucose,23, 266 and recently vitamin B6 has been used to support AIP 
patients in remission.9, 10 An earlier report suggests no clinical improvement in two 
AIP patients who were vitamin B6 (pyridoxine) deficient.13 The two patients were 
given a single 100 mg dose of pyridoxine, however this may not have been enough to 
show any improvement whereas another study at a similar time reports progressive 
improvement in two severe cases over three months with vitamin B6 (PLP) 400 
mg/day.12 Since the acute symptoms of VP and HCP result from the depression of 
PBGD by protoporphyrinogen and coproporphyrinogen, treatments that are successful 
for AIP may also be effective for these two porphyrias. 
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Some livers are not capable of converting pyridoxine hydrochloride, the vitamin B6 
form that is common in supplements, into PLP (the active coenzyme form of vitamin 
B6).267 This is the case when folate, vitamin B2, and vitamin B12 levels are not 
sufficient.268, 269 It is possible that this is also the case in the acute hepatic porphyrias. 
If so, supplementation with pyridoxine would not be effective and the PLP form of 
the vitamin should be administered. PLP has a half-life of 23.1 hrs in the circulation, 
and this may underpin the ineffectiveness of a single dose.270 
 
The successful treatment of the acute porphyrias with folate originates from a report 
that folate administration enhances PBGD,271 the enzyme deficient in AIP, thus 
normalizing the pathway and ameliorating the porphyria crisis.15, 24, 272 This provides 
evidence in support of the cofactor treatment of metabolic disorders discussed 
earlier.258 Folate treatment also normalizes acute symptoms in VP and HCP;273 these 
porphyrias produce elevated levels of coproporphyrinogens and protoporphyrinogens 
which suppress PBGD activity through feedback inhibition (Figure 2.1) resulting in 
AIP-like symptoms.93 Folate, B6, and B12 supplementation together have better 
results in treating a folate deficiency than folate alone suggesting that the B-vitamins 
should be given together to avoid depletion of any not given.274 Folate (30mg) in 
addition to a commercial B-complex tablet and two to four tablespoons of glucose 
syrup daily has been reported to be beneficial in the control and suppression of acute 
attacks and is the treatment of choice in Argentina.24, 275  
 
(ii) Antioxidants and Minerals 
The antioxidants vitamin E and vitamin C  have also been reported to successfully 
treat VP through decreasing plasma and neutrophil oxidative damage and restoring 
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PPOX expression.29 Another report relating to two AIP patients observed no 
beneficial effects of these or other antioxidants.276 If the antioxidants that successfully 
treated VP did so through restoring PPOX expression, this may explain why this 
treatment was successful in VP and not in AIP. One must also remember that due to 
the rarity of porphyria, it is difficult to get statistically significant results.  
 
Melatonin is another important and powerful antioxidant which will be discussed 
further in Section 5.3.2. Melatonin has been shown to protect against ALA-induced 
oxidative damage, preventing cell injury.130, 132, 277, 278 This suggests that melatonin 
may have potential in the treatment of the acute porphyrias.   
 
In addition to B vitamins and antioxidants in treatment of the acute porphyrias, zinc 
sulphate has been reported to provide pain relief in AIP patients.26, 27 The mechanism 
of this is suggested to be due to the remediation of a free zinc deficiency, resulting 
from zinc chelation by overproduced porphyrins. Some acute porphyria symptoms are 
similar to those in zinc deficiency.  Magnesium has also been used as a therapeutic 
aid in acute attacks for the control of seizures.28 
4.5.2.2 Treatment of Chronic Hepatic Porphyrias with Micronutrients 
(i) B-vitamins 
The non-acute porphyrias have also been treated with vitamins. Intravenous injection 
of PLP (500 mg/day) in four PCT patients decreased urinary porphyrin excretion and 
reduced serum iron levels.32, 280 If PLP is a non-essential activator of ferrochelatase, 
the enzyme that inserts iron into heme, it could be playing a role here.96, 97 A 
supporting study of two PCT patients treated by the same method  (intravenous 
vitamin B6 500 mg/day for a month) resulted in relief of symptoms, including 
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complete disappearance of the erupting bullae and fragile skin.33 There have been 
reports of B vitamins treating PCT in different countries and languages including 
German,34, 36, 266 Russian,37, 38 Croatian, 35 and Spanish 281. 
(ii) Antioxidants 
Antioxidants have treated the cutaneous hepatic porphyrias as well, with vitamin E as 
the main antioxidant used to treat PCT.31, 40-43, 282 Vitamin E is an antioxidant and has 
been shown to reduce oxidative stress in PCT.44 In addition, it is suggested that it 
increases UROD activity and thus lowers urinary excretion of porphyrins.39 Vitamin 
E deficiency has been reported to decrease ALAD activity40 and capacity to 
synthesise heme resulting in decreased levels of heme proteins;283-286 this supports the 
hypothesis that it plays a role in heme synthesis.  
 
4.5.2.3 Treatment of Cutaneous Porphyrias with Micronutrients 
(i) B-vitamins 
The cutaneous erythropoietic porphyrias have also been successfully treated with 
vitamin B6 leading to symptom relief and light tolerance in EPP.46 This protective 
effect could be due to PLP’s possible role in activating FECH,96, 97 thus correcting its 
deficient activity.96, 97 In a case of CEP, subcutaneous injection of pyridoxal-5-
phosphate at 30 mg/day resulted in urinary porphyrin excretion returning to normal 
and cutaneous lesions disappearing within a year.55  
(ii) Antioxidants and Minerals 
Beta-carotene has also been reported to reduce photosensitivity and increased the time 
EPP patients could spend in the sun;48, 279, 287, 288 vitamin C has been reported to 
provide possible benefits as well.47 In addition, the antioxidant N-acetyl-cysteine has 
! 72!
been suggested to reduce photosensitivity in EPP.51, 52, 289 An emergency liver 
transplantation was averted in a case of EPP through intravenous N-acetyl-cysteine 
treatment; this case was continuously controlled successfully through ongoing N-
acetyl-cysteine supplementation.54 
 
Zinc sulphate has been reported to reduce photosensitivity in EPP likely through 
chelating free protoporphyrins.50 Zinc-protoporphryins are less phototoxic than metal-
free protoporphyrins.  
 
4.6 Discussion 
Heme biosynthesis is a complex pathway involving many factors and levels of 
control. It is tightly regulated and requires many nutrient cofactors that are  either  
directly  involved  in  the  pathway  or  indirectly involved through related pathways 
that feed into the heme biosynthetic pathway. Heme and glucose both regulate the 
first step of the pathway, and although treatment of acute porphyria with heme and 
glucose has had positive results, there is a continuing need to investigate possible 
alternative treatments that may have similar results without some of the deleterious 
side effects such as weight gain290 or diabetes.  
 
Micronutrient depletions or deficiencies could play a role in the manifestation of 
some of the symptoms of porphyria because of their interplay with heme biosynthesis 
(Table 2.1). Interestingly, the peripheral neuropathy of vitamin B6 deficiency is very 
similar to the peripheral neuropathy of acute porphyria120, 121 suggesting that PLP 
depletion may play a role.12, 264 This is reinforced by the knowledge that vitamin B6 
deficiency has been documented in the porphyrias. In Argentina, folate treatment of 
AIP is widely practiced and is known to aid and alleviate symptoms yet is more 
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effective when given with a vitamin B-complex as well.24 These possible connections 
provide an area for further research.  
 
If a nutrient cofactor is depleted through an overactive heme pathway, it may not be 
possible to obtain enough of the nutrient from the diet. Vegetarian, vegan, and Atkins 
diets, as well as diets high in processed food can result in nutritional deficiencies of 
certain nutrients further aggravating any underlying deficiency or deficiencies. 
Micronutrient deficiencies are prevalent in the general population with high rates of 
modest, non-symptomatic nutrient deficiencies.291, 292 A porphyria patient with 
vitamin deficiencies may be more susceptible to an external provoking factor thus 
becoming symptomatic. Once a porphyric attack is triggered, nutritional deficiencies 
may become exacerbated as enzyme activity is up-regulated prior to the enzymatic 
‘bottleneck’ in the heme biosynthetic pathway resulting in increased micronutrient 
cofactor consumption. If more of a particular nutrient is required than is possible to 
get from a normal diet, supplementation may be a possible therapeutic aid for relief of 
symptoms. Prevention of acute porphyric attacks by avoidance of triggering factors 
and by maintaining an optimal nutritional status is a safe approach toward prophylaxis 
of the porphyrias. Ames and his team258 presented evidence in 2002 supporting the 
treatment of genetic disorders that are due to defective enzymes with high doses of 
the vitamin cofactor component of the corresponding enzyme. This may partially 
restore enzyme activity and increase the enzymes affinity for the corresponding 
cofactor, so relieving some of the symptoms in the porphyrias. 
 
Another area of porphyria treatment being investigated is gene therapy. Recent pre-
clinical studies of liver-directed RNA interference therapy for ALAS1 mRNA is a 
current area of research.293 A separate study in macaque monkeys Macaca 
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fascicularis suggests intravenous infusion of PBGD into AIP patients could also 
correct the disorder by correcting the enzyme deficiency.294 Eight AIP patients are 
currently in phase I trials of this therapy.294 
 
In conclusion, micronutrient therapy appears to stand out as a safe alternative to heme 
and glucose therapy in the acute porphyrias. Even liver transplantation due to liver 
failure caused by EPP has been simply averted with high doses of N-acetyl-cysteine.54 
Neuronal damage is not reversed with glucose or heme therapy201 but there is 
evidence that B-vitamins might support nerve regeneration.295-297 However, to make 
vitamin therapy an effective treatment, studies must be done to evaluate the most 
efficient combination of micronutrients as well as dosage. Micronutrient therapy is 
not a cure for the genetic mutations that result in diminished heme biosynthesis, 
however, it may reduce the risks associated with these disorders and may prevent the 
manifestation or exacerbation of the symptoms of the porphyrias. The object of 
nutrition management of the porphyrias is to provide a biochemical environment that 
supports normal heme biosynthesis. Evidence of successful treatments highlights the 
need for further studies of porphyria in relation to micronutrient cofactor treatment 
that could shed further light on these disorders. Studies on porphyria can be difficult 
due to the rarity of this disease as well as the fact that not all persons with the genetic 
defects display symptoms. There is enough evidence to suggest that some 
micronutrients play a role in the porphyrias. Further research in this area is required to 
elucidate the importance they play. A better understanding of the heme biosynthetic 
pathway as well as the interconnecting pathways involving micronutrient substrates 
and cofactors will shed light on the pathogenesis of the porphyrias and help develop 
safer and more effective treatments.   
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CHAPTER 5.  THE BIOCHEMISTRY OF THE ACUTE ATTACK 
5.1 The Acute Attack 
As previously discussed, most acute hepatic porphyria patients are asymptomatic with 
normal heme levels despite the underlying genetic mutation(s) that results in reduced 
enzyme activity.147, 298 Additionally, many patients with reduced activity of a heme 
biosynthetic pathway enzyme produce high levels of heme precursors without ever 
exhibiting any toxic symptoms.14 Because of this high rate of latent porphyria and 
high levels of precursors in some asymptomatic patients, it has been suggested that 
the genetic mutation resulting in diminished activity of heme biosynthesis pathway 
enzyme(s), while necessary, is not sufficient to produce the clinical symptoms of the 
porphyrias. For this reason it is thought that there is at least one other pathogenic 
factor involved in the manifestation of the symptoms of porphyria.91, 299  
 
In symptomatic porphyria patients heme production is slowed resulting in reduced 
heme levels and excess free iron; this results in increased ALAS activity due to lack 
of feedback inhibition by heme. The increased activity of the initial rate-controlling 
enzyme in the liver leads to overproduction and increased excretion of porphyrins or 
porphyrin precursors, ALA and PBG, without heme production. The biochemical 
mechanism of the acute porphyrias thus likely includes toxic effects of over-produced 
heme precursors, iron accumulation, and heme deficiency. These factors explain some 
but not all of the acute porphyria symptoms91 and the mechanism for the peripheral 
neuropathy of the acute porphyrias has not yet been described.  
 
As previously discussed, the heme biosynthetic pathway is also dependent on a 
variety of micronutrients which act as cofactors. Therefore nutritional status, 
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deficiencies, increased demand, and imbalances of micronutrients may also play a 
role in the manifestation of the porphyrias. This is supported by the many symptoms 
of porphyria that are analogous to micronutrient deficiencies  (Table 4.1). 
 
There are many theories of what might occur biochemically during an acute attack. In 
this chapter, possible mechanisms will be discussed and a hypothesis for the 
biochemistry underlying acute porphyria will be presented.   
 
5.2 Elevated Precursor Levels 
Elevated levels of ALA have been suggested to be a factor causing acute attacks in 
porphyria; possibly by a direct neurotoxic mechanism, oxidative damage to neuronal 
and membrane structures, or through interference with neurotransmitters (see below). 
High levels of ALA have been suggested to result in a variety of symptoms which 
affect both the neurological and gastrointestinal systems300 although the mechanism 
for this is still speculative.  
 
5.2.1 Neurotoxic Precursors 
Excess levels of circulating ALA and PBG are found in AIP, VP, and HCP, and it has 
been suggested that these heme precursors are neurotoxic resulting in the acute 
symptoms.301-304 Patients with ALAD-P or tyrosemia, however, are characterised by 
the over-production of ALA, without an increase in PBG. As these two disorders have 
the same neurological symptoms as the other acute porphyrias it is unlikely that PBG 
plays a role in an acute attack. Although porphyrins may accumulate during an acute 
attack305 it is unlikely they have neurotoxic effects as they also accumulate in the 
cutaneous porphyrias, which do not present with acute neurological manifestations. 
The ALA toxicity theory is supported by the fact that levels of ALA are increased in 
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all the acute porphyrias and acute attacks occur only when excretion of ALA is 
increased. In addition, it has been reported that the excessive levels of ALA and PBG 
are normalised or lowered along with a reduction of acute symptoms following 
intravenous heme therapy.306 However, the ALA toxicity theory assumes that over-
expressed ALA in the liver can cross the blood brain barrier (BBB).307  
 
The BBB is the membrane barrier that separates the circulating blood from the brain 
extracellular fluid in the CNS and controls access of compounds to neurons. It limits 
the entry of harmful substances into the CNS while allowing transport of essential 
nutrients that are required for maintaining proper neuronal function to neurons. ALA 
and PBG appear only to cross the BBB in small amounts308 and studies suggest the 
concentrations of these precursors in the brain of porphyria patients is below that 
required to induce neurotoxicity in vivo.309, 310 A more recent review speculates that 
AIP patients who suffer from severe reversible posterior encephalopathy syndrome 
during acute attacks may have increased permeability of the BBB304 although this is 
unproven. The mechanism of any transport of ALA into the brain has been suggested 
to be either through passive diffusion through the BBB,311 through a peptides 
selective transporter,312, 313 or through oxidative damage of the BBB through protein 
polymerisation and lipid oxidation.304 There is, at this time, no conclusive evidence of 
ALA transport across the BBB in porphyria.  
 
5.2.2 Oxidative Damage 
Excess ALA has been reported to have toxic effects resulting in oxidative damage to 
lipids, protein, and DNA.304, 314 ALA is a pro-oxidant that can undergo enolization 
and aerobic oxidation in vitro and in vivo, yielding oxyradicals and other pro-
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oxidants.304 Treatment of human hepatocellular carcinoma cells with ALA results in 
induced reactive oxygen species production, which increases with ALA 
concentration.315 The major pro-oxidants that are produced after ALA administration 
in animal models include superoxide, hydrogen peroxide, hydroxyl radicals and 4,5-
dioxovaleric acid.304 High levels of ALA in vitro and in animal models result in 
oxidative damage to lipids, protein, and DNA as well as increasing permeability of 
biological membranes.304 It is possible that ALA may increase permeability of the 
BBB through oxidative damage, perhaps allowing neurotoxins, including ALA, to 
diffuse into the CNS.  
 
5.2.3 ALA as a GABA Mimic 
Another theory for the mechanism of behind the effect ALA in the porphyrias is its 
structural similarity to the neurotransmitter γ-aminobutyric acid (GABA) and thus its 
potential to mimic and perturb GABA. GABA is the chief inhibitory neurotransmitter 
in the mammalian CNS.  In humans it is directly responsible for the regulation of 
muscle tone as well as its principal role of reduction of neuronal excitability.316 ALA 
has a structure similar to both GABA and glutamate (Figure 5.1). At relatively high 
concentrations, ALA has been suggested to inhibit GABA uptake and increase GABA 
efflux from rat cortical synaptosomes.307 Studies in rat brains treated with ALA report 
modified release of both GABA and glutamate from central synaptosomes317, 318 most 
likely through its structural similarity allowing it to act as an agonist of GABA and 
glutamate receptors.318 This suggests that ALA may act as a GABA agonist which 
could provide a rationale for some of the CNS dysfunction in the porphyrias, but only 
if ALA crosses the BBB.  
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Figure 5.1 Structures of ALA, GABA and glutamate showing their structural analogies.  !
5.2.4 Is ALA a Factor in the Pathogenesis of Porphyria? 
ALA-induced oxidative stress is likely to be a factor in the acute porphyrias, although 
intracellular levels of ALA and oxidative species are unknown in AIP patients. 
Although ALA accumulation appears necessary to trigger an acute attack, it is 
unlikely that ALA is the sole mechanism for triggering such attacks as injection of 
ALA into a healthy volunteer produced no clinical manifestations319 and oral 
administration to AIP patients as well as volunteers also produced no symptoms.320-322 
There is also poor correlation between levels of blood ALA and neurological 
symptoms323-325 with abnormally high levels of ALA in many symptomless AIP 
patients. This suggests that there must be at least one other factor involved in the 
symptomology of the acute porphyrias. ALA unarguably plays some role in the acute 
attack as levels are elevated in all of the acute porphyrias; possibly through oxidative 
damage of the BBB allowing the entry of neurotoxins into the CNS. However, ALA 
is unlikely to be the sole contributor to acute porphyric symptoms.  
 !  
ALA GABA Glutamate
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5.3 Heme Deficiency  
5.3.1 Heme Deficiency Affects a Variety of Systems 
Heme deficiency might play an important role in the pathophysiology of the acute 
porphyrias;91, 326 by leading to decreased levels of hemoproteins, which results in 
direct or indirect effects on the nervous system. Heme is a prosthetic group in 
hemoglobin, myoglobin, catalases, peroxidases and the cytochromes as well as being 
important in regulation of its own synthesis through negative feedback inhibition of 
ALAS (Section 2.2.12). Deficiency of heme enzymes that are required for myriad 
essential processes can result in severe consequences. Effects of heme deficiency 
include increased enzymatic activity of heme precursor enzymes resulting in heme 
precursor accumulation (characteristic of the porphyrias) as well as reduced activity 
of essential heme enzymes. 
 
The majority of hepatic heme (65% of total hepatic heme)98 is utilized for the 
synthesis of cytochromes P450 which are required for a variety of essential reactions 
including the synthesis and breakdown of hormones as well as detoxification 
pathways. As mentioned previously, drugs and chemicals which are metabolized by 
the cytochrome P450 detoxification pathway trigger acute attacks. The synthesis of 
cytochrome P450 enzymes is up-regulated in response to toxins that are metabolized 
by cytochrome P450 enzymes. This up-regulation would increase the demand for 
heme and result in the up-regulation of ALAS leading in turn to increased heme 
precursor accumulation due to the ‘bottleneck’ of enzyme activity in the porphyric 
heme pathway.327  
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Another important pathway which requires a cytochrome P450 enzyme is vitamin D 
activation.328 This makes vitamin D deficiency an additional risk in the context of 
heme depletion. As vitamin D activation also requires UV radiation from sun 
exposure, the porphyrias with severe photosensitive cutaneous symptoms are more 
susceptible to vitamin D deficiency due to avoidance of sunlight in the management 
of skin symptoms. There are reports of vitamin D deficiency associated with 
porphyria (Table 4.2). 
 
Heme is also an essential constituent of complex IV of the electron transport chain; 
thus heme depletion can result in impaired ATP production, oxidative stress, and 
oxidative damage. ATP transports chemical energy between cells and its production is 
essential for the normal function of every cell. Mitochondrial complex IV activity and 
protein content is reduced by 95% with heme deficiency, suggesting a decrease in 
successful assembly and resulting in detrimental consequences.329  
 
Another major heme-dependent enzyme is tryptophan pyrrolase which catalyses a 
step in the synthesis of NAD+ from tryptophan.109 Deficiency of this enzyme results 
in altered tryptophan metabolism with severe consequences. This pathway will be 
discussed in more detail as it is likely a major contributor to the biochemistry of the 
acute porphyric state.  
 
5.3.2 Tryptophan Pyrrolase  
Tryptophan metabolism leads to the generation of neuroactive compounds within the 
CNS and is highly regulated. These compounds include serotonin, kynuramines, 
melatonin, and tryptamine.330 Heme is a prosthetic group of tryptophan pyrrolase, the 
rate limiting step of tryptophan degradation through the kynurenine pathway (Figure 
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5.2). Tryptophan pyrrolase has a low affinity for heme. When heme is deficient, 
tryptophan is shunted from the kynurenine pathway to the serotonin pathway (Figure 
5.2).326, 331 Because of this, in heme deficient states there are increased levels of 
tryptophan in the liver and the flux of tryptophan to serotonergic pathways.326, 331 
 
High levels of tryptophan and serotonin have been recorded in the brains of heme 
deficient rats326 due to altered tryptophan metabolism. Serotonin is an important 
neurotransmitter involved in multiple processes and is essential to nerve cells and 
brain function. Abnormally elevated levels of serotonin result in serotonin syndrome, 
a potentially life threatening disorder with symptoms that range from mild to severe 
(Table 5.1).105 Serotonin syndrome is caused by high doses of serotonergenic drugs or 
combinations of drugs that synergistically increase serotonin levels in the CNS.332 
Some of the symptoms of this disorder (Table 5.1) are similar to those in acute 
porphyria and increased serotonin levels in the CNS may play a role in the 
pathophysiology of the acute attack.91, 105, 307  
 
Table 5.1 Common Serotonin Syndrome Symptoms. 
Serotonin Syndrome 
System affected  Symptoms 
Mental  Agitation, hallucinations, confusion, hypomania, unresponsiveness or coma 
Cardiovascular  Tachycardia, arrhythmia, high blood pressure 
Muscular 
Loss of coordination, muscle spasms (myoclonus), overactive reflexes (hyperreflexia), 
muscle rigidity, uncoordinated movements (ataxia), headache, seizures 
Thermia  Fever, heavy sweating not due to physical activity, shivering 
Gastro  Diarrhea, nausea, vomiting  
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 Figure 5.2 Tryptophan Metabolism Pathways.  
This figure represents the major fates of tryptophan. PLP is included where it acts as essential 
cofactor in these pathways.  
 
Serotonin synthesis in the brain is regulated by the transport of tryptophan across the 
BBB. This occurs through a competitive transport carrier shared by several large 
neutral amino acids including tyrosine, phenylalanine, leucine, isoleucine, and 
valine.330 Serotonin itself does not cross the BBB under normal conditions and its 
synthesis in the brain is thus reliant on tryptophan transport. 
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Serotonin levels have been found to be elevated in a study of 12 AIP patients with 
recurrent acute attacks; yet its metabolite, melatonin (Figure 5.2), was found to be 
decreased.333 After treatment of these patients with heme arginate, serotonin levels 
returned to normal, while melatonin levels remained reduced. Other studies show that 
melatonin is decreased in rats with high levels of ALA.334, 335 GABA has been shown 
to have an inhibitory effect on melatonin synthesis and, as ALA has a similar 
structure (Figure 5.1), ALA has been suggested to also inhibit melatonin synthesis by 
acting as a GABA mimic.334 As high levels of ALA occur in the acute porphyrias, it is 
possible that ALA interferes with the metabolism of serotonin to melatonin thus 
contributing to the high serotonin levels found in AIP.  
 
As mentioned previously, ALA is a pro-oxidant, capable of producing a variety of 
oxyradicals. Melatonin is a powerful antioxidant and has been shown to have 
beneficial effects on oxidative damage, preventing cell injury277 as well as 
successfully inhibiting ALA-induced oxidative damage.131, 132 Thus, a decreased 
melatonin synthesis from serotonin will result not only in elevated serotonin levels 
but also increased oxidative damage potential.   
 
In summary, altered tryptophan metabolism due to heme deficiency results in elevated 
levels of serotonin. High levels of serotonin result in a number of symptoms (Table 
5.1) that are similar to some, but not all (Table 3.1) of the symptoms of acute 
porphyria.91 This provides evidence that altered tryptophan metabolism plays a role in 
the biochemistry of the acute porphyrias, but it does not explain the peripheral 
neuropathy associated with acute attacks. 
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5.4 PLP Deficiency 
As previously discussed, it has been postulated that high doses of vitamin cofactors 
may optimise corresponding coenzymes partially overcoming deficiencies in enzyme 
activity.258 It is possible that individuals with asymptomatic porphyria remain 
asymptomatic through optimal nutrient status due to the major role nutrients play in 
heme biosynthesis as cofactors.  
 
There are numerous reports of high doses of B-vitamins treating both acute and 
cutaneous porphyria symptoms, although this is not widely reported in the current 
literature (Table 4.3). Vitamin B6 stands out as the one supplement reported to correct 
the disordered biochemistry in porphyria and alleviate the symptoms of the major 
acute as well as non-acute porphyrias (Table 4.3). Symptoms of vitamin B6 
deficiency are similar to symptoms of porphyria and include reduced immune 
function, neurological abnormalities, peripheral neuropathy, seizures, psychiatric 
disturbances, paresthesia, burning and painful dysthestias, lesions of the skin and 
mucous membranes, anemia and thermal sensations. The peripheral neuropathy of 
vitamin B6 deficiency is very similar to that found in the porphyrias120-122 and it has 
been previously postulated that vitamin B6 depletion may be a factor in the 
neuropathy of porphyria due to its role in the first and rate limiting step of heme 
synthesis.122, 336 Vitamin B6 deficiency has been reported in AIP patients,11-13, 264 and 
PLP therapy has been reported to successfully alleviate the symptoms of AIP,12 as 
well as CEP,55 PCT,32, 33 and EPP46 symptoms. Here we will discuss the importance 
of vitamin B6 and its coenzyme form of PLP in heme biosynthesis and why PLP may 
treat all of the porphyrias. 
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5.4.1 Causes of Micronutrient Deficiency 
“In order for vitamins to be useful to the metabolic activity of the nervous system, 
they must first gain entry into the tissue, where they are converted into their active 
cofactor form and where they interact with presumably specific apoenzyme proteins” 
– Dreyfus.337  
 
The five possible causes of all nutrient deficiency include inadequate dietary 
ingestion, increased excretion, increased requirement, inadequate absorption, and/or 
inadequate utilization.338  
 
As vitamin B6 is present in almost all foods, vitamin B6 deficiency due to insufficient 
dietary intake is reputed to be rare.339 However, vitamin B6 deficiency prevalence has 
been reported to range from 0.6% to 68% in developed countries.340As there have not 
been many dietary studies of porphyria patients, insufficient dietary intake of vitamin 
B6 cannot be ruled out as a possible contributor to vitamin B6 deficiency. Insufficient 
dietary intake is, however, unlikely the only cause of vitamin B6 deficiency in the 
porphyrias. 
 
Impaired absorption of vitamin B6 across the gastrointestinal tract and/or impaired 
metabolism of vitamin B6 into the active coenzyme form of PLP could also result in a 
vitamin B6 deficiency. Vitamin B6 exists as pyridoxine, pyridoxal, and pyridoxamine 
as well as their 5-phosphorylated compounds of which the major coenzyme is 
pyridoxal-5-phosphate (PLP) (Figure 5.3).340  Metabolism of PLP can be impaired by 
a number of factors, including drugs or chemicals, impaired liver function, hereditary 
factors, or other micronutrient deficiencies such as riboflavin, zinc or magnesium. 
Zinc is required for vitamin B6 phosphorylation; riboflavin is required for conversion 
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to the active form of PLP; and magnesium is required for vitamin B6 uptake into 
tissues (Figure 5.3).  
 
Figure 5.3 Vitamin B6 Metabolism.  
The structures of the major forms of vitamin B6 and the interconversions between these forms is 
illustrated. Essential nutrient cofactors are shown in red. FMN, flavin mononuleotide (riboflavin). !
Inadequate supply of heme to meet metabolic demands due to a partial enzymatic 
‘block’ in the heme pathway results in the accelerated production of ALAS, the rate 
limiting step of heme biosynthesis. As ALAS is a PLP-dependent reaction, enhanced 
activity of ALAS may utilise abnormally high amounts of PLP. In a porphyric state, 
PLP is required and may be utilised in excess due to the demand from the up-
regulated PLP-dependent ALAS enzyme. Severe vitamin B6 deficiency does not 
impair ALAS induction or activity in vitamin B6 (pyridoxine) deficient rats.341 This 
suggests that ALAS has a high affinity for PLP in comparison to other PLP-dependent 
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enzymes. If this is the case, in a vitamin B6 deficient state, ALAS will be a ‘high 
priority’ enzyme and will utilise and deplete PLP from other tissues further 
aggravating and worsening a vitamin B6 deficiency as well as straining other PLP-
dependent pathways. It takes eight molecules of ALA (and its substrates) to make 
each porphyrin ring. ALAS requires two bound PLP to function properly. In theory, it 
therefore takes 16 molecules of PLP to make each porphyrin ring. However, it is 
important to take into account that PLP can be recycled and thus the actual amount of 
PLP utilized may not completely represent the stoichiometry suggested here. 
However, it is easy to imagine that large amounts of PLP and other micronutrient 
substrates of heme are tied up in the enzymatically aberrant heme biosynthetic 
pathway. Therefore, the main cause of vitamin B6 deficiency in the porphyrias may 
be due to consumptive tissue depletion from blood and tissue due to the increased 
activity of ALAS.  
 
5.4.2 The Cascading Effects of a PLP Deficiency 
As discussed, vitamin B6 is a water-soluble vitamin. with pyridoxal-5-phosphate 
being the major coenzyme form of the vitamin and is an essential cofactor in over 300 
enzymatic reactions. Due to PLP’s essential role in so many enzymatic reactions, PLP 
deficiency has been related to a number of clinical symptoms.9 
 
In a deficiency state, some PLP functions may be adequately compensated but others 
may not.342 Various PLP-dependent enzymes have inherently different binding 
affinities with the coenzyme. Thus, those with the greatest affinity for the coenzyme 
are affected less than those with lower binding affinities which are the first to be 
affected by a PLP deficiency and the last to recover upon replenishment with the 
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coenzyme.112 A few of the many detrimental effects resulting from a PLP deficiency 
will be discussed here. 
 
5.4.3.1 Multiple Deficiencies 
Multiple cascading deficiencies can result from a PLP deficit including, but not 
limited to, insulin deficiency, magnesium deficiency, zinc deficiency, and deficiency 
of other B vitamins. We will explore some of these cascading deficiencies resulting 
from a vitamin B6 deficiency here.  
 
When a vitamin B6 deficiency is present, other micronutrient deficiencies are present 
as well; vitamin B6 deficiency usually occurs in combination with other B-complex 
vitamin deficiencies.339 The fact that these B-vitamin deficiencies aggravate each 
other is an important factor when discussing the effects of any B-vitamin deficiency.  
Deficiency of PLP impairs vitamin B12 absorption in rats102 resulting in the 
coexistence of vitamin B6 and B12 deficiency. A study on patients presenting with 
B12 deficiency neuropathy show riboflavin and vitamin B6 (pyridoxal) are also 
reduced.127 In addition, supplementation with a single B-vitamin can induce a 
functional deficiency of another B-vitamin.274 This emphasises the importance of 
supplementing with vitamin B-complex rather than a solitary B-vitamin.  
 
Vitamin B6 is also crucial to Ca2+ and Mg2+ balance.119  A PLP deficiency has also 
been shown to result in increased urinary Mg2+ excretion leading to a negative Mg2+ 
balance.119, 343 Mg2+ is also an essential cofactor of over 300 enzymes and a 
deficiency of this mineral results in its own myriad of consequences. The presence of 
Mg2+ ions are essential in all enzymes that utilise ATP as an energy source and those 
that synthesise DNA and RNA from nucleotides.344 In the context of the current 
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discussion it is remarkable how so many micronutrients are interconnected; changing 
the levels of one results in deficiencies elsewhere. Thiamine concentration has been 
shown to be lower in Mg2+ deficient rats suggesting that Mg2+ deficiency may inhibit 
thiamine-related enzyme systems,345 while another study suggests that thiamine 
deficiency inhibits Mg2+ utilization.346 Mg2+ deficiency can additionally result in a 
Ca2+ deficiency (also reported in vitamin B6 deficiency), as well as iron 
accumulation, and is associated with impaired vitamin B6 status as it is required to 
activate vitamin B6 phosphorylation (Figure 5.3). Mg2+ deficiency results in reduced 
alkaline phosphatase activity, the metalloenzyme required for uptake of PLP by tissue 
(Figure 5.3).347 If a vitamin B6 deficiency leads to Mg2+ deficiency119, 343 and Mg2+ 
deficiency leads to vitamin B6 deficiency,347 a deficiency in either may result in a 
vicious cycle. Mg2+ may also protect against the mitochondrial damage promoted by 
ALA-generated free radicals;348 another mechanism suggested to play a role in acute 
porphyria. Interestingly, hypomagnesia is common in acute porphyria attacks.22 Could 
this be related to a vitamin B6 deficiency? 
 
Another detrimental effect of PLP depletion is hyperhomocysteinemia, which is 
common in the porphyrias.  Hyperhomocysteinemia in the porphyrias has been 
suggested to result from consumptive tissue depletion of PLP.11 Deficiencies of 
thiamine, riboflavin, folic acid, vitamin B12, and biotin, in addition to vitamin B6 are 
associated with central nervous system abnormalities.126 Santhosh-Kumar et al.349 has 
suggested that the neuropsychiatric manifestations of some of these B-vitamin 
deficiencies may be due to disrupted homocysteine catabolism in the brain. Vitamin 
B6, folate and vitamin B12 supplemented together have resulted in better results than 
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any of the afore mentioned B-vitamins on their own in lowering homocysteine 
levels.274  
 
The interactions between vitamin B6, other B-vitamins, as well as other 
micronutrients are overwhelmingly complex and it is easy to imagine how a 
deficiency of one will result in deficiencies of many others.  
 
5.4.3.2 PLP as an Essential Coenzyme 
“PLP is one of nature’s most versatile cofactors” - Schneider et al.350  
 
PLP is an essential coenzyme to a wide variety of enzymatic reactions including 
transamination, decarboxylation, racemization, amine oxidation, aldol reactions, 
cleavage, deamination, dehydration, and synthesis. It is also involved in fatty acid 
metabolism and nucleic acid synthesis as well as membrane function and stability. It 
is notable that many pathways are affected by a PLP deficiency; only a few of them 
already known to play a role in porphyria will be briefly mentioned.  
 
We already know that PLP is an essential cofactor for the rate-limiting ALAS enzyme 
of heme synthesis and that mutations of this enzyme that alter PLP-binding to the 
enzyme cause XLSA.116 PLP has also been suggested to play a role in heme synthesis 
as a cofactor of ferrochelatase, the final enzyme of the heme pathway. PLP deficiency 
causes protoporphyrinemia with correlation between ferrochelatase activity and PLP 
concentration.96 In addition, PLP deficiency is shown to stimulate increased iron 
deposits117 commonly found in porphyrias which leads to increased oxidative damage.  
 
Vitamin B6 is also important in the maintenance of Na+and K+ balance118 and water 
homeostasis has been reported to be impaired in a PLP deficient state, through a study 
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involving vitamin B6 deficient rats.118 Na+ levels were found to be elevated and K+ 
levels reduced in the serum of the vitamin B6 deficient rats suggesting a role of B6 in 
the maintenance of Na+ and K+ balance. Another study suggests a delayed diuretic 
response to water loading in rats maintained on diets deficient in either pyridoxine or 
pantothenate.351 Inappropriate secretion of antidiuretic hormone is a common 
complication of the acute porphyrias manifesting as dilution hyponatremia and 
hypokalemia and increased total body fluid.228, 230-233, 245, 352, 353 This may be due to 
vitamin B6 deficiency.  
 
5.4.3.3 Tryptophan - a Common Issue 
Other important PLP reactions are the conversion of tryptophan to both niacin and 
serotonin (Figure 5.2). PLP is an essential cofactor of kynurinase, an enzyme in the 
tryptophan-niacin pathway. Kynurinase has a low binding affinity with PLP and its 
activity is highly impaired by low levels of PLP. This is the basis of the tryptophan 
load test that has been used to measure PLP status. PLP deficiency therefore impairs 
kynurinase activity and disrupts tryptophan metabolism resulting in a number of 
detrimental biochemical sequelae. Kynurinase impairment leads to diminished niacin 
synthesis and niacin deficiency. Pellagra is the classical niacin deficiency syndrome 
and can be fatal if untreated. Vitamin B6 deficiency has been shown to induce niacin 
deficiency120 and there are reports of pyridoxine pellagra.354 Some of the symptoms of 
pellagra resemble those of the cutaneous porphyrias. A niacin deficiency could 
possibly aggravate the known role that porphyrins play in the skin manifestations in 
these porphyrias. Kynurenase activity has been reported to be reduced in patients with 
PCT355 possibly due to diminished vitamin B6 status.  
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A block in tryptophan-niacin metabolism due to kynurinase impairment caused by a 
vitamin B6 deficiency also leads to increased xanthurenic acid levels.356 A 
computational model of tryptophan modeled a vitamin B6 deficient state and 
predicted increased serotonin as well as xanthurenic acid levels correlated with 
diminished PLP levels.357 Xanthurenic acid readily binds with insulin impairing its 
function by making it less effective.358 Insulin deficiency has been reported in PLP 
deficiency and is believed to be due to reduced pancreatic synthesis of the 
hormone.113 Vitamin B6 deficiency resulting in reduced insulin availability359 may be 
an additional factor in the onset of diabetes often seen in porphyria (Section 4.2). This 
may contribute to the biochemical basis of the disordered carbohydrate metabolism 
found in the acute porphyrias and play a part in the “glucose effect” as insulin inhibits 
ALAS1 induction. 
5.4.3.4 GABA 
A previously discussed theory behind the acute attack in porphyria is the structural 
similarity of ALA to GABA and thus its ability to mimic GABA. GABA is largely 
formed from glutamate in the presence of glutamate decarboxylase which is a PLP-
dependent enzyme. Vitamin B6 deficient states result in lower levels of GABA 
production and as GABA mediates post-synaptic inhibition, failure of its synthesis 
can lead to seizures.360 Therefore, in a vitamin B6 deficient state, ALA may have 
reduced competition from GABA potentiating the ability of ALA to act as a GABA 
agonist (Section 5.2.3).  
 
5.4.4 The PLP Deficit  
Nutrients play an important role in heme synthesis (Table 2.1). Deficiencies of 
essential vitamins and minerals can provide a plausible explanation for why some 
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patients with a porphyric mutation may experience an acute attack in response to a 
trigger, while other patients with the same mutation may remain asymptomatic. 
Between 70-90% of the carriers of a genetic mutation associated with a porphyria 
remain latent or asymptomatic;147, 298 thus an additional factor is required in the 
manifestations of this disorder. Additionally, many patients with deficiency in activity 
of a heme biosynthetic enzyme produce high levels of heme precursors without ever 
exhibiting symptoms.14 Because of this high rate of latency and high levels of 
precursors in some asymptomatic patients, it has been suggested that the genetic 
mutation resulting in a diminished heme biosynthesis pathway enzyme, while 
necessary, is not sufficient to produce the clinical symptoms and that there is at least 
one other pathogenic factor involved in the manifestation of the symptoms of acute 
porphyria.91 
 
Rapid tissue consumption of PLP leading to depletion of its in vivo concentration due 
to the increased activity of the initial steps of the heme biosynthetic pathway in the 
acute porphyrias is hypothesized to be one of the precipitating factors in the 
pathogenesis of the acute attack.122, 336 Terroine and Adrian361 demonstrated that 
deficiency of PLP also results in reduced concentration of riboflavin, pantothenic acid 
and nicotinamide in the liver. Terman and Farmer,362 suggest that it is deficiencies of 
these B-vitamins in conjunction with vitamin B6 that result in the clinical and 
pathological manifestations of AIP. As seen above and in the heme biosynthesis 
chapter (Chapter 2), these cofactors have interconnected pathways and their levels 
correlate together. Emphasis must thus be placed on the fact that a PLP deficiency is 
correlated with changed levels of other key micronutrient cofactors. If PLP deficiency 
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plays a role in porphyria it will be due to a combination of other micronutrient 
deficiencies as well.  
 
5.5 Discussion and Hypothesis 
There have been several hypotheses to explain what occurs during an acute attack of 
porphyria, the most popular being high levels of ALA and heme deficiency. Another 
hypothesis that has been suggested but is often disregarded307 in the current literature 
is a consumptive tissue depletion of vitamin B6 by increased activity of ALAS in a 
porphyric state. This theory is often disregarded due to lack of evidence of successful 
pyridoxine supplementation.363 However, the most cited paper found through a 
literature review that suggests no effect of pyridoxine supplementation in the 
porphyrias used only a single dose of 100 mg of pyridoxine orally on two patients.363 
The authors reported increased plasma pyridoxine values that rapidly decreased to 
subnormal values again with no clinical improvement in these two cases. This same 
paper reports PLP deficiency in a study of 21 AIP patients and reported a generally 
lower PLP concentration during acute attacks, which supports the PLP-deficit theory. 
In another report published at a similar time, treating AIP patients with vitamin B6 
(pyridoxine) 400 mg/day resulted in some improvement after 3 months,12 possibly 
due to the higher dose and continuous dosage. One must also consider, that the 
pyridoxine form of vitamin B6 may not be being converted effectively into PLP due 
to co-existent B-vitamin deficiencies. Therefore the coenzymated form of the vitamin 
may present with better results by overcoming any potential metabolic obstacles to 
the conversion of the vitamin to its cofactor form.  
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In conclusion, the acute porphyric attack is most likely due to a combination of 
factors including toxic effects of ALA, deficiency of the heme enzyme tryptophan 
pyrrolase leading to increased serotonin levels, as well as consumptive tissue 
depletion of essential micronutrient cofactors. These factors are intimately connected. 
Heme deficiency results in many altered processes which require heme components 
including that of tryptophan pyrrolase, resulting in a deficiency of this enzyme. 
Tryptophan pyrrolase deficiency leads to elevated levels of circulating serotonin, 
which is in turn not converted to melatonin due to inhibition, possibly through the 
high levels of ALA which acts as a GABA agonist, leading to serotonin toxicity 
symptoms. This secondary ‘serotonin syndrome’ could also be initiated or enhanced 
by a vitamin B6 deficiency due to the important roles of vitamin B6 (PLP) in 
tryptophan metabolism. ALA may, as previously suggested, have some oxidative 
effect in porphyrias although this cannot be the sole mechanism of porphyria as levels 
do not correlate with acute attacks,323-325 and oral administration of ALA will not 
cause an acute attack.319, 320, 322 However, oxidative damage by ALA may disrupt the 
BBB resulting in increased permeability, perhaps leading to elevated serotonin levels 
in the CNS. Elevated serotonin levels in the CNS account for most of the symptoms 
of acute porphyria.91 However, the only mechanism that accounts for the peripheral 
neuropathies is essential micronutrient deficiencies; in particular a vitamin B6 deficit. 
Could this be the final piece in the puzzle of the biochemistry of the acute attack? A 
vitamin B6 deficiency on its own causes myriad cascading effects and leads to altered 
metabolism of essential processes as well as aggravation of other vitamin and mineral 
deficiencies resulting in additional symptoms. In summary, heme deficiency resulting 
in altered tryptophan metabolism in addition to ALA over-accumulation can explain 
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all of the porphyric symptoms other than the peripheral neuropathies.91 Peripheral 
neuropathy is proposed to be due to a vitamin B6 deficit.  
 
To gain a better understanding of what occurs biochemically during an acute attack of 
porphyria, further investigation into the heme biosynthetic pathway as well as the 
many interconnected pathways that may also contribute is essential.  
 
The role of PLP in tryptophan metabolism has recently been investigated through the 
creation of a mathematical model of tryptophan metabolism based on enzyme kinetics 
of published literature.357 This model was able to calculate the flux of metabolites and 
simulate a vitamin B6 deficiency resulting in increased serotonin and decreased 
tryptophan, which is known to occur in vivo. This was done through calculating 
response of enzymes to varying PLP concentrations rather than changing enzyme 
activities directly. This successful modeling of tryptophan metabolism suggests that a 
similar model of the heme biosynthetic pathway may also be able to measure changes 
with varying PLP concentrations and thus test the hypothesis.  
 
!  
Hypothesis  
It is hypothesized that a PLP deficit is induced or exacerbated in the porphyrias by the 
up-regulated activity of the early steps of the heme biosynthetic pathway and that this 
PLP deficit and the subsequent cascade of biochemical insults resulting from this deficit 
is the precipitaiting factor required in addition to the genetic mutation for the 
manifestation of the symptomology of the acute porphyrias. 
! 98!
CHAPTER 6.  BUILDING THE MODEL 
6.1 Introduction to Biomodeling  
“Modeling allows one to do “what-if” experiments leading to new hypotheses that 
can later be put to test experimentally” – Mitchell and Mendes.367 !
In the previous chapter we have seen that the flux of metabolites through the heme 
biosynthetic pathway are relevant to porphyria. The investigations into the 
biochemistry of the acute porphyrias, and the resulting proposed hypothesis presented 
in Chapter 5, demonstrates the requirement for further investigation of this heme 
biosynthetic flux. In order to investigate the hypothesis, theoretical tools are needed to 
improve understanding of these complex pathways. Systems biology and 
computational modeling provide potential tools for the modeling and investigating of 
the heme biosynthetic pathway in the context of porphyria.  
 
Systems biology, the study of complex interactions within biological systems, is 
becoming an increasingly popular and useful area of research and is expanding our 
knowledge of biochemical processes.364-366 In particular, the investigation of complex 
biological systems through computational and mathematical modeling provides 
methodology and potential for advances in biomedical and biologically scientific 
research.365, 367 
 
Biochemical networks are sets of reactions linked together by common substrates and 
products.368 Computational models of biochemical pathways and networks require 
rate laws and enzyme kinetic data to model each reaction. Due to this requirement and 
increasing demand for this data, enzyme kinetics, a century old area of research, is 
regaining popularity as a key area of biochemical research.368 Quantitative modeling 
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of biochemical networks using enzyme kinetic data allows theoretical investigations 
into metabolic pathways. Pathway flux as well as metabolic interconnections can be 
investigated and later tested experimentally.  
 
A computational model of the heme biosynthetic pathway would considerably 
advance the understanding of the complex interrelationships and regulation of heme 
synthesis. As the altered biochemistry of the acute porphyrias is not fully understood, 
a model of the heme biosynthetic pathway could be used to not only investigate the 
biochemistry of the porphyrias and test current hypotheses but also to develop new 
hypotheses for the pathophysiology of acute attacks. As the heme biosynthetic 
pathway is inherently dependent on other pathways, such as cofactor synthesis and the 
TCA cycle (Table 2.1), such a model would ideally be complex enough to include 
these interconnected pathways.  
 
In order to build a realistic model which can be used to mimic the heme biosynthetic 
pathway, rate laws as well as kinetic data for the parameters of each of the enzymes 
and individual steps of heme biosynthesis are required.  For the model to be relevant 
for investigations into porphyria biochemistry in humans, the values used should 
preferably be derived from human studies. The parameters entered into the model will 
provide the best results if they have been measured under similar conditions and, if 
possible, from the same tissue source. Mathematical and computational models of 
systems are not complete representations of their corresponding living system, and 
detailed knowledge of the kinetic parameters involved are essential for a model to 
mirror its living system. The closer these parameters are to that in real systems the 
more meaningful, in an in vivo context, the result. These parameters are usually 
derived from in vitro experiments and thus may not compare completely with in vivo 
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situations. Nonetheless models can still give us valuable information about fluxes and 
interactions within systems. 
 
The model presented in Chapter 7 will utilise data from each of the individual steps of 
the heme biosynthetic pathway to measure metabolite flux through the pathway. This 
chapter will discuss enzyme parameters of the heme biosynthetic pathway enzymes 
compiled from an exhaustive literature review and the parameter values that have 
been used as the basis for parameterising the metabolic model of the heme 
biosynthetic pathway which is presented in Chapter 7. The data presented here will 
compliment the background of heme biosynthesis described in Chapter 2. 
 
6.2 Building the Model 
6.2.1 Kinetic Background  
The rate of a reaction is determined by substrate concentration, enzyme concentration, 
concentrations of inhibitors and activators and by specific kinetic parameters that 
measure the rate of the reaction.369 A simple one step irreversible enzyme catalysed 
reaction can be described by the Michaelis-Menten (M-M) model that assumes a 
simple 2-step reaction: (1) substrate binds to enzyme, (2) substrate is converted to 
product and released. The irreversible form of this simple reaction is shown in 
Equation 6.1. 
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Equation 6.1:  
 
Where Vmax represents the maximum rate achieved by the reaction at saturating 
substrate concentrations, and KM characterises the interaction between enzyme and 
substrate (A) and corresponds to the substrate concentration at which the reaction is at 
50% of Vmax. KM is an inverse measure of affinity between the substrate and enzyme; 
a lower KM represents a higher affinity between the substrate and enzyme. M-M 
kinetics describe enzyme reactions exhibiting simple hyperbolic kinetics rather than 
cooperative kinetics found in regulated enzyme activity.  
 
6.2.2 Literature Search 
All eight of the enzymes involved in heme synthesis have recorded literature values 
for Vmax and KM. It is assumed that all the enzymes obey simple M-M kinetics unless 
otherwise stated (Equation 6.1). For simplicity the literature search was limited to 
these two parameters in order to have consistency between the different enzymes; the 
turnover number (kcat), specific activity, and other kinetic parameters were ignored.  
 
Finding the relevant data for each of the enzymes involved in the heme biosynthetic 
pathway proved to be an arduous task. It was a challenge finding the data required to 
create a heme biosynthesis model that is relevant for humans and particularly relevant 
for the porphyrias. Although there are many databases available today providing 
kinetic parameters and enzyme data, there are still many gaps in the data available for 
heme enzymes and extensive investigation into the current body of literature was 
required. For each enzyme, BRENDA (BRaunschweig ENzyme DAtabase),370 which 
is the kinetic scientist’s “bible” for enzyme information, was the starting point for 
A→ B
v = Vmax ⋅ AKM + A
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gathering kinetic parameters. As the BRENDA database did not include all of the 
parameters required for modelling each of the heme enzymes, an expanded search in 
PubMed371 and other databases was also conducted.  
 
This review will present some kinetic parameters of heme enzymes found in the 
literature; this augments the background of heme biosynthesis presented in Chapter 2, 
and creates a groundwork for the construction of a computational model of the heme 
biosynthetic pathway. 
 
6.2.2.1  Aminolevulinate Synthase (ALAS) 
glycine + succinyl-CoA ! ALA +CoA + CO2 
 
ALAS  (EC 2.3.1.37), as discussed in Section 2.2.5, is a homodimer and catalyses the 
first step of the heme biosynthetic pathway. This enzyme is believed to be rate-
limiting for the pathway as it has the lowest activity of all of the enzymes of the heme 
biosynthetic pathway.372 The enzyme catalyses the condensation reaction between 
succinyl-CoA and glycine to produce ALA with the release of CoA and CO2.  
 
ALAS requires two PLP cofactors; it has two active sites per dimer which each bind a 
PLP molecule symmetrically.116, 373 The reaction mechanism occurs via ordered 
binding of glycine which forms a PLP-glycine complex followed by binding of 
succinyl-CoA which donates a succinyl group via PLP.72, 374  
 
As discussed throughout earlier chapters, ALAS1 activity is tightly regulated through 
feedback inhibition by heme. The mechanism of feedback inhibition may be at the 
transcriptional, translational and transport levels and is not fully understood.73, 375 As 
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Figure 6.1 ALAS Mechanism.  
Suggested mechanism for the PLP-dependent ALAS reaction reproduced from Hunter and Ferreira.72 
 
 
regulation of ALAS is not completely understood, feedback inhibition of the enzyme 
by heme was not considered at this stage and M-M kinetics was assumed as a 
simplifying assumption for the development of the initial model.  
 
A stepwise, ordered bi uni mechanism has been suggested for ALAS:(Hunter and 
Ferreira 2007;2011) 
 !
 
However, even this mechanism is not complete as it does not include PLP binding. 
For the first simple model of heme biosynthesis, ‘Stage 1’ (which will be presented in 
E + G↔EG + SCoA↔EGSCoA↔EQ↔EALA1↔EALA2↔E + ALA
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Chapter 7), a single, irreversible bi reaction was assumed for simplicity, rather than 
the more complicated six step reaction mechanism above (Equation 6.2). 
 
Equation 6.2:  
v = Vmax ⋅ A ⋅ BKMa ⋅ KMb + A ⋅ KMb + B⋅ KMa + A ⋅ B  
 
The KM and Vmax parameters found from the literature for this enzyme through the 
literature search are recorded in Table 6.1. All parameters listed in Table 6.1 are 
derived from studies of erythrocytes and values may be different than those from 
hepatocytes. It must be considered that parameters from different sources may vary, 
and kinetic values from erythrocytes may be more relevant to investigations into the 
erythropoietic porphyrias rather than the hepatic porphyrias. 
 
Gong et al.377 also recorded dissociation constants for glycine, pyridoxal-5-phosphate, 
and aminolevulinate at 22 mM, 1.6 µM and 25 µM respectively. These parameters 
may be useful for creating a subsequent model which includes reversible reactions. 
However, it should be noted these values are measured in murine rather than human 
tissue.  
 
The last three rows in Table 6.1 show values from human models. Ducamp et al.77 
recorded a KM value for succinyl-CoA that was significantly lower then the Bishop et 
al. values.78, 378 This could possibly be due to different assay conditions as they used a 
lower temperature and pH. For the ‘Stage 1’ model of heme synthesis in the following 
chapter, the average of the KM and Vmax of references 28 and 360 were used (Table 
7.2). 
A+B→C
!!!! ! !
!! ! !!!! Table!6.1!KM!and!Vmax!Parameters!Found!for!ALAS.!!
Organism Location 
Vmax Gly 
(µmol/l*min) 
Vmax S-CoA 
(µmol/l*min) 
KM Gly 
(µM) 
KM S-CoA 
(µM) 
KM PLP 
(µM) 
pH °C Reference 
Mouse Erythrocyte — — 51000 55 — 7.2 37 376 
Mouse Erythrocyte — — 23000 2.3 — 7.2 30 377 
Human Erythrocyte — — 15000 4.3 — 7.2 30 77 
Human Erythrocyte 5.2 5.15 9300 40.7 0.0215 7.4 37 78 
Human Erythrocyte 4.975 — 10200 47 0.0278 7.4 37 378 
   Recorded values for KM and Vmax parameters found for ALAS in the literature.  
 
 
 
 
 
!!!! ! !106!
112! !6.2.2.2 Aminolevulinate Dehydratase (ALAD) !
ALA + ALA ! PBG + 2 H2O 
 
The next step in heme biosynthesis involves ALA transportation into the cytosol 
(parameters unknown) where it is converted into PBG. ALAD (EC 4.2.1.24) then 
catalyses the condensation and cyclisation of two molecules of ALA to form PBG.379  
 
This enzyme, found in the cytosol, exists primarily as a homo-octamer and requires 
zinc ions for activity with the ability to bind up to eight zinc ions.380, 381 However, it is 
suggested that only four zinc ions are required for optimal activity (reference). Zinc 
ions may play a role as a facilitator for the binding and reactivity of the active site 
towards ALA or through maintaining the stability of the enzyme structure.382 
 
ALAD also exists as a low activity hexamer at higher pH levels,383 and it is thought 
that some mutations that are the underlying cause of ALAD-P may result in 
stabilisation of this hexameric form.384  
 
The enzyme obeys M-M kinetics and the irreversible M-M equation (Equation 6.1) 
was used for simplicity in the ‘Stage 1’ model of heme synthesis (Chapter 7). In later 
models, a more complicated rate law will better represent the stoichiometry of this 
reaction. 
 
Values for KM and Vmax for ALAD from the literature search are shown in Table 6.2. 
For the ‘Stage 1’ model, KM and Vmax values from Anderson and Desnick385 were 
chosen as they reported a usable Vmax from human tissue (Table 7.2).  
 
   
!!!! ! !107!
112! !Table 6.2 KM and Vmax Parameters Found for ALAD. 
Organism Location 
Vmax 
(µmol/l*min) 
KM (µM) pH °C Reference 
Bacillus 
subtilis 
— — 118 9.0 37 382 
Bovine Liver — 273 6.8 37 382 
Mouse Hepatic 5.95 320 6.4 37 386 
Human Erythrocyte 1.26 270 6.8 37 385 
Human Whole blood — 287 6.8 37 380 
Human Plasmid — 200 6.2-9.2 37 383 
     Recorded values for KM and Vmax parameters found for ALAD in the literature.  
6.2.2.3 Porphobilinogen Deaminase (PBGD) !
PBG + PBG + PBG + PBG ! HMB + 4 NH3 
 
PBGD (EC 2.5.1.61), the third enzyme in the heme biosynthetic pathway which 
converts four PBG molecules into HMB, utilises an unusual dipyrromethane cofactor. 
This enzyme is a monomer found in the cytosol. 
 
There is evidence that suggests that folate may also be involved in this reaction as a 
non-essential activator of PBGD.83 This study in rat liver suggests that folate produces 
an increase in Vmax without altering the KM value.83 This could be significant when 
investigating the mechanism of folate treatment of the acute porphyrias as it has been 
suggested that high doses of coenzymes may correct and treat enzyme deficiencies 
that correspond to metabolic disorders.258  
 
There is also feedback inhibition of this enzyme by coproporphyrinogen and 
protoporphyrinogen in HCP and VP.93 These porphyrinogens, when added to PBGD 
in control lymphoblasts, decrease PBGD’s Vmax and result in sigmoidal PBGD 
substrate-velocity curves.93 Incorporating details of this feedback inhibition will be 
!!!! ! !108!
112! !important in the development of computational models of heme synthesis for investigation of HCP and VP.  
 
PBGD utilises a covalently bound dipyrromethane cofactor, which is the result of 
autocatalytic coupling of PBG as a primer. Another four molecules of PBG are then 
linked in a head-to-tail fashion to the dipyrromethane to form a protein bound linear 
chain of six PBG units forming a hexapyrrole. Hydroxymethylbilane (four PBG) is 
then cleaved off leaving the dipyrromethane cofactor still attached to the enzyme.56 
This enzyme’s kinetics are complex due to its quirky chemistry. A study of the 
enzyme in E. coli suggests that PBG first binds the dipyrromethane (PBG-PBG) 
cofactor and then forms a complex with each of the next PBG molecules through ES, 
ES2, ES3, and ES4 states and then releases HMB leaving the cofactor still bound.387 
This can be summarized as follows: !
Where D is the cofactor dipyrromethane, S is the substrate (PBG), and P is the 
product (HMB). From a study in rat kidney,388 Noriega proposed the best rate law to 
fit the experimental data was Equation 6.3:  
Equation 6.3: 
!
!
They reported the apparent kinetic constants:  V1 = 1017.41 pmol/min mg, K1 = 2.08 
± 0.01 µM, V2 = 86.10 ± 0.19 pmol/min mg, K2 = 0.102 ± 0.003 µM388. A separate 
Vmax and KM was also recorded as 439.73 ρmol/min/mg and 0.855 µM respectively. 
However, the complexity of this rate law was not appropriate in the ‘Stage 1’ model 
and again M-M irreversible kinetics was assumed as there are readily available KM 
E + D→ ED→ EDS→ EDS2→ EDS3→ EDS4→ ED + P
v = V1[ S] +  V2[ S]21 +  K1[ S] +  K2[ S]2  
!!!! ! !109!
112! !and Vmax values recorded in the literature (Table 6.3). More sophisticated models of the heme biosynthetic pathway will require the incorporation of a more accurate rate 
law.  
 
Vmax and KM values for this enzyme from the literature are recorded in Table 6.3. 
Values measured from AIP patients are highlighted in blue. Data from Bustad et al.389 
was chosen for the ‘Stage 1’ model in Chapter 7 as this author also reported values in 
AIP patients which can be compared to the “normal” values during model 
investigations. 
 
Table 6.3 KM and Vmax Parameters Found for HMBS. 
Organism Location 
Vmax 
(µmol/l*min) 
KM (µM) pH °C Reference 
E. coli — — 7.0 8.3 20-25 390 
Rat Erythrocyte — 15.3 8.0 37 391 
Rat Kidney — 0.855 (app) 8.2 37 388 
Human Erythrocyte — 8.9 8.5 37 93 
Human Erythrocyte — 6 6.8 37 392 
Human — 
0.105  
(0.051 AIP) 
48  
(1579 AIP) 
8.2 37 389 
Human Erythrocyte — 5.9 (app) 8.1 37 393 
Human Erythrocytes 
0.693  
(0.325 AIP) 
12.3  
(6.2 AIP) 
7.4 37 394 
Human Erythrocytes 0.000035 77 7.4 37 395 
KM and Vmax parameters found for hydroxymethylbilane synthase (HMBS). Values highlighted red 
were measured in AIP patients; (app) indicates an apparent parameter. 
 !  
!!!! ! !110!
112! !6.2.2.4 Uroporphyrinogen Synthase (UROS) !
HMB ! uroporphyrinogen III + H2O 
 
UROS (EC 4.2.1.75) is a monomer also found in the cytoplasm. It catalyses the rapid 
closure of the linear HMB to form the first porphyrin ring of the pathway 
uroporphyrinogen III (Figure 2.7).  
 
A study in rat hepatocytes suggests that folate may also affect the UROS reaction.87 
Further studies into this possible mechanism may shed new light on the effects of this 
vitamin on porphyria.  
 
UROS has a higher rate of activity then PBGD, HMB never accumulates in vivo and 
PBGD and UROS work together to form uroporphyrinogen III exclusively.396 For this 
one-substrate, one-product reaction, M-M irreversible kinetics (Equation 6.1) was 
assumed. KM and Vmax values from the literature are shown in Table 6.4. For the 
‘Stage 1’ model, values from Cunha et al.397 and Omata398 were used as the lower KM 
values utilised HMB faster which, as previously stated, never accumulates in vivo. 
 
        Table 6.4 KM and Vmax Parameters Found for UROS. 
Organism Location 
Vmax 
(µmol/l*min) 
KM (µM) pH °C Reference 
Human Liver 0.000225 1.01 7.4 37 398 
Human Erythrocyte — 5.0-20.0 7.4 37 399 
Human Erythrocyte — 1.5 8.2 37 400 
Human  Erythrocyte — 0.15 7.4 37 397 
Human  Erythrocytes 0.000023 51 7.4 37 395 
 KM and Vmax parameters found for UROS from the literature.  
 
HMB is extremely unstable, and undergoes rapid non-enzyme catalysed cyclisation to 
form uroporphyrinogen I. However, under physiological conditions there is normally 
!!!! ! !111!
112! !an excess of UROS capacity and little of the I isomer forms.3 The non-enzymatic conversion of HMB was not included in the ‘Stage 1’ model.  
 
6.2.2.5 Uroporphyrinogen Decarboxylase (UROD) !
uroporphyrinogen III ! coproporphyrinogen III + 4CO2 
 
UROD (EC 4.1.1.37), the fifth enzyme of the pathway, is a dimer and also resides in 
the cytoplasm.  It forms coproporphyrinogen III from uroporphyrinogen III as well as 
coproporphyrinogen I from uroporphyrinogen I.  
 
UROD catalyses the stepwise decarboxylation of the four acetate substituents on the 
beta carbon of uroporphyrinogen III to form coproporphyrinogen III via hepta-, hexa-, 
and penta-carboxylate intermediate forms.401 This enzyme has complex kinetics as all 
of these intermediates have reported KM’s for the enzyme402 and can each act as a 
substrate as well as accumulate as their corresponding porphyrins in porphyria (Figure 
2.9). 
 
This enzyme is also capable of metabolising uroporphyrinogen I to 
coproporphyrinogen I via hepta-, hexa- and penta-carboxylate intermediates as well, 
further complicating the enzyme’s already complex enzymes kinetics. 
Coproporphyrinogen I, however, plays no further role in the heme pathway,401 and in 
the ‘Stage 1’ model (Chapter 7) this branch of the heme biosynthetic pathway is not 
considered. 
 
KM and Vmax values from the literature for both the I and III porphyrinogen isomers 
are shown in Table 6.5. Warby et al.403 reports a much higher KM and lower Vmax than 
!!!! ! !
 
 
 
 
Table 6.5 KM and Vmax Parameters Found for UROD. 
Organism Location 
Vmax I 
(µmol/l*min) 
Vmax III 
(µmol/l*min) 
KM I (µM) KM III (µM) pH °C Reference 
Rats/mice Liver 0.096 0.19572 2.1 2.7 6.8 37 404 
Human Leukocytes 0.0000732 0.000186 38.1 10.8 6.8 37 403 
Human Erythrocytes 0.03325 0.06425 1 0.4 6.75  37 402 
Human Erythrocytes — — 0.8 0.35 6.8 37 405 
     KM and Vmax parameters found for uroporphyrinogen synthase (UROS). Values for both the I and III isomers are included.  
!!!! ! !113!
112! !the other investigations reported; this could possibly be due to the differences in tissue source (leukocytes) and or the higher pH conditions than the other references from 
human sources.  Data from de Verneuil et al.402 was used in the ‘Stage 1’ model.  
 
6.2.2.6 Coproporphyrinogen Oxidase (CPOX) 
 
coproporphyrinogen III + O2 + 2H+ ! protoporphyrinogen IX + 2CO2 + 2 H2O 
 
Coproporphyrinogen III is then transported back into the mitochondria (transport 
parameters unknown) where it can be ultimately formed into heme. CPOX (EC 
1.3.3.3), the sixth enzyme of the heme biosynthetic pathway, is found back in the 
mitochondria and is a homodimer. Protoporphyrinogen IX is formed from 
coproporphyrinogen III via oxidative decarboxylation.  
 
CPOX is specific to coproporphyrinogen III. Coproporphyrinogen I cannot be utilised 
as a substrate for this enzyme and, as previously stated, the latter plays no further role 
in the pathway.  
 
CPOX may require copper for optimal activity91 although some studies suggest 
otherwise.92 Copper will not be considered in the ‘Stage 1’ model (next chapter). The 
reported kinetic parameters from the literature are displayed in Table 6.6; the 
parameter values are relatively consistent from the different sources. Data from Li and 
Woods406 although derived from liver studies, was used for the ‘Stage 1’ model 
because this source provides a recorded Vmax value that was compatible with the 
model. Parameters derived from erythrocytes was not an option for modeling this 
enzyme as none of the data found through the literature search was based on 
erythrocyte studies (Table 6.6).  
!!!! ! !114!
112! !Table 6.6 KM and Vmax Parameters Found for CPOX. 
Organism Location 
Vmax 
(µmol/l*min) 
KM (µM) pH °C Reference 
Human Plasmid — 0.6 8.0 37 92 
Human Liver 0.004176 0.291 7.2 37 406 
Human Plasmid — 0.68 7.2 37 407 
Human Lymphocytes — 0.21 7.2 37 408 
 KM and Vmax parameters found for coproporphyrinogen oxidase (CPOX).  
 
6.2.2.7 Protoporphyrinogen Oxidase (PPOX) !
protoporphyrinogen IX + 3O2 ! protoporphyrin IX + 3H2O2 
 
PPOX (EC 1.3.3.4) is a dimer and a mitochondrial enzyme found in the inner 
membrane. It catalyses the conversion of protoporphyrinogen IX into protoporphyrin 
IX in a three-step, six-electron oxidative reaction.91 However, a simple two-step 
irreversible M-M rate law (Equation 6.1) will again be assumed for this enzyme.  
 
PPOX utilises an FAD (flavin adenine dinucleotide) cofactor which transfers 
electrons from the substrate to the electron acceptor oxygen.94, 95 The KM value of 
PPOX for the FAD cofactor, if found, could be incorporated into future versions of 
the ‘Stage 1’ model. 
 
The parameters found from the literature for PPOX are presented in Table 6.7. The 
KM values for protoporphyrinogen IX of this enzyme range from 0.85-9.75 (Table 
6.7). Again this variation is potentially due to different sources, techniques and pH. 
Values from Shepherd and Dailey409 were used for the ‘Stage 1’ model in Chapter 7.  
 !  
!!!! ! !115!
112! !Table 6.7 KM and Vmax Parameters Found for PPOX. 
Organism Location 
Vmax 
(µmol/l*min) 
KM (µM) pH °C Reference 
A. tuberculosis — — 1.12 7.4 37 410  
Human Plasmid — 0.85 8.2 37 411  
Human Placenta — 1.7 8.1 37 412  
Human Plasmid 3.8 3.8 (app) 8.0 37 409  
Human Erythrocyte — 9.78 8.6 37 413  
Human Plasmid — 2.33 7.4 37 414 
KM and Vmax parameters found for protoporphyrinogen oxidase (PPOX); (app) indicates an apparent 
parameter. 
 
6.2.2.8 Ferrochelatase (FECH) !
protoporphyrin IX + Fe2+ ! protoheme + 2H+ 
 
FECH (EC 4.99.1.1), the final enzyme of the heme biosynthetic pathway, catalyses 
the insertion of the ferrous form of iron into protoporphyrin IX forming heme. This 
enzyme is located in the mitochondrial inner membrane and is a dimer with each 
subunit consisting of similar domains. 
 
FECH requires both iron and copper for activity and utilizes an iron-sulfur cluster as a 
cofactor. Copper stimulates the activity of FECH and decreases its KM for iron 
although the exact mechanism for this is unknown. Ferrous iron is utilised as a 
substrate and inserted into protoporphyrin IX to form protoheme.  
 
It has also been suggested that PLP may act as a factor or non-essential activator of 
FECH although this has not been confirmed.96, 97 The potential mechanism and 
parameters for the involvement of PLP as an activator of FECH requires further 
investigation.  
! ! ! ! !
!!! ! !
 
 
 
 
Table 6.8 Vmax and KM Parameters Found for FECH. 
Organism Location 
Vmax 
(µmol/l*min) 
KM PPIX 
(µM) 
KM Fe2+ 
(µM) 
KM Zn2+ 
(µM) 
pH °C Reference 
Mouse Plasmid — 15.3 11.1 — 8.1 37 415  
Mouse Plasmid — 1.4 1.9 — 8.1 30 416  
Human Plasmid 6.6 9 9.3 — 8.1 25 417  
Human Erythrocytes — 1.49 — 8.33 8.6 37 413 
Human Plasmid — 16.8 10 — 8.1 37 415  
  KM and Vmax parameters found for ferrochelatase (FECH). 
! ! ! ! !
!!! ! !117!
116! ! The parameter values from human sources reported KM values of FECH and Fe2+ as  
close between references (9.3 and 10 µM), but the reported KM for PPIX in humans 
varies significantly (from 1.49 - 16.8) (Table 6.8). For the ‘Stage 1’ model, data from 
Sellers et al.,417 is used as this study reported a Vmax value that is compatible with the 
model.  
 
6.3 Summary of Chapter 6 
In this chapter, the KM and Vmax values for heme biosynthetic pathway enzymes found 
from an exhausted literature review are reported. A table of all of the values used in 
the simple model can be found in Chapter 7 (Table 7.2). The complexity of heme 
biosynthesis is highlighted by the complex kinetic mechanisms of many of the 
enzymes discussed in this chapter. 
 
The rate limiting enzyme ALAS has feedback inhibition and regulation at a number of 
levels, the kinetic parameters of which are not fully known. The combination of two 
of the same substrate (ALA) to form one product (PBG) by ALAD suggests there 
may be two different binding affinities; one for binding of the first ALA and one for 
binding of the second ALA to the enzyme already complexed with one ALA. 
However only one KM value was found measured in the literature search and the 
simple irreversible M-M kinetics (Equation 6.1) was assumed.  
 
PBGD is arguably the most complex enzyme of heme biosynthesis with the utilisation 
of two of its substrates bound together as a dipyrromethane cofactor (PBG-PBG) 
followed by the stepwise addition of four more of the same substrate. Again, only one 
! ! ! ! !
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116! !KM value was found to represent this reaction, and Equation 6.1 is used to represent this reaction; this is a simplification of the kinetics involved.  
 
The conversion of uroporphyrinogen III (or I) by UROS to coproporphyrinogen III 
(or I) is not a single-step reaction and occurs via intermediates which are also capable 
of spontaneous oxidation into porphyrins. While the KM values of these intermediates 
are recorded in the literature,402 this reaction will be treated as a single step reaction in 
the ‘Stage 1’ model of heme biosynthesis (Chapter 7) to provide a level of 
consistency with the other reaction parameters used in the model.  
 
Although many of the parameters required to model the heme biosynthetic pathway 
have been found, there are still gaps in the parameter values needed for the creation of 
a comprehensive heme biosynthetic pathway model. More affinity constants (KM 
values) were found recorded than Vmax values.  For consistency, all kinetic parameters 
chosen and used in the model described in Chapter 7,  are from human sources with 
pH and temperature variables taken into account. Also, as Vmax values are often found 
reported in different units, most of the values from the literature needed to be 
converted into common units (µmol/min*l) that could be utilised in the model 
described in the following chapter. If there was not enough information to report a 
usable value for an enzyme, it was not included in the tables in this chapter.  
 
It is difficult to get accurate values that correlate well for every enzyme, due to the 
many variables and different sources of information resulting from a literature search 
of enzyme parameters. The different techniques, temperatures, and pH used to 
measure enzyme kinetic parameters by individual authors will result in some 
limitations to the accuracy of a system model using parameters from a literature 
! ! ! ! !
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116! !review. In addition, enzyme kinetic parameters derived from different sources (e.g., erythrocytes or hepatocytes) may have different parameter values. The parameters 
selected for use in the ‘Stage 1’ model were chosen based on a number of criteria 
designed to provide a level of  consistency between the different enzymes whenever 
possible; parameters chosen were taken from the same species; recorded in the same 
units; and measured under similar pH and temperature conditions.  
 
Other parameters that will be required to create more complicated future models of 
the heme biosynthetic pathway include feedback inhibition parameters, transport 
parameters between the cytosol and mitochondria as well as parameters for the 
reverse reactions of each enzyme in order to develop a model that is reversible and 
more relevant to in vivo conditions. The framework for the building of a complete 
functional computational model of heme biosynthesis will be presented in Chapter 7. 
 
 
! ! ! ! !
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116! !CHAPTER 7. ‘STAGE 1’ MODEL 
7.1 Computational Modeling  - COPASI 
 Biochemical modeling allows investigations of biological pathways through 
parameterization of individual reactions that are linked together through common 
substrates and products.368 This allows for more holistic investigations into a process. 
Computational models are generally made up of ordinary differential equations 
(ODEs) that represent the rate of changes of the concentrations of chemical species 
within a system.365, 368, 418 For the purposes of systems biology it has been suggested 
that it is sufficient to represent each enzyme-catalysed reaction as a single step and 
assign to it an appropriate integrated rate law.368 For this reason, it has been proposed 
that rate laws for computational models can use generic rate laws to calculate fluxes 
through systems.419 This has been termed “convenience kinetics”, and is usually based 
on a generalised form of M-M kinetics. However, mechanistic details may affect the 
dynamics of systems, especially when there is inhibition or regulation of an enzyme 
involved.368 Therefore, when simple kinetics are assumed, it must be remembered that 
there will be limitations to how accurately a model can represent a real system.  
 
COPASI (COmplex PAthway SImulator) is an open source biochemical network 
modelling and simulation software package.364 It is a stand-alone program that allows 
modelling of a system as well as investigations into the system using built in kinetic 
software. COPASI uses ODEs to represent the changes of chemical species in a 
system and was created for the simulation and analysis of biochemical networks. To 
date, no comprehensive model of heme biosynthesis has been created. In this chapter 
the creation of a simple model of heme biosynthesis based on published data of 
! ! ! ! !
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116! !individual enzymatic reactions is described. COPASI is the software used here to develop an initial heme biosynthetic pathway model; because of the models 
preliminary nature it is named:  ‘Stage 1’. 
 
7.2 Stage 1 - Building a Simple Functional Model 
7.2.1 Introduction 
A simple and functional model of heme biosynthesis was created. Each step of the 
heme biosynthetic pathway was entered into a new COPASI model and parameterized 
primarily using the data reported in Chapter 6. The first step in the model is the ALAS 
reaction of succinyl-CoA and glycine to produce ALA (Table 7.1). This is followed 
by the other 7 enzymatic steps of the heme biosynthetic pathway. As heme is 
distributed, utilised, and degraded in vivo, there is a final ninth step in the model 
representing the flux into heme metabolism that occurs in vivo. This is represented as 
a single step. The assumptions and theory of the creation of this model will be 
discussed  below.  
 
7.2.2 ‘Stage 1’ Model 
For this initial model of the heme biosynthetic pathway a few arbitrary settings were 
assumed. For ease of calculations, all units of time were set to minutes, quantity units 
to µmoles, and volume units to liters. Only one compartment was opened in the 
model. In COPASI, compartments allow for representation of different biochemical 
locations (e.g. mitochondria and cytosol). As the parameters for transport between the 
cytosol and mitochondria were unknown, only one compartment was used in the 
model. 
 
! ! ! ! !
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116! !Each step of the heme biosynthetic pathway was assigned a reaction and rate law (Table 7.1). Cofactors and side products (i.e. PLP, CO2, H2O) were ignored for 
simplicity in this first functioning model. Other than ALAS and FECH all enzymatic 
reaction rate laws were set as irreversible and represented by M-M irreversible rate 
laws (Equation 6.1). As the ALAS and FECH catalyzed reactions utilize two different 
substrates with known KM values, they were accordingly set as Bi irreversible  
(Equation 2). The final step of the pathway, heme utilisation, was represented as a 
non-enzymatic single step with a mass action rate law. This final step of the pathway 
allows the model to reach a steady state, as in normal in vivo situations, heme 
synthesis is in perfect balance with heme metabolism and does not accumulate in 
excess. For simplicity, feedback inhibition was not included in this model. Rate laws 
and reactions for each step in the model are summarised in Table 7.1.  
 
The specific kinetic parameters for each of the rate laws were selected from the 
literature review as described in Chapter 6 and the parameters are summarised in 
Table 7.2. All enzymatic parameters chosen were either from human subjects or from 
human protein expressed in E. coli. For the final step of the model, heme utilisation, 
the rate was chosen through a trial and error process to find a rate that would balance 
heme synthesis with heme metabolism and allow the model to reach a steady state.  
! ! ! ! ! !
!!! ! !
 
 
 
 
Table 7.1 Reactions and rate laws for ‘Stage 1’ model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Table recording the enzymes, reactions, rate laws and flux of reactions in the ‘Stage 1’ model. 
 
! ! ! ! ! !
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123! !Table 7.2 ‘Stage 1’ parameters. Enzyme Rate Law KM (µmol/l) Vmax (µmol/(l*min) Reference 
ALAS Bi Glycine: 9,750 
Succinyl-CoA: 43.9 
5.09 78, 378 
ALAD M-M 270 1.26 385 
PBGD M-M 48  0.105  389 
UROS M-M 0.15 
 
0.00023 397 
UROD M-M 0.4 0.004176 402 
CPOX M-M 0.291 0.264 x 10-9 406 
PPOX M-M 3.8 0.285 409  
FECH Bi PPIX: 9 
Fe2+: 9.3 
6.6 417  
HemeD Mass action 0.003 (1/min) n/a 
Rate law and KM and Vmax parameters used for each step of the heme biosynthetic pathway in the 
‘Stage 1’ model of heme biosynthesis.  
 
The concentrations of the initial precursors glycine, succinyl-CoA and Fe2+ were set 
as ‘fixed’; that is set at a constant concentration that is not altered by changes 
elsewhere in the pathway. As these three substrates feed into the heme biosynthetic 
pathway this was done to reflect constant flux into the heme biosynthetic pathway. 
All other metabolite (species) concentrations of intermediates of the heme 
biosynthetic pathway were set to ‘reactions’ in COPASI which allows the 
concentrations of these species to be altered by flux of the heme biosynthetic 
pathway.  
 
The initial concentrations of the precursors glycine and succinyl-CoA were set at the 
fixed concentration of 0.5 µM, an arbitrary physiologically reasonable concentration, 
to allow constant flux into the model. This is summarized in Table 7.3. As adequate 
concentrations of Fe2+ proved important in the model at the final enzymatic step of 
the pathway, Fe2+ concentration was set at the high concentration of 100 µM. 
Significantly lowering concentration of Fe2+ resulted in lowered output of heme and 
! ! ! ! ! !
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123! !higher concentrations of protoporphyrin IX. All other porphyrin precursors were set initially at 0 µM in order to measure flux through the heme biosynthetic pathway as 
concentrations in vivo are difficult to quantify (Table 7.3).  
 
Table 7.3 Species, reactions, and intitial concentrations. 
 Summary of species and initial concentrations of the ‘Stage 1’ model of the heme biosynthetic 
pathway. 
 
7.2.3 Steady State 
As previously mentioned, a steady state is reached when the concentrations of the 
intermediates of a pathway remain constant because the rates of formation have come 
to be in exact balance with their rate of utilization. In order to reach a steady state, the 
end product of the pathway, in this case protoheme, was assumed to be utilised (Table 
7.1). If this assumption is removed from the model, heme concentration rises 
continuously and a steady state is not reached (Figure 7.2). 
! ! ! ! ! !
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Figure 7.1 Flux of metabolites of ‘Stage 1’ model.  
Model has reached steady state due to the 9th step of the ‘Stage 1’ model: heme utilization.  
 
 
One of the useful features of COPASI is the way it summarises information. The 
steady state of the ‘Stage 1’ model is summarized in Table 7.4. This table shows the 
concentrations of each metabolite (species) at steady state. As we would expect to see 
in vivo, protoheme has the highest concentration and there are very low levels of the 
porphyrinogens. However, we would expect to see much lower calculated 
concentrations of HMB than the porphyrinogens as HMB is highly unstable and never 
accumulates in vivo. In a future models the non-enzymatic cyclisation of HMB to 
uroporphyrinogen I can be added as a side pathway (see Figure 2.1); this may resolve 
the discrepancy and deliver lower calculated concentrations of HMB in the 
protoheme
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 Figure 7.2 Flux of metabolites of ‘Stage 1’ model without heme utilization.  
When heme utilization is removed, protoheme continuously rises and the model does not reach a steady 
state. 
 
model. In conclusion, the model did successfully reached a steady state which is 
critical before performing investigations into the effect of changing enzyme 
parameters of the model to investigate the porphyrias. Concentrations of metabolites 
at steady state, rate of metabolism and time it took to reach steady state are 
summarised in Table 7.4 and reflect the flux of the pathway shown in Figure 7.1.  
 
 !  
protoheme
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Steady state calculations of the ‘Stage 1’ model are summarized including: 
concentration at steady state, rate, and transition time. 
 
 
7.2.4 Stoichiometry Analysis 
As discussed in previous chapters, it takes eight molecules of succinyl-coA and eight 
molecules of glycine at the beginning of the pathway to result in one molecule of 
heme. This relates to the stoichiometry of the model. Stoichiometric coefficients 
report the proportions between substrate and product molecules involved in a process. 
In Table 7.5, the stoichiometry of species in relation to individual reactions is shown. 
Positive values are shown in green and negative values are shown in red, this 
represents the creation and utilization of metabolites. For example, we can see in 
column ALA, row (2 ALAD), that 2 molecules of ALA are being utilised in the 
ALAD reaction. This describes the stoichiometry known to occur in vivo. The 
proportion of species utilised in the overall pathway is shown in Table 7.6. 
 
! ! ! ! ! !
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 Table 7.5 Stoichiometry analysis of reactions. 
 
 
 
 
 
 
 
 Columns represent reactions and rows represent species altered by the reaction. Positive values are green and negative values are red.  
 
Table 7.6 Stoichiometry analysis of overal pathway. 
 
Representation of the stoichiometry of the species (metabolites) in the overall heme biosynthetic pathway.  
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Metabolic control analysis is a method of quantifying how much the rates of 
individual reactions affect the concentrations and fluxes of the steady state. The rate-
limiting step of a pathway is defined as the slowest step. However, in a metabolic 
steady state all of the individual reactions are going at the same rate. Therefore 
metabolic control analysis is relevant to measure how a change in an individual 
reaction will affect the steady state. COPASI provides the software technology to 
easily perform metabolic control analysis through the creation of reports of 
elasticities, flux control coefficients and concentration control coefficients which will 
each be described.  
 
Elasticity coefficients reflect the relationship between the change of a reaction rate 
with the change of the concentration of a chemical species.368 COPASI calculates the 
elasticities of all the reactions with respect to all of the species in a model. A positive 
value denotes metabolites that stimulate the rate of a reaction and negative values 
denote metabolites that inhibit a reaction. The elasticity coefficients simulated by 
COPASI for the ‘Stage 1’ model are shown in Table 7.7. It should be noted that the 
elasticity table created by COPASI does not list the metabolite concentration columns 
in the order they appear in the heme biosynthetic pathway.  All values shown in Table 
7.7 are positive values and represent the affect of a substrate(s) on its reaction(s). This 
is to be expected with the simple ‘Stage 1’ model as no feedback inhibition is 
included. Future models, that include the feedback inhibition of protoheme on ALAS 
as well as of porphyrinogens on PBGD will produce negative elasticity coefficients at 
the respective enzymatic steps that are inhibited. Glycine, succinyl-CoA, and Fe2+ are 
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Flux control coefficients, unlike elasticities, are global properties that depend on the 
model as a whole.368 They record the extent of change in the flux of a reaction when 
another reaction is made to go faster or slower. In other words, they represent how 
much the steady state flux of a step in a metabolic pathway will change with altering 
the enzyme concentration of another step. If a flux coefficient is low, changing the 
concentration of that enzyme will have less effect on the pathway. Again, in Table 
7.8, negative values reflect negative effect while positive values reflect a positive 
effect. The metabolic control analysis of the ‘Stage 1’ model by COPASI generated a 
table of flux control coefficients for the model with columns representing cause and 
rows representing effect (Table 7.8). Interestingly, PPOX and FECH appeared to have 
minor effects on the flux of later steps of the pathway, whereas CPOX significantly 
affected the flux through UROD, and ALAD affected flux of PBGD. However, the 
most significant result of Table 7.8 is the fact that ALAS had an effect on the flux of 
every step of the pathway, which is known to be the case in vivo. This supports the 
reported fact that ALAS is effectively the rate-limiting enzyme of the heme 
biosynthetic pathway and supports the validity of the ‘Stage 1’ model as a simple 
representative of heme biosynthesis.  
 
Concentration control coefficients are similar to flux control coefficients, yet they 
describe changes in steady-state concentrations of species rather than flux through a 
step in response to changes of specific reaction rates.368 Flux control coefficients of 
the ‘Stage 1’ model are shown in Table 7.9 with columns representing cause and rows 
representing effect. Again, it should be noted that in Table 7.9 COPASI does not  
! ! ! ! ! !
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Table 7.7 Metabolic control analysis: Elasticities. 
   (rows = effect; columns = cause) 
 
Table 7.8 Flux control coefficients. 
  (rows = effect; columns = cause)
! ! ! ! ! !
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 Table 7.9 Concentration control coefficients. 
 
    (rows = effect, columns = cause) - green = positive value, red = negative value 
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(highlighted in red). Because the flux of succinyl-CoA and glycine as well as Fe2+ are 
not affected by the model, they are not reported in Table 7.9. However, the ‘Stage 1’ 
model, does report a positive concentration control coefficient of ALAS for every 
variable substrate of the model which is also in support of the rate-limiting role of this 
enzyme in heme biosynthesis.  
 
7.2.8 Summary of ‘Stage 1’ Model 
“Everything should be made as simple as possible but not too simple” - Albert 
Einstein.  
 
In summary, a model of the heme biosynthetic pathway has been created with the use 
of a number of simplifying assumptions. The model successfully reached a steady 
state and flux through the pathway resembles that which occurs in vivo. Having 
achieved this, the ‘Stage 1’ model was investigated to discern what happens to the 
flux of the modeled pathway with a change in one of the parameters. The outcome of 
changing individual parameters allows strengths and weaknesses of the model for 
future iterations to be evaluated.  
 
7.3 Stage 2 - Investigations into AIP 
7.3.1 Modeling AIP 
The ability of the ‘Stage 1’ model to describe the biochemical effects of a porphyria 
was undertaken for AIP. This porphyria was chosen because KM and Vmax parameters 
for this PBGD have been recorded in both normal and AIP subjects (Table 6.3). As 
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the vitamin B6-related hypothesis for the biochemistry of acute attacks. Changing 
activities of CPOX or PPOX (mutations of which cause HCP and VP respectively) 
would not represent the biochemistry of acute porphyria in the simple ‘Stage 1’ model 
as the relevant feedback inhibition has not been incorporated.93 Thus PBGD presented 
itself as a good choice for the initial modeling of a simplistic porphyric state.  
 
The KM and Vmax values of PBGD were changed to 1579 µM and 0.051 µmol/(l*min) 
respectively, values measured in AIP patients.389 These values were from the same 
source as the ‘normal’ parameters of PBGD used in the ‘Stage 1’ model. All other 
parameters values were kept the same as in the ‘Stage 1’ model. 
 
7.3.2 Steady State and Metabolic Control Analysis 
This new ‘AIP’ model showed increased concentration of PBG and decreased rate of 
heme formation at steady state (Figure 7.3). The ‘AIP’ model took longer to reach a 
steady state (Table 7.10) than in the previous ‘Stage 1’ model (Table 7.4). The ‘AIP’ 
model reported PBG concentration at steady state to be considerably elevated (Figure 
7.3). This is expected with diminished activity of PBGD and occurs in AIP 
patients.301-304 The transition time to reach a steady state concentration of PBG was 
also considerably increased (Table 7.10) in comparison with the initial model (Table 
7.4). Although this is a step in the right direction for modelling the biochemistry of 
AIP, PBG levels alone were elevated, whereas in AIP both ALA and PBG levels are 
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 Figure 7.3 Model of the flux through the ‘AIP’ version of the ‘Stage 1’ model. 
 
elevated (Table 3.1). This is likely due to the irreversible rate laws assumed for the 
enzymatic reactions of the model, whereas in physiological conditions there would be 
some flux in both directions at each step. This could also be due to the lack of either 
representation of feedback inhibition of ALAS by heme or the ALAS up-regulation  
when heme levels are diminished.  
 
    !  
protoheme
PBG
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 Figure 7.4  ‘AIP’ Model With PBG Levels Removed.  
Model of the flux through the ‘AIP’ version of the ‘Stage 1’ model with PBG levels removed. This can 
thus be compared with Figure 7.1. at a similar scale. 
 
Table 7.10 Steady State of the "AIP" Model. 
 
 
 
 
 
 
 
 Steady state calculations of the ‘AIP’ model are summarized including: concentration 
at steady state, rate, and transition time. 
 
protoheme
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scale, heme is still being formed at similar levels although the rate of the initial heme 
formation is slower (Figure 7.4). This shows that the rate of protoheme formation is 
slower in the AIP model yet it still reaches the same concentration level at steady state 
(0.00122472) (Tables 7.4 and 7.10). !!
7.3.3 Summary of AIP Model  
The fact that changing the parameters of one of the enzymes associated with 
porphyria resulted in changes of flux through the heme biosynthetic pathway shows 
promise for future investigations. However, the ‘AIP’ model also reflects some of the 
limitations of this preliminary model as it does not completely represent AIP 
biochemistry. These results are useful as they highlight changes that are needed to 
produce future heme biosynthesis models that will more accurately model porphyria 
biochemistry.  
 
7.4 Stage 3 - Future work 
Although this model utilises a number of assumptions, it is a useful starting point for 
the building of more complex models that can be used to investigate the heme 
biosynthetic pathway and the porphyrias. The fact that the model has reached a steady 
state and can measure flux through the pathway, as well as represent some of the 
biochemical changes associated with porphyria, shows promise for future work. A 
number of changes will be presented that are needed before the model can represent a 
physiologically relevant situation with some accuracy.  
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of reversible rate laws. The fact that the “AIP” model did not completely reflect actual 
AIP metabolite flux, may be due to the fact that simple irreversible reactions were 
assumed. In order to include these rate laws, the parameters for both the forward and 
reverse reactions would need to be measured experimentally. The reversible M-M rate 
law is (Equation 6.4): 
Equation 6.4: !
!
 
To be more biologically relevant, new rate laws should include a direct parameter for 
enzyme concentration. As enzyme concentration is not directly written into Equation 
6.4, perhaps the parameter kcat (turnover number) would be a better parameter to use 
rather than Vmax; Vmax is defined as the product of kcat and enzyme concentration. 
Thus Equation 6.4 would be written as:   
Equation 6.5: 
!
 
With an enzyme concentration value incorporated into the model, effects of changes 
in gene expression and hence enzyme concentrations could also be altered in order to 
investigate porphyria. Some porphyria mutations appear to result in lowered enzyme 
concentration rather than altered enzyme binding (KM) or Vmax. Suggested 
“convenience kinetics” reversible rate laws for computational modelling of biological 
A + B→ P 
v = Vmaxfor ⋅KMpVmaxrev ⋅KMs
v = E ⋅ kcatfor ⋅KMp
E ⋅ kcatrev ⋅KMs
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levels of substrate binding in the ALAD and PBGD reactions.  These parameters 
could then be integrated into future rate laws although this is not essential for the 
purpose of computational models of whole systems.  
 
Transport parameters were not included in the model. With further development of 
the model, these parameters would ideally be included. COPASI is capable of 
representing multiple ‘compartments’ within a system. Heme biosynthesis occurs in 
both the mitochondria and the cytosol with transport of heme precursors between 
these two ‘compartments’. However, as values for transport parameters were not 
found from the literature search, they were not incorporated into the ‘Stage 1’ model.  
 
7.4.2 Regulation and Inhibition 
As the feedback inhibition of ALAS by heme is important in the regulation of the 
pathway as well as being significant in the pathophysiology of the porphyrias, this 
must also be included in an upgraded version of the model. This would prove 
beneficial even if the mechanism of the first step of the pathway is represented by 
simple uncompetitive inhibition kinetics and a reasonable arbitrary value is inserted as 
the inhibition constant to mimic in vivo situation.  
 
In addition, as HCP and VP present with acute symptoms due to inhibition of PBGD 
(the enzyme deficient in AIP) by coproporphyrinogens and protoporphyrinogen 
inhibition, parameters for these heme precursors should be incorporated into the rate 
law of PBGD. Any other known inhibitors and activators should also be incorporated, 
i.e. lipoic acid at UROD. 
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included. HMB’s ability to non-enzymatically cyclise into uroporphyrinogen I as well 
as the conversion of uroporphyrinogen I into coproporphyrinogen I by UROS should 
be included (Figure 2.1). It may be the lack of this side pathway that resulted in the 
higher than expected (although still low) concentrations of the unstable HMB in the 
‘Stage 1’ model of the heme biosynthetic pathway. The parameters for the enzymatic 
reaction of porphyrinogen I isomers have been reported in the literature (Table 6.5). 
 
Another side-pathway that may be worth including is porphyrinogens to porphyrins. 
Porphyrinogen precursors of heme are rapidly oxidised to porphyrins with a loss of 
six protons upon exposure to air. As it is the porphyrins rather than porphyrinogens 
that accumulate in the porphyrias, it may be worth including these rapid oxidation 
reactions in future models as well. 
 
7.4.4 Cofactors  
It has been suggested that: “The distinction between substrates and coenzymes, useful 
though it may be in physiological studies, has no meaning in relation to enzyme 
mechanisms” – Cornish-Bowden.420  
 
Bearing this in mind, in the next stage of the model it would be useful to include 
cofactors into the rate laws and reactions. This would allow investigations of the 
pathways in relation to dependence and utilisation of the cofactors which we have 
previously suggested may have a significant affect in the pathophysiology of the 
porphyrias. This is essential to future investigations of the hypothesis presented in 
Chapter 5. 
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depletion (Chapter 5), interconnected biochemical pathways would also need to be 
parameterised. These pathways would include the TCA cycle, cofactor synthesis and 
metabolism, as well as some of the pathways that protoheme feeds into including the 
tryptophan/serotonin pathway, which has already been modeled.357 This begins to get 
exceedingly complex and it would require methodical ‘step by step’ additions to the 
pathway, which would lead to a more complicated model further down the track.  
 
7.4 Summary of Chapter 7 
Although the model presented as ‘Stage 1’ is very simplistic, it presents the 
groundwork for the creation of more complex as well as more physiologically 
significant models of heme biosynthesis. “Despite considerable advances in the 
topological analysis of metabolic networks, inadequate knowledge of the enzyme 
kinetic rate laws and their associated parameter values still hampers large-scale 
kinetic modelling” – Adiamah et al.421  
 
More knowledge of the kinetic rate laws and parameters of the heme biosynthetic 
pathway enzymes are required to successfully advance the model. However, there is 
undoubtably potential in utilising a future, more complex, model in carrying out 
“what-if” experiments relevant to porphyria. This could allow for breakthroughs into 
the understanding of the mechanism behind the acute porphyric attack as well as 
investigations with the focused on safer and more effective treatment regimes.  
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8.1 Aims of Thesis 
The aims at the start of this thesis were to: 
 
1.) Review literature on effects of micronutrients in the porphyrias with the aim of 
developing a testable hypothesis that could aid future treatments.  
 
2.) Develop a methodology suitable for testing the hypothesis. 
 
8.2 Conclusion of Thesis  
As seen throughout this thesis, the porphyrias are a diverse and complex family of 
disorders. This complexity is reflected in the fact that some patients with the 
underlying genetic defect(s) remain latent while others are symptomatic. This 
indicates there is at least one other factor required in addition to a genetic defect for 
the development of porphyria symptoms.  A systematic review of the relationships 
between heme biosynthesis, the porphyrias, and micronutrients was undertaken. A 
component of this provided a much needed review of reported micronutrient 
treatments of the porphyrias while another component inspected possible mechanisms 
for the acute attack of porphyria.  
 
Evidence of micronutrient deficiencies were found to be widely reported among the 
porphyrias (Table 4.2) as was successful micronutrient treatment (Table 4.3) albeit 
only in restricted locations. This adds credibility to the proposal that micronutrient 
deficiencies, in particular vitamin B6 (PLP) may play a role in the pathogenesis of 
both the acute and cutaneous porphyrias. Many of these reports were written in 
languages other than English. Controlled trials to determine the effectiveness of these 
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Through considerations of the heme biosynthetic pathway (as well as connected 
pathways), clinical presentation of the porphyrias, successful treatments of porphyria, 
and suggested mechanisms for the pathophysiology of the acute porphyric attack, a 
hypothesis was formed for the etiology of the manifestations of acute porphyria: 
 
The ‘biochemical insults’ that could result from a vitamin B6 (PLP) deficiency are 
numerous and include additional micronutrient deficiencies, altered processes that 
require PLP-cofactors (e.g. tryptophan/serotonin pathways), and reduced GABA 
synthesis. The altered tryptophan/serotonin pathway could lead to higher levels of 
circulating serotonin with serotonergenic effects. Reduced synthesis of GABA, an 
important neurotransmitter, may result in lack of competition with ALA due to their 
similar structures resulting in increased ALA toxicity. Although hypotheses of in vivo 
biochemistry can be difficult to ‘prove’, further studies of PLP as a treatment of 
porphyria as well as measuring PLP levels in both symptomatic and asymptomatic 
porphyria patients could support or disprove this hypothesis. However, due to the 
!
It is hypothesized that a PLP deficit is induced or exacerbated in the porphyrias by the 
up-regulated activity of the early steps of the heme biosynthetic pathway and that this 
PLP deficit and the subsequent cascade of biochemical insults resulting from this deficit 
is the precipitaiting factor required in addition to the genetic mutation for the 
manifestation of the symptomology of the acute porphyrias. !
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In order to develop another mechanism to test this hypothesis, a novel new approach 
was taken through building a computational model of heme biosynthesis. This model 
was parameterised using kinetic data from a literature review which added to the 
reservoir of knowledge of the individual reactions of heme biosynthesis. Numeric 
modeling using the program COPASI was applied to create a simple model with a 
steady state that simulated a simple reflection of in vivo heme biosynthesis. However, 
changing the parameters of an enzyme to model the mutation found in AIP did not 
completely represent the biochemistry of AIP. This highlights limitations of the 
model and areas for future work. There are significant gaps in the literature available 
for kinetic parameters of heme biosynthesis, thus hindering model expansion. More 
information is currently available is required before a full capacity model can be built 
with the potential to investigate the hypotheses proposed in previous chapters. 
 
Heme biosynthesis is a fascinating and complex process. The building of a 
comprehensive model of the heme biosynthetic pathway will allow testing of different 
hypotheses in an area where this was previously unable. Although the model 
presented in this thesis does not yet reflect a fully functioning representation of heme 
synthesis it provides a simple functioning model that lays the groundwork for future 
studies.  
 
In conclusion, it has been hypothesized that a PLP (vitamin B6) deficiency may be the 
risk factor necessary in conjunction with the genetic defect in porphyria to trigger 
acute attacks. If this is the case, micronutrient therapy may provide a safe method for 
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biochemistry of the porphyrias as well as the aid the discovery of new methods of 
treatment and symptom control.  !  
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 GENERAL ABBREVIATIONS 
A list of abbreviations used: 
 
AIP acute intermittent porphyria NAD+ nicotinamide adenine 
dinucleotide 
ALA aminolevulinate NADP(H) nicotinamide adenine 
dinucleotide phosphate 
ALAD-P aminolevulinate dehydratase 
deficiency porphyria 
ODE ordinary differential equation 
ALAS aminolevulinate synthase PBG porphobilinogen 
BBB blood brain barrier PBGD porphobilinogen deaminase 
BRENDA braunschweig enzyme 
database 
PCT porphyria cutanea tarda 
CEP congenital erythropoietic 
porphyria 
PGC-1 proliferator-activated 
receptor coactivator 1 
CNS central nervous system PLP pyridoxal 5’phosphate 
CoA coenzyme A PPOX protoporphyrinogen oxidase 
COPASI complex pathway simulator TCA tricarboxylic 
CPOX coproporphyrinogen oxidase THFA tetrahydrofolic acid 
EPP erythropoietic protoporphyria ThPP thiamine pyrophosphate 
FAD flaven adenine dinucleotide IU international unit 
GABA γ-aminobutyric acid UROD uroporphyrinogen 
decarboxylase 
HCP hereditary coproporphyria UROS uroporphyrinogen synthase 
HEP hepatoerythropoietic porphyria UV ultraviolet 
HIV human immunodeficiency 
virus 
VP variegate porphyria 
HMB hydroxymethylbilane XLPP X-linked dominant 
protoporphyria 
IV intravenous XLSA X-linked sideroblastic 
anemia !
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Key Abbreviations ADP! ALAD!deficiency!porphyria!AIP! acute!intermittent!porphyria!ALAD6P!! aminolevulinate!ALAD! aminolevulinate!dehydratase!ALAS!! aminolevulinate!synthase!CEP! congenital!erythropoetic!porphyria!CPOX! coproporphyrinogen!oxidase!EPP! erythropoetic!porphyria!!FECH! ferrochelatase!HCP! hereditary!coproporphyria!HEP! hepatoerythropoetic!porphyria!HMB! Hydroxymethylbilane!synthase!PBG! porphobilinogen!PBGD! porphobilinogen!deaminase!PCT! porphyria!cutanea!tarda!PPOX! protoporphyrinogen!oxidase!UROD! uroporphyrinogen!decarboxylase!UROS! uroporphyrinogen!III!synthase!VP! variegate!porphyria!XLPP! X6linked!protoporphyria!XLSA! X6linked!sideroblastic!anemia!
HEME BIOSYNTHETIC 
PATHWAY
ALAS
ALAD
PBGD
UROS
UROD
CPOX
PPOX
FECH
XLSA,
XLPP
Glycine
Succinyl-CoA
ALA
PBG
Uroporphyrinogen III
Coproporphyrinogen III
Protoporphyrinogen IX
Protoporphyrin IX
Heme
HMB
+
ALAD-P
EPP
VP
HCP
PCT, HEP
CEP
AIP
METABOLITES
PORPHYRIAS
ENZYMES
